Shaker A. Mousa, Ph.D., MBA, FACC, FACB, FAHA, FNAI

DR. MOUSA is a tenured and endowed professor of Pharmacology at Albany College of Pharmacy, Executive VP and chairman of PRI in Albany, NY. Dr. Mousa held a

senior, principal research scientist and a research fellow at DuPont Pharmaceuticals Company for over 20 years. He is also a Visiting Scholar at the Johns Hopkins University and holds academic appointments of Adjunct Professor in the Department of Medicine, Sol Sherry Thrombosis Research Center, at Temple University, the Department of Medicine of the State University of New York at Buffalo, and the Department of Pharmacology of the University of Pennsylvania in Philadelphia. Awarded the 2017 Kuwait Foundation for Advancement in Sciences (KFAS) Laureate for Applied Sciences in Medicine.

The Pharmaceutical Research Institute (PRI) is a research and development institute dedicated to cutting-edge research, pharmaceutical services, mentoring and education. Under Dr. Mousa’s direction, the Institute has obtained dozens of research grants (NIH, DOD, NSF, foundation and Pharmaceutical firms) and equipment donations totaling over $25 million. PRI’s staff has grown from three employees to forty-eight over the past five years, with international experts in the fields of nanotechnology, chemistry, molecular biology, cell biology, stem cell, drug delivery and development. Dr. Mousa’s work has been reported in over 1,000 peer reviewed publications and holds over 350 US and International Patents. He contributed to the discovery and development of many products/clinical candidates: Cardiolite (myocardial imaging), Marluma (breast cancer detection), Tc99m platelet GPIIb/IIIa antagonist for thrombus imaging in venous and arterial thrombotic disorders), anti-platelet/Anti-thrombotic agent, ultra-short acting beta blocker, Esmolol and analogs (cardiovascular safety), angiotensin receptor blocker, Losartan, and several key concepts in vascular, cardiovascular, oncology, and ophthalmology diseases. Google Citation ~25,000 and h-index 81. PRI continuously contributes to the success of several regional, national and international academic, biotechnology and pharmaceutical institutes. Dr. Mousa’s expertise in drug discovery and development during his 17 years at DuPont-Merck Pharmaceuticals help facilitate the success of several start up regional, national biotechnology and pharmaceutical companies. These include the followings: Emisphere Technologies, AGTT Pharmaceuticals, Delcath Systems Inc., Cytogel, Inc., SelectX Pharmaceuticals, Vascular Vision Pharmaceuticals Co., Othera Pharmaceuticals, PolyMedix, Pharmion Corp, Nova Decision, DuPont, Merck, Sanofi-Aventis, GlaxoSmithKline, Pfizer, AstraZeneca, Leo Pharm, Takeda, Abbott, Hospira, Eisai pharmaceuticals, Endo Pharmaceuticals, and several other biotech and pharmaceutical companies. Another one of Dr. Mousa passions is fostering interest in research among students in the local community, with over 60 high school and college students conducting research annually at PRI. Additionally, Dr. Mousa established several exchange programs with Universities from the Middle East, Europe, Japan, China, South Korea, and others.

Dr. Mousa received a Ph.D. in Pharmacology from Ohio State University in Columbus, Ohio, completed postdoctoral research in Cardiovascular Pharmacology at the University of Kentucky in Lexington, Kentucky, and earned his MBA from Widener University in Chester, Pennsylvania. He was elected a Fellow of the American College of Cardiology (FACC) and a Fellow of the National Academy of Clinical Biochemistry (FACB). He is a member of several national and international societies. In addition, he serves on the editorial boards and as a reviewer for a number of scientific and medical journals including Cardiovascular Therapeutics, Atherosclerosis, Thrombosis & Vascular Biology, Circulation, Lab Investigation, JCI, JBC, Expert Opinion series, and Current Drugs. Elected in 2018 Fellowship of the National Academy of Inventors (FNAI).

Shaker A. Mousa, Ph.D. CURRICULUM VITAE Page 2 of 92

Home Address:

5 Fox Glove Ct., Wynantskill, NY 12198 (518)-283-7659 (Phone) mousasa1@aol.com

Office Address:

The Pharmaceutical Research Institute (PRI),

Albany College of Pharmacy and Health Sciences 1 Discovery Drive, Rensselaer, NY 12144 (518)-694-7397 (Phone) (518)-694-7567 (Fax) shaker.mousa@acphs.edu

POSITIONS 2002 - Present Tenure Professor and endowed chair at

Albany College of Pharmacy and Health Sciences Executive Vice President and Chairman of PRI at Albany, NY 2010 - 2018 Vice Provost for Research

Albany College of Pharmacy and Health Sciences, Albany, NY 2003 - Present Research & Educational Consultant

Veterans’ Administration Medical Center, Albany, NY 1993 - 2002 Research Fellow

Working Group Chairman - Platelet GPIIb/IIIa Antagonist, Angiogenesis & Cell Adhesion Molecules Research Programs DuPont Pharmaceuticals Co., Wilmington, DE

1992 - 1993 Senior Principal Research Pharmacologist

Working Group Chairman -Thrombosis - Platelet GPIIb/IIIa Program DuPont Merck Co., Wilmington, DE

1991 - 1992 Principal Research Pharmacologist Working Group Chairman -Thrombosis Program

DuPont Merck 1989 - 1991 Senior Research Pharmacologist Thrombosis Research- Antiplatelets, Thrombin

Inhibitors, others Du Pont Pharmaceutical & Imaging Agents

1987 - 1989 Senior Research Investigator Program Leader: Anti-ischemia Drug Discovery, Cardiovascular Safety Evaluations Du Pont Critical Care, Waukegan, IL 1985 - 1987 Program Leader: Radiopharmaceutical Res. Div.,

Shaker A. Mousa, Ph.D. CURRICULUM VITAE Page 3 of 92

Duties: Carry out and prepare the preclinical Research for IND and NDA submissions to the FDA (non-invasive diagnosis of ischemic heart

diseases: CardioliteR Du Pont / Biomedical Dept., N. Billerica, MA SCHOLASTIC RECORD

1998 MBA, Widener Univ., School of Management,

Rochester, PA, USA. Postgraduate Training Postdoctoral Fellow, PSP Fellowship

1983 -1985 Department of Medicine, Division of Endocrinology UK Medical Center, University of Kentucky Lexington, KY - Supervisor Dr. G. Van Loon MD, Ph.D. 1980-1983 Ph.D. Pharmacology Department of Pharmacology College of Medicine, Ohio State University Columbus, Ohio - Supervisor Dr. D. Couri, Ph.D. 1974-1976 M. Sc. Pharmacology Department of Pharmacology College of Pharmacy, Alexandria, University Alexandria, Egypt 1969-1973 B.Sc. Pharmacy (Ranked 1st in class of 500 students each year for 5 years)

College of Pharmacy, Alexandria University, Alexandria, Egypt

PERSONAL DATA Marital Status: Married, Children: Shaymaa, Ahmed, Sarah, Adam, Deena Residency: US Citizen. Languages Spoken: English, Arabic, and French APPOINTMENTS 2002 – Present Tenured Professor and endowed chair of Pharmacology, Chairman and

executive VP of PRI at Albany, Albany, NY 2010 – 2018 Vice Provost of Research at ACPHS

Shaker A. Mousa, Ph.D. CURRICULUM VITAE Page 4 of 92

2008 – Present Consultant and Advisory Board member, Center of Excellence of osteoporosis, King Abdel Aziz University, Jeddah, Saudi Arabia

2009 – Present Adj. Professor, Rensselaer Polytechnic Institute, Troy, NY 2009 – 2015 Visiting Professor, King Saud University, Riyadh, Saudi Arabia 2003 – Present Adj. Professor, University at Albany, Chemistry Depart. Albany, NY 2000 – 2005 Adj. Professor, University of Delaware, Newark, DE 1999 – 2015 Adj. Professor of Pharmacology, Temple University School of Medicine,

Sol Sherry Thrombosis Research Center, Philadelphia, PA 1998 – 2016 Visiting Scholar, Johns Hopkins University, Baltimore, MD 1997 – 2010 Adj. Professor of Pharmacology, Dept. of Pharmacology, College of Medicine, University of Pennsylvania, PA 1997 – 2001 Research Fellow Head of Angiogenesis & Vascular Biology Du Pont Pharmaceutical Co., Wilmington, DE 1996 – 2010 Adj. Professor of Pharmacology, Dept. of Medicine, State University of New York (SUNNY) at Buffalo, Buffalo, NY 1988 – 1990 Adjunct Professor at Dept. of Biotechnology, Illinois Institute of Technology, Chicago, IL 1983 – 1985 Adjunct Faculty at Department of Pharmacology, College of Medicine, University of Kentucky 1983 – 1985 Adjunct Faculty at Department of Pharmacology, College of Medicine, Ohio State University 1973 – 1983 Faculty Position at Department of Pharmacology & Toxicology, College of Pharmacy, Univ. of Alexandria, Alexandria, Egypt Other Appointments: 2009 – Present Chairman of the Advisory Board, Center of excellence of Osteoporosis, Kingdom

of Saudi Arabia Specialty: Cardiovascular, Oncology, Ophthalmology & Neurology Drug Discovery & Drug Development

Shaker A. Mousa, Ph.D. CURRICULUM VITAE Page 5 of 92

Supervisor and Mentor:

Supervised and mentored over 100 MS, PhD, MD, and Post-doctoral fellows during my tenure at DuPont Pharmaceuticals.

Supervise and mentored over 50 PhD, MD, and Post-doctoral fellows at the Pharmaceutical Research Institute that he founded in 2002.

Supervised Ph.D. graduate students at University of Pennsylvania PA, Johns Hopkins University MD, Illinois Institute of Technology IL, University at Albany, NY, and other international Universities

Supervise and mentor annually over 200 Pharm D, MD students and fellows in various research activities.

Supervise and mentor annually over 100 High School Students and

undergraduate students in various research activities.

Mentor Pharmacy Practice and junior faculty

TEACHING EXPERIENCE 2010 – Present Teaching Graduate Core Courses for Medical Graduates: Experimental and

Clinical Research Design, Pharmacogenomics and Personalized Medicine, Translational Research

2015 – Present Teaching and coordinating PHM 324 “Pharmaceutical and Biopharmaceutical Industry” with Ingelhieum.

2010 – Present Research Advisor for 20 MS graduate students in Biotechnology and

Pharmaceutical Sciences 2002 – Present Teachings in Cardiovascular topics, drug discovery and drug development topics

to Pharm D and other graduate students 2002 – Present Pharm D rotations in Drug Discovery and Drug Development 1985 – Present Participating with various academic institutes in giving seminars to faculty,

undergraduate and graduate students. Those institutes include the following: Ohio State Univ., MIT, Temple Univ., Univ. of Delaware, Harvard, Univ. of Kentucky, Univ. of Illinois, Univ. of Pennsylvania, Johns Hopkins, and State Univ. of New York at Buffalo.

1983 – 1984 Department of Pharmacology, College of Medicine University of Kentucky, Lexington, KY

Shaker A. Mousa, Ph.D. CURRICULUM VITAE Page 6 of 92

1980 – 1982 Participated in the following courses: Pharmacology 400, 700, 702, 820 and Toxicology 610 Department of Pharmacology, College of Medicine, Ohio State University, Columbus, Ohio 1973 – 1978 Pharmacology, Biochemistry, Bioassay and Toxicology,

College of Pharmacy, Alexandria University, Alexandria, Egypt

AWARDS AND HONORS

Elected in 2018 Fellow of the National Academy of Inventors (FNAI). Awarded the 2017 Kuwait Foundation for Advancement in Sciences (KFAS) Laureate for Applied Sciences in Medicine. Top ten Biotechnology driver in upstate New York, USA Top 1% most cited author in life sciences and translational research worldwide

Listed in Frontier of Science and Technology, US Marquis Who is who Nominated to the National Academy of Science (Institute of Medicine) Fellow of the National American Clinical Biochemistry (FACB), 1997- Present Fellow of the American College of Cardiology (FACC), 1995-Present

Fellow of the American Hear Association (FAHA) and Circulation Council, 1994-Present First Summit Award, Du Pont Merck Pharmaceutical Co., 1992. Marketing Excellence Award, Du Pont Merck Pharmaceutical & Diagnostic Imaging, 1991 Marketing Excellence Award, Biomedical Dept. Diagnostic Imaging Research Div., E.I. Du Pont de Nemours Co. (Inc.), 1988 Clayton and Smith Memorial Award for Excellence in Original Research, Department of Pharmacology, College of Medicine, Ohio State Univ., 1981, 1982 ICSABER Award for the top Research Project presented, Ohio State Univ., 1982

Scholarship Graduate Research Associate, Pharmacology Department, Ohio State University, Columbus, Ohio, 1980-1983

Shaker A. Mousa, Ph.D. CURRICULUM VITAE Page 7 of 92

CID-Pharmaceutical Company First prize for Honor Distinction in B. Pharm. Program Alexandria University, Alexandria, Egypt, 1973 NILE-Pharmaceutical Company, First prize for 5 Year first class Ranking in B. Pharm. Program, Alexandria University, Egypt, 1973 MEMPHIS-Pharmaceutical Company First prize for Pharmacognosy, Medicinal Plant & Natural Products College of Pharmacy, Alexandria University, Alexandria, Egypt, 1973 Scholarship, College of Pharmacy, Alexandria University, Egypt, 1968-1973

President ISCC, West Chester, PA, 1994-1998 Chairman MEDS International, 1995- 1998

Who is who in Medicine & Healthcare?

Who is who in the World? SOCIETY MEMBER Fellow of the American Hear Association (FAH) and Circulation Council America Society of Clinical Oncology (ASCO) American Association for Advancement of Science Fellow of the National Academy of Inventors (FNAI) Fellow of the American College of Cardiology (FACC)

Fellow of the American Clinical Biochemistry (FACB) American Association of Cancer Research (AACR) Association for Research in Vision and Ophthalmology (ARVO)

New York Academy of Sciences International Society for Heart Research (ISHR)

American Society of Pharmacology & Exp. Therapeutics. (ASPET)

American Society of Hematology (ASH) International Society of Angiology

Shaker A. Mousa, Ph.D. CURRICULUM VITAE Page 8 of 92

Honorary Member of Pan Arab Society of Hematology Honorary Member of the Middle East and North Africa Thrombosis and Hemostasis Society Honorary Member of Egypt Vascular Society

Honorary Member of Egypt Cardiology Society American Heart Association - Thrombosis Council - Circulation Research Councils

International Xenobiotic Metabolism and Disposition Society (IXMDS) Honored member of Phi Kappa Phi Society, Highest cumulative graduate GPA American Physiological society American-Egyptian Scholar International Fibrinolysis Society International Society of Thrombosis and Hemostasis Grant Review Committees: Member of NIH Study Section Fellowships (F30-F33)

Member of NIH Study Section for R21, R15, R03 Vascular Biology

Member of NIH Scientific Advisory Committee

American Institute of Biological Science

Member of NIH Study Sections SBIR/STTR

Member of Department of Defense Study Section, Member: Several ad hoc NIH study sections

Department of Veteran Affairs Review Committee

Member of various pharmaceutical and Biotechnology Company grant review committees

Reviewer for foundations including the Swiss National Science Foundation and the Australian

National Science Foundation

NCI Study Section-Angiogenesis & Anti-angiogenesis

Member: Medical and Scientific Review Committee of Charitable Leadership Foundation

Member: Several ad hoc NIH study sections

Reviewer for the Australian National Science Foundation

Reviewer for the Qatar Science Foundation

Shaker A. Mousa, Ph.D. CURRICULUM VITAE Page 9 of 92

Committee Member of Several National and International Academic Institutes: Member of the Faculty Promotion committee at various Universities In the Middle East, Asia, USA, Canada, and Europe Member of International Expert Panel representing the US and Middle East: International Clinical Practice Guidelines on the curative and preventive treatment of thrombosis in cancer patients. The panel met in October 2010 and have scheduled regular meeting in France and Japan to finalize the global guidelines. RESEARCH GRANTS Ongoing Grant Research Awards:

NanoPharmaceuticals LLC. Mousa (PI) 07/01/2014 – 06/30/2021 $1,500,000 “Nanoformulation, Pharmacodynamic and Pharmacokinetic of Nanotetrac”

NanoPharmaceuticals LLC. Mousa (PI) 03/01/2017 – 06/30/2020 $900,000 “IND studies for Clinical Lead Candidate in GBM and Pancreatic Cancer” Pro-Al Medico (AGTT). Mousa (PI) 04/01/2018 – 12/30/2019 $185,000 Synthesis of L-T3 nanoformulations for Cardiac Resuscitation NIH 1R44HL137449-01 PI (Mousa/ Elshourbagy) 09/01/2017-09/30/2019 $1,500,000 “Development of Oral Small Molecule PCSK9 Antagonist” 1R21AI134568-01 PI (Li) 07/01/2017-06/30/2019 275,000 “New use of old drug for Zika virus” Description: Nanoformulation of novel anti-viral lead compounds for improved PK and PD Completed Grant Research Award Support: 1R01HL096972-01 Mousa (Co-PI) 08/01/2009 – 06/30/2015 NIH $5,500,000 “Development of a Bioengineered Heparin from a Non-Animal Source” This proposal has four specific aims. (1). Optimize the production of bioengineered heparin; (2). Confirm chemical equivalence of bioengineered heparin with USP heparin; (3). Confirm bioequivalence of bioengineered heparin with USP heparin; and (4). Scale-up and produce a kilogram of bioengineered heparin while maintaining chemical and bioequivalence. R01HL059901-10A2 Mousa (PI) 05/01/2010 – 7/30/2015 NIH $1,250,000

Shaker A. Mousa, Ph.D. CURRICULUM VITAE Page 10 of 92

“A mechanism for suppression of TNF-alpha induced endothelial dysfunction” The goal of this project is to define the mechanisms involved in the suppression of TNF-alpha-mediated endothelial dysfunction. 2U01A1056546-06 Mousa (PI) 08/01/2008 – 07/31/2014 NIH $6,200,000 “Development and testing of polyvalent anthrax toxin inhibitors” Major goal: Optimize in vivo efficacy of polyvalent anti-anthrax using nanoformulations with optimal stability and PK profiles. 2R44HL092712-02 Mousa (Co-PI) 04/01/2010 – 06/30/201 NIH $1,550,000 “Structure-Based Search for Novel Anti-hypercholesterolemic Agents” The goal of this proposal was to identify inhibitors of the enzymatic activity of PCSK9 as novel drugs for LDL-cholesterol lowering. W81XWH-10-1-0245 Mousa (Co-PI) 04/15/2010 – 04/14/2013 DOD $350,000 “Sustained Release Oral Nanoformulated Green Tea for Prostate Cancer” The goal of this project was to develop an oral nanoformulation that would provide improved PK profiles and enhance suppression of prostate tumor progression. 1R21CA124931-01 Mousa (PI) 08/01/2009 – 07/31/2012 NIH $440,000 “Site Directed Chemotherapy for breast cancer using novel angiogenesis inhibitors” The goal of this project was to develop a site directed delivery of chemotherapy using novel angiogenesis inhibitor that target cell surface thyroid receptor and alpha v beta 3 integrin receptor on cancer and endothelial cells in the microenvironment of the tumor.

1R41CA153973-01 Mousa (PI) 09/16/2010 – 08/31/2012 NIH $280,000 “Enabling high dose regional chemotherapy while minimizing systemic toxicity” The goal of this project was to develop a novel coating technology for optimal removal of chemotherapy along with optimal blood biocompatibility. 1R41CA153973-01 Mousa (PI) 09/16/2010 - 08/31/2012 NIH-NCI $300,000 “Enabling high dose regional chemotherapy while minimizing systemic toxicity” The goal of this project is to develop a novel coating technology for optimal removal of chemotherapy along with optimal blood biocompatibility. 1R21CA124931-01 Mousa (PI) 04/1/2008 - 02/28/2011 NIH/NCI $440,000 “Experimental Models for testing novel targets in pancreatic cancer cell invasion” Major goals: 1) to utilize a novel in vitro human vessel segment model to study the mechanisms involved in the early stages of tumor metastasis. 2) To validate the findings from the in vitro model in a mouse model of pancreatic cancer.

Shaker A. Mousa, Ph.D. CURRICULUM VITAE Page 11 of 92

DASNY Mousa (PI) 04/01/2008 - 03/31/2012 NY State $ 500,000.00 Capital Project Infrastructure Shifa Biomedical- Mousa (PI) 01/01/2010 - 03/31/2012 $ 296,499.87 Structure Based Search for Novel Antihyper-cholestrolemic Agent BIO11-002-019 - Mousa (PI) 01/10/2007 - 03/09/2010 NIH (USDA) $ 120,000.00 “Nanoparticle targeting of Cathepsin-L inhibitor and Paclitaxel in Breast Cancer” Major goals: 1) to train post-doctoral students from Egypt in technology (chick Chorioallantoic membrane assay – CAM) for screening therapeutic agents for anti-tumor and anti-angiogenesis activities. 2) To train these students in preparation of nanoparticle reagents for encapsulation of cancer drugs. Othera Pharmaceuticals Mousa (PI) 07/01/2006 – 12/30/2008 Ophthalmology and Oncology Programs $1,500,000 Novel Anti-oxidant and NFkB inhibitors in Angiogenesis Modulation: Molecular Mechanisms and Potential Implication in ocular and oncological disorders. Major goals: 1) To screen for optimal lead candidate; 2) To define the pharmacological impacts of dual anti-oxidant and NFkB inhibitors in cancer and ophthalmological disorders Trans Molecular Pharmaceuticals Mousa (PI) 02/01/2006 – 03/30/2009 Anti-angiogenesis efficacy and mechanisms of TM601 $ 500,000 TM601 is novel scorpion venom peptides - Major goals: 1) To compare anti-angiogenesis efficacy of lead compound TM601 with standard anti-angiogenesis drugs; 2) To determine molecular mechanisms for TM601 using functional genomics and proteomics. CLF MTAP Mousa (PI) 01/01/2008 - 12/30/2009 IP Discovery and Development $250,000 “Evaluations of Anti-Angiogenesis efficacy on various thyroid antagonists’ nanoformulations” Sanofi and GSK Mousa (PI) 11/01/2006 - 07/30/2008 Expanded Pharmacology of FDA approved drug $105,700 “Comparative effects between Fondaparinux and Enoxaparin on wound healing and role in cancer” CLF MTAP Mousa (PI) 02/01/2009 - 12/30/2009 IP Discovery and Development $175,000 “Eye drop thyroid antagonist’s nanoformulations” CLF MTAP Mousa (PI) 03/01/2009 - 12/30/2009 IP Discovery and Development $225,000 “Encapsulation of various drugs in Tetrac immobilized PLGA nanoformulations” R41 CA128152-01 Mousa (PI) 11/01/2007 - 10/30/2009 National Institutes of Health/NCI $128,500 “Nanoparticles Targeting of Cathepsin-L inhibitor and Doxorubicin in breast cancer”

Shaker A. Mousa, Ph.D. CURRICULUM VITAE Page 12 of 92

Major goals: 1) to test the efficacy of alpha v beta 3–targeted PLGA nanoparticles containing Doxorubicin, with or without NACH, for reducing tumor growth, metastasis and angiogenesis. 2) To study the efficacy of these formulations in reducing development of chemotherapeutic drug resistance. CLF MTAP Mousa (PI) 9/01/2005 - 12/30/2007 IP Discovery and Development $231,250 Nanoformulation and Efficacy in various Oncology Models CLF MTAP Mousa (PI) 10/01/2005 - 08/30/2007 IP Discovery and Development $84,375 “Physicochemical characterization and initial stability assessment of AFP-derived antistrophic octapeptide” CLF MTAP Mousa (PI) 10/01/2005 - 09/30/2007 IP Discovery and Development $125,000 “Generation of PQQ Conjugated Polymers Physicochemical Characterization and Initial Stability Assessment” Emisphere Biopharmaceuticals Mousa (PI) 10/05/2001 - 10/30/2007 Clinical Trial Monitoring (PK/PD) $165,750 “A single-dose randomized, open-label, four-way crossover study to characterize plasma Heparin and to evaluate the pharmacokinetic/pharmacodynamics profile of Heparin and SNAC following oral Heparin/SNAC capsules administration versus intravenous Heparin injection or oral Heparin in healthy male subjects.” Othera Pharmaceuticals # I Mousa (PI) 10/01/2005 - 08/30/2007 Discovery and Development $24,000 “Potential Anti-Angiogenesis Efficacy of Othera's Novel Antioxidants” Othera Pharmaceuticals # II Mousa (PI) 01/01/2006 - 12/30/2007 Discovery and Development $57,600 “Anti-angiogenesis efficacy and mechanism(s) of Othera's novel antioxidant, TPH and its impact on the Anti-angiogenesis efficacy of potential strategies for Ocular Neovascularization-mediated disorders in human endothelial 3-dimensional sprouting model” Othera Pharmaceuticals # III Mousa (PI) 03/01/2006 - 12/30/2007 Drug Discovery and development $38,400 “Anti-angiogenesis efficacy of intravenously administered TPH alone or in combination with Avastin or Macugen in the CAM model” Othera Pharmaceuticals # IV Mousa (PI) 03/01/2006 - 01/30/2007 Drug Discovery and development $54,000 “Cellular and molecular mechanisms of TPH in the modulation of complement activation and inflammation” Othera Pharmaceuticals # V Mousa (PI) 10/01/2006 - 06/30/2007

Shaker A. Mousa, Ph.D. CURRICULUM VITAE Page 13 of 92

Drug Discovery and development $56,000 “Neuroprotective effects of Othera’s Novel Compounds” Aventis Pharmaceuticals Mousa (PI) 06/01/2006 - 05/30/2007 Drug Discovery $100,000 “Role of 1, 6 Anhydro in Enoxaparin Fractions in the Modulation of Endothelial Tissue Factor Pathway Inhibitor” CLF MTAP Mousa (PI) 02/01/2006 - 12/30/2006 IP Discovery and Development $100,000 “Generation of Tetrac conjugate polymers, physiochemical characterization, and initial stability assessment” CLF MTAP Mousa (PI) 02/01/2006 - 08/30/2006 IP Development $25,000 “Ten gram scale up and characterization of PQQ-PVA conjugated polymer” NIH SBIR Phase I-Kininogen Mousa (PI) 10/01/2005 - 12/30/2006 Role of kininogen in diabetic retinopathy $140,000 NIH SBIR Phase I-Anti-TF Mousa (PI) 06/01/2006 - 05/30/2008 Role of Tissue factor/factor VIIa in diabetic retinopathy $150,000 NIH SBIR Phase I-NACH Mousa (PI) 09/01/2007 - 08/30/2008 Heparin derivatives in enhancing chemo-uptake $165,000 MTAP Wound Healing Mousa (PI) 04/01/2006 - 03/30/2007 IP Discovery and Development $306,900 Wound healing and hemostatic treatment using novel pharmaceutical Nano-polymer or Nanoparticles formulation of thyroid hormone T4 analogs” While at DuPont Pharmaceuticals: R01 - NIH Mousa (Co-PI) $1,250,000 "Studies of the Interaction of Osteopontin with Adhesion Receptors - Structural & Functional Studies" In Collaboration with Dr. Joel Bennett, Professor of Medicine & William DeGrado, Professor of Biochemistry, University of Pennsylvania R01 - NIH Mousa (Co-PI) Temple University and DuPont Pharma $1,250,000 “Studies of The Role of Kininogen in Angiogenesis” In Collaboration with Dr. Robert Colman, Professor of Hematology, Temple University, School of Medicine, Philadelphia, PA During Postdoctoral Program: Tobacco & Health Research Institute Mousa (Research Associate) University of Kentucky $96,000 "Peripheral Nicotinic Regulation of Lymphatho-adrenal Secretion"

Shaker A. Mousa, Ph.D. CURRICULUM VITAE Page 14 of 92

During Ph.D. Program: Adria Laboratory Mousa (PI) 03/01/1981 – 12/30/1981 Analgesic Properties of Caerulein" $3,000 EDITORIAL BOARDS/ REVIEWER/ ADVISORY BOARD: Biomedicines Chief-In Editor Thrombosis and Hemostasis Biochemical Archives Current Drugs - Atherosclerosis & Vascular Biology Carcinogenesis Nanomedicine Editor Mayo Clinic Proceedings J. Medicinal Chemistry PPAR Editor J. Pharmacol. Exp. Thera. J. Cardiovascular Pharmacology Editor Advances in Anticoagulants, Antithrombotic, Thrombolytic Drug & Market Development Circulation Molecular Medicine Today New England Journal of Medicine Applied Clinical Thrombosis & Hemostasis Exp. Cell Research Life Sciences Thrombosis Research Investigational Ophthalmology & Visual Sciences Section Editor: Expert Opinion in Cardiovascular, Renal and Pulmonary Drugs, Current Drug Ltd. Cardiovascular Therapeutics Editor Current Medicinal Chemistry-Cardiovascular & Hematological Agents Patents: Dr. Mousa holds over 400 US and International Patents for discovering novel anti-angiogenesis strategies, antithrombotic, anti-integrins, anti-cancer, and non-invasive diagnostic approaches (Selected examples listed at the end). PUBLICATIONS: ORIGINAL ARTICLES- Selected from over 1,000 peer reviewed articles Salaheldin TA, Loutfy SA, Ramadan MA, Youssef T, Mousa SA. IR-enhanced photothermal therapeutic effect of graphene magnetite nanocomposite on human liver cancer HepG2 cell model. Int J Nanomedicine. 2019 Jun 17;14: 4397-4412

Shahein SA, Aboul-Enein AM, Higazy IM, Abou-Elella F, Lojkowski W, Ahmed ER, Mousa SA, AbouAitah K. Targeted anticancer potential against glioma cells of thymoquinone delivered by mesoporous silica core-shell nanoformulations with pH-dependent release. Int J Nanomedicine. 2019 Jul 19;14: 5503-5526.

Shaker A. Mousa, Ph.D. CURRICULUM VITAE Page 15 of 92

Abd-Rabou AA, Bharali DJ, Mousa SA. Viramidine-Loaded Galactosylated Nanoparticles Induce Hepatic Cancer Cell Apoptosis and Inhibit Angiogenesis. Appl Biochem Biotechnol. 2019 Jul 26. doi: 10.1007/s12010-019-03090-2. [Epub ahead of print]

Chen YR, Chen YS, Chin YT, Li ZL, Shih YJ, Yang YSH, ChangOu CA, Su PY, Wang SH, Wu YH, Chiu HC, Lee SY, Liu LF, Whang-Peng J, Lin HY, Mousa SA, Davis PJ, Wang K. Thyroid hormone-induced expression of inflammatory cytokines interfere with resveratrol-induced anti-proliferation of oral cancer cells. Food Chem Toxicol. 2019 Jul 20; 132: 110693. doi: 10.1016/j.fct.2019.110693. [Epub ahead of print]

Rajabi M, Adeyeye M, Mousa SA. Peptide-Conjugated Nanoparticles as Targeted Anti-angiogenesis Therapeutic and Diagnostic in Cancer. Curr Med Chem. 2019 Jun. doi: 10.2174 [Epub ahead of print]

Li W, Yalcin M, Bharali DJ, Lin Q, Godugu K, Fujioka K, Keating KA, Mousa SA. Pharmacokinetics, Biodistribution, and Anti-Angiogenesis Efficacy of Diamino Propane Tetraiodothyroacetic Acid-conjugated Biodegradable Polymeric Nanoparticle. Sci Rep. 2019 Jun 21; 9(1):9006. doi: 10.1038/s41598-019-44979-6.

Darwish NHE, Sudha T, Godugu K, Bharali DJ, Elbaz O, El-Ghaffar HAA, Azmy E, Anber N, Mousa SA. Novel Targeted Nano-Parthenolide Molecule against NF-kB in Acute Myeloid Leukemia. Molecules. 2019 Jun 3; 24(11). pii: E2103. doi: 10.3390/molecules24112103. Stryker ZI, Rajabi M, Davis PJ, Mousa SA. Evaluation of Angiogenesis Assays. Biomedicines. 2019 May 16; 7(2). pii: E37. Chin YT, He ZR, Chen CL, Chu HC, Ho Y, Su PY, Yang YSH, Wang K, Shih YJ, Chen YR, Pedersen JZ, Incerpi S, Nana AW, Tang HY, Lin HY, Mousa SA, Davis PJ, Whang-Peng J. Corrigendum: Tetrac and NDAT Induce Anti-proliferation via Integrin αvβ3 in Colorectal Cancers with Different K-RAS Status. Front Endocrinol (Lausanne). 2019 Apr 9; 10:241. doi: 10.3389/fendo.2019.00241. Lebda MA, El-Hawarry WN, Shourbela RM, El-Far AH, Shewita RS, Mousa SA: Miswak (Salvadora persica) dietary supplementation improves antioxidant status and nonspecific immunity in Nile tilapia (Oreochromis niloticus).Fish Shellfish Immunol. 2019 Mar 16; 88:619-626. [Epub ahead of print] Pastor RE and Mousa SA: Current management of neuroblastoma and future direction. Critical Reviews in Oncology/Hematology Volume 138, June 2019, 38-43. Chin YT, He ZR, Chen CL, Chu HC, Ho Y, Su PY, Yang YSH, Wang K, Shih YJ, Chen YR, Pedersen JZ, Incerpi S, Nana AW, Tang HY, Lin HY, Mousa SA, Davis PJ, Whang-Peng J:. Tetrac and NDAT Induce Anti-proliferation via Integrin αvβ3 in Colorectal Cancers with Different K-RAS Status. Front Endocrinol (Lausanne). 2019 Mar 12; 10: 130. doi:10.3389/fendo.2019.00130. Mousa SA, Ayoub BM. Repositioning of dipeptidyl peptidase-4 inhibitors and glucagon like peptide-1 agonists as potential neuroprotective agents. Neural Regen Res. 2019 May; 14(5):745-748.

Shaker A. Mousa, Ph.D. CURRICULUM VITAE Page 16 of 92

Cress BF, Bhaskar U, Vaidyanathan D, Williams A, Cai C, Liu X, Fu L, M-Chari V, Zhang F, Mousa SA, Dordick JS, Koffas MAG, Linhardt RJ. Heavy heparin: A stable isotope-enriched, chemoenzymatically-synthesized, poly-component drug. Angew Chem Int Ed Engl. 2019 Mar 14. doi: 10.1002/anie.201900768. [Epub ahead of print]. Knotts TL, Mousa SA. Anticoagulation in Venous Thromboembolism Prophylaxis in Medically Ill Patients: Potential Impact of NOACs. Am J Cardiovasc Drugs. 2019 Feb 27. doi: 10.1007/s40256-019-00329-5

Anber NH, El-Sebaie A, Darwish N, Mousa S, Shamaa S. Prognostic Value of some Inflammatory Markers in Patients with Lymphoma. Biosci Rep. 2019 Feb 27. pii: BSR20182174. doi: 10.1042/BSR20182174.

Al Jaouni SK, Hussein A, Alghamdi N, Qari M, El Hossary D, Almuhayawi MS, Olwi D, Al-Raddadi R, Harakeh S, Mousa SA. Effects of Phoenix dactylifera Ajwa on Infection, Hospitalization, and Survival among Pediatric Cancer Patients in a University Hospital: A Nonrandomized Controlled Trial. Integr Cancer Ther. 2019 Jan-Dec; 18:1534735419828834

Leith JT, Mousa SA, Hercbergs A, Lin HY, Davis PJ. Radioresistance of cancer cells, integrin αvβ3 and thyroid hormone. Oncotarget. 2018 Dec 11;9(97):37069-37075.

Davis PJ, Tang HY, Hercbergs A, Lin HY, Keating KA, Mousa SA. Bioactivity of Thyroid Hormone Analogs at Cancer Cells. Front Endocrinol (Lausanne). 2018 Dec 4; 9:739.

Abou-El-Naga AM, Mutawa G, El-Sherbiny IM, Mousa SA. Activation of polymeric nanoparticle intracellular targeting overcomes chemodrug resistance in human primary patient breast cancer cells. Int J Nanomedicine. 2018 Nov 29; 13:8153-8164.

Leith JT, Hercbergs A, Kenney S, Mousa SA, Davis PJ. Activation of tumor cell integrin αvβ3 by radiation and reversal of activation by chemically modified tetraiodothyroacetic acid (tetrac). Endocr Res. 2018 Nov; 43(4):215-219.

Atta MS, El-Far AH, Farrag FA, Abdel-Daim MM, Al Jaouni SK, Mousa SA. Thymoquinone Attenuates Cardiomyopathy in Streptozotocin-Treated Diabetic Rats. Oxid Med Cell Longev. 2018 Oct 30; 2018:7845681.

Davis PJ, Mousa SA, Schechter GP. Interfaces of Thyroid Hormone Actions with Blood Coagulation and Thrombosis. Clin Appl Thromb Hemost. 2018 Oct; 24(7):1014-1019.

El-Far AH, Al Jaouni SK, Li W, Mousa SA. Protective Roles of Thymoquinone Nanoformulations: Potential Nanonutraceuticals in Human Diseases. Nutrients. 2018 Sep 25;10(10). pii: E1369.

Shaker A. Mousa, Ph.D. CURRICULUM VITAE Page 17 of 92

Lin HY, Chin YT, Shih YJ, Chen YR, Leinung M, Keating KA, Mousa SA, Davis PJ. In tumor cells, thyroid hormone analogues non-immunologically regulate PD-L1 and PD-1 accumulation that is anti-apoptotic. Oncotarget. 2018 Sep 25; 9(75):34033-34037

Chamcheu JC, Siddiqui IA, Adhami VM, Esnault S, Bharali DJ, Babatunde AS, Adame S, Massey RJ, Wood GS, Longley BJ, Mousa SA, Mukhtar H. Chitosan-based nanoformulated (-)-epigallocatechin-3-gallate (EGCG) modulates human keratinocyte-induced responses and alleviates imiquimod-induced murine psoriasiform dermatitis. Int J Nanomedicine. 2018 Jul 20; 13:4189-4206 Davis PJ, Mousa SA, Lin HY. Tetraiodothyroacetic acid (tetrac), integrin αvβ3 and disabling of immune checkpoint defense. Future Med Chem. 2018 Jul 1; 10(14):1637-1639. Ardawi MM, Rouzi AA, Al-Senani NS, Qari MH, Elsamanoudy AZ, Mousa SA. High Plasma Sphingosine 1-phosphate Levels Predict Osteoporotic Fractures in Postmenopausal Women: The Center of Excellence for Osteoporosis Research Study. J Bone Metab. 2018 May; 25(2):87-98. Ayoub BM, Mowaka S, Safar MM, Ashoush N, Arafa MG, Michel HE, Tadros MM, Elmazar MM, Mousa SA. Repositioning of Omarigliptin as a once-weekly intranasal Anti-parkinsonian Agent. Sci Rep. 2018 Jun 12; 8(1):8959. Lin HY, Mousa SA, Davis PJ. Demonstration of the Receptor Site for Thyroid Hormone on Integrin αvβ3. Methods Mol Biol. 2018; 1801:61-65. Sielaff CM, Mousa SA. Status and future directions in the management of pancreatic cancer: potential impact of nanotechnology. J Cancer Res Clin Oncol. 2018 May 2. doi: 10.1007/s00432-018-2651-3. Leith JT, Hercbergs A, Kenney S, Mousa SA, Davis PJ. Activation of tumor cell integrin αvβ3 by radiation and reversal of activation by chemically modified tetraiodothyroacetic acid (tetrac). Endocr Res. 2018 Apr 3:1-5. El-Far AH, Oyinloye BE, Sepehrimanesh M, Allah MAG, Reidah IA, Shaheen HM, Razeghian-Jahromi I, Alsenosy AEA, Noreldin AE, Al Jaouni SK, Mousa SA. Date Palm (Phoenix dactylifera): Novel Findings and Future Directions for Food and Drug Discovery. Curr Drug Discov Technol. 2018 Mar 19. doi: 10.2174/1570163815666180320111937 Rajabi M, Yalcin M, Mousa SA. Synthesis of new analogs of tetraiodothyroacetic acid (tetrac) as novel angiogenesis inhibitors for treatment of cancer. Bioorg Med Chem Lett. 2018 Apr 15; 28(7):1223-1227 Abd-Rabou AA, Bharali DJ, Mousa SA. Taribavirin and 5-Fluorouracil-Loaded Pegylated-Lipid Nanoparticle Synthesis, p38 Docking, and Antiproliferative Effects on MCF-7 Breast Cancer. Pharm Res. 2018 Feb 27; 35(4):76. Hercbergs A, Mousa SA, Leinung M, Lin HY, Davis PJ. Thyroid Hormone in the Clinic and Breast Cancer. Horm Cancer. 2018 Jun;9(3):139-143

Shaker A. Mousa, Ph.D. CURRICULUM VITAE Page 18 of 92

Hercbergs A, Mousa SA, Davis PJ. Nonthyroidal Illness Syndrome and Thyroid Hormone Actions at Integrin αvβ3. J Clin Endocrinol Metab. 2018 Feb 1. doi: 10.1210/jc.2017-01939. Davis PJ, Leonard JL, Lin HY, Leinung M, Mousa SA. Molecular Basis of Nongenomic Actions of Thyroid Hormone. Vitam Horm. 2018; 106:67-96. El-Far AH, Oyinloye BE, Sepehrimanesh M, Allah MAG, Reidah IA, Shaheen HM, Razeghian-Jahromi I, Alsenosy AEA, Noreldin AE, Al Jaouni SK, Mousa SA. Date Palm (Phoenix dactylifera): Novel Findings and Future Directions for Food and Drug Discovery. Curr Drug Discov Technol. 2018 Mar 19. doi: 10.2174/ 1570163815666180320111937. [Epub ahead of print] PMID: 29557751 Abdel-Daim MM, Eltaysh R, Hassan A, Mousa SA. Lycopene Attenuates Tulathromycin and Diclofenac Sodium-Induced Cardiotoxicity in Mice. Int J Mol Sci. 2018 Jan 24; 19(2). pii: E344. PMID: 29364179 Martínez-Zapata MJ, Mathioudakis AG, Mousa SA, Bauersachs R. Tinzaparin for Long-Term Treatment of Venous Thromboembolism in Patients With Cancer: A Systematic Review and Meta-Analysis. Clin Appl Thromb Hemost. 2018 Mar; 24(2):226-234. PMID: 28288527 Block E, Bechand B, Gundala S, Vattekkatte A, Wang K, Mousa SS, Godugu K, Yalcin M, Mousa SA. Fluorinated Analog NMR s of Organosulfur Compounds from Garlic (Allium sativum): Synthesis, Chemistry and Anti-Angiogenesis and Antithrombotic Studies. Molecules. 2017 Nov 28; 22(12). pii: E2081. PMID: 29182588

Potts JW, Mousa SA. Recent advances in management of autosomal-dominant polycystic kidney disease. Am J Health Syst Pharm. 2017 Dec 1; 74(23):1959-1968. PMID: 29167138 Abdel-Latif MA, El-Far AH, Elbestawy AR, Ghanem R, Mousa SA, Abd El-Hamid HS. Exogenous dietary lysozyme improves the growth performance and gut microbiota in broiler chickens targeting the antioxidant and non-specific immunity mRNA expression. PLoS One. 2017 Oct 23; 12(10):e0185153. PMID: 29059196

Block RC, Holub A, Abdolahi A, Tu XM, Mousa SA, Oda MN. Effects of aspirin in combination with EPA and DHA on HDL-C cholesterol and ApoA1 exchange in individuals with type 2 diabetes mellitus. Prostaglandins Leukot Essent Fatty Acids. 2017 Nov; 126:25-31. PMID: 29031392 Fu L, Li K, Mori D, Hirakane M, Lin L, Grover N, Datta P, Yu Y, Zhao J, Zhang F, Yalcin M, Mousa SA, Dordick JS, Linhardt RJ. Enzymatic Generation of Highly Anticoagulant Bovine Intestinal Heparin. J Med Chem. 2017 Oct 26; 60(20):8673-8679. PMID: 28972371 Gladfelter P, Darwish NHE, Mousa SA. Status and future direction in the management of malignant melanoma. Melanoma Res. 2017 Oct; 27(5):403-410. PMID: 28800028 Rajabi M, Mousa SA. The Role of Angiogenesis in Cancer Treatment. Biomedicines. 2017 Jun 21; 5(2). pii: E34. PMID: 28635679

Shaker A. Mousa, Ph.D. CURRICULUM VITAE Page 19 of 92

Ayoub BM, Mowaka S, Elzanfaly ES, Ashoush N, Elmazar MM, Mousa SA. Pharmacokinetic Evaluation of Empagliflozin in Healthy Egyptian Volunteers Using LC-MS/MS and Comparison with Other Ethnic Populations. Sci Rep. 2017 May 31; 7(1):2583. PMID: 28566743

Muralidharan-Chari V, Kim J, Mousa SA. Reversal of anticoagulant activity of heparin and low molecular weight heparins by poly-l-lysine: A comparative 'in vitro' study versus protamine sulfate. Thromb Res. 2017 Jul; 155:128-130. PMID: 28538195 Elberry MH, Darwish NHE, Mousa SA. Hepatitis C virus management: potential impact of nanotechnology. Virol J. 2017 May 2; 14(1):88. PMID: 28464951 Atta MS, Almadaly EA, El-Far AH, Saleh RM, Assar DH, Al Jaouni SK, Mousa SA. Thymoquinone Defeats Diabetes-Induced Testicular Damage in Rats Targeting Antioxidant, Inflammatory and Aromatase Expression. Int J Mol Sci. 2017 Apr 27; 18(5). pii: E919. PMID: 28448463 Sudha T, Bharali DJ, Yalcin M, Darwish NH, Debreli Coskun M, Keating KA, Lin HY, Davis PJ, Mousa SA. Targeted delivery of paclitaxel and doxorubicin to cancer xenografts via the nanoparticle of Nano-diamino-tetrac. Int J Nanomedicine. 2017 Feb 15; 12:1305-1315. PMID: 28243091

Sudha T, Bharali DJ, Yalcin M, Darwish NH, Coskun MD, Keating KA, Lin HY, Davis PJ, Mousa SA. Targeted delivery of cisplatin to tumor xenografts via the nanoparticle component of Nano-diamino-tetrac. Nanomedicine (Lond). 2017 Feb; 12(3):195-205. PMID: 28102776 Li W, Yalcin M, Lin Q, Ardawi MM, Mousa SA. Self-assembly of green tea catechin derivatives in nanoparticles for oral lycopene delivery. J Control Release 2017 Feb 28; 248:117-124. PMID: 28077264 Sahli ZT, Jo J, Mousa SA, Tarazi FI. Clinical management of restless legs syndrome in end-stage renal disease patients. CNS Spectr. 2017 Feb; 22(1):14-21. PMID: 27702420 Bharali DJ, Sudha T, Cui H, Mian BM, Mousa SA. Anti-CD24 Nano-targeted delivery of docetaxel for the treatment of prostate cancer. Nanomedicine. 2017 Jan; 13(1):263-273. PMID: 27565690 Hsieh MT, Wang LM, Changou CA, Chin YT, Yang YSH, Lai HY, Lee SY, Yang YN, Whang-Peng J, Liu LF, Lin HY, Mousa SA, Davis PJ. Crosstalk between integrin αvβ3 and ERα contributes to thyroid hormone-induced proliferation of ovarian cancer cells. Oncotarget 2017 Apr 11; 8(15):24237-24249. PMID: 27458161 Sudha T, Bharali DJ, Sell S, Darwish NH, Davis PJ, Mousa SA. Nanoparticulate Tetrac Inhibits Growth and Vascularity of Glioblastoma Xenografts. Horm Cancer.doi: 10.1007/s12672-017-0293-6. [Epub ahead of print], 2017. Martínez-Zapata MJ, Mathioudakis AG, Mousa SA, Bauersachs R. Tinzaparin for Long-Term Treatment of Venous Thromboembolism in Patients with Cancer. Clin Appl Thromb Hemost. 1076029617696581. doi: 10.1177/ 1076029617696581, [Epub ahead of print], 2017.

Shaker A. Mousa, Ph.D. CURRICULUM VITAE Page 20 of 92

Sudha T, Bharali DJ, Yalcin M, Darwish NH, Debreli Coskun M, Keating KA, Lin HY, Davis PJ, Mousa SA. Targeted delivery of paclitaxel and doxorubicin to cancer xenografts via the nanoparticle of Nano-diamino-tetrac. Int J Nanomedicine. 12:1305-1315. doi: 10.2147/IJN.S123742, 2017. Leith JT, Davis PJ, Mousa SA, Hercbergs AA. In vitro effects of Tetraiodothyroacetic acid combined with X-irradiation on basal cell carcinoma cells. Cell Cycle 16(4):367-373, 2017. Sudha T, Bharali DJ, Yalcin M, Darwish NH, Coskun MD, Keating KA, Lin HY, Davis PJ, Mousa SA. Targeted delivery of cisplatin to tumor xenografts via the nanoparticle component of Nano-diamino-tetrac. Nanomedicine (Lond). 12(3):195-205, 2017. Li W, Yalcin M, Lin Q, Ardawi MM, Mousa SA. Self-assembly of green tea catechin derivatives in nanoparticles for oral lycopene delivery. J Control Release. 248:117-124, 2017. Bharali DJ, Sudha T, Cui H, Mian BM, Mousa SA. Anti-CD24 Nano-targeted delivery of docetaxel for the treatment of prostate cancer. Nanomedicine. 13(1):263-273, 2017. Srinivasan M, Bharali DJ, Sudha T, Khedr M, Guest I, Sell S, Glinsky GV, Mousa SA. Downregulation of Bmi1 in breast cancer stem cells suppresses tumor growth and proliferation. Oncotarget. doi: 10.18632/oncotarget.16317., [Epub ahead of print], 2017. Abou-ElNaga A, Mutawa G, El-Sherbiny IM, Abd-ElGhaffar H, Allam AA, Ajarem J, Mousa SA. Novel Nano-Therapeutic Approach Actively Targets Human Ovarian Cancer Stem Cells after Xenograft into Nude Mice. Int J Mol Sci. 18(4). pii: E813. doi: 10.3390/ijms18040813, 2017. Acheampong A, Mousa SA. Targeting strategies of cancer stem cells in the management of solid tumors. Journal of Stem Cell Research and Transplantation. 3(1):1023, 2016. Alshaiban A, Muralidharan-Chari V, Nepo A, Mousa SA. Modulation of sickle red blood cell adhesion and its associated changes in biomarkers by sulfated non-anticoagulant heparin derivative. Clinical and Applied Thrombosis and Hemostasis. 22(3):230-238, 2016. Ardawi MS, Badawoud MH, Hassan SM, Rouzi AA, Ardawi JM, AlNosani NM, Qari MH, Mousa SA. Lycopene treatment against loss of bone mass, microarchitecture and strength in relation to regulatory mechanisms in a postmenopausal osteoporosis model. Bone.83: 127-140, 2016. Brady SM, Shapiro L, Mousa SA. Current and future direction in the management of scleroderma. Archives of Dermatological Research. 308(7):461-471, 2016. Darwish NH, Sudha T, Godugu K, Elbaz O, Abdelghaffar HA, Hassan EE, Mousa SA. Acute myeloid leukemia stem cell markers in prognosis and targeted therapy: Potential impact of BMI-1, TIM-3 and CLL-1. Oncotarget. 7 (36):57811-57820, 2016. Abouelnaga A, Mutawa GA, Abdelghaffar H, Sobh M, Hamed S, Mousa SA. Establishment and characterization of primary human ovarian cancer stem cell line (CD44+ve). Journal of Cancer Research Updates. 5(2), 2016.

Shaker A. Mousa, Ph.D. CURRICULUM VITAE Page 21 of 92

Davis PJ, Glinsky GV, Lin HY, Mousa SA. Actions of thyroid hormone analogues on chemokines. Journal of Immunology Research. 3147671, 2016. Della Badia LA, Elshourbagy NA, Mousa SA. Targeting PCSK9 as a promising new mechanism for lowering low-density lipoprotein cholesterol. Pharmacology & Therapeutics; 164: 183-194, 2016. El-Far AH, Shaheen HM, El-Daim MA, Jaouni SKA, Mousa SA. Date palm (phoenix dactylifera): Protection and remedy food. Current Trends in Nutraceuticals. 1(2) 2016. Falcone R, Davis PJ, Stain SC, Mousa SA. Emerging therapies for pancreatic ductal carcinoma. Journal of Solid Tumors. 6(1):65-77, 2016. Hercbergs A, Davis PJ, Lin HY, Mousa SA. Possible contributions of thyroid hormone replacement to specific behaviors of cancer. Biomedicine & Pharmacotherapy. 84: 655-659, 2016. Hsieh MT, Wang LM, Changou CA, Chin YT, Yang YS, Lai HY, Lee SY, Yang YN, Whang-Peng J, Liu LF, Lin HY, Mousa SA, Davis PJ. Crosstalk between integrin αvβ3 and ERα contributes to thyroid hormone-induced proliferation of ovarian cancer cells. Oncotarget. Jul 21. [Epub ahead of print], 2016. Lin HY, Chin YT, Nana AW, Shih YJ, Lai HY, Tang HY, Leinung M, Mousa SA, Davis PJ. Actions of l-thyroxine and Nano-diamino-tetrac (nanotetrac) on PD-L1 in cancer cells. Steroids. 114: 59-67, 2016. Muralidharan-Chari V, *Kim J, Abuawad A, Naeem M, Cui H, Mousa SA. Thymoquinone modulates blood coagulation in vitro via its effects on inflammatory and coagulation pathways. International Journal of Molecular Sciences. 17(4):474, 2016. Muralidharan-Chari V, Kohan HG, Asimakopoulos AG, Sudha T, Sell S, Kannan K, Boroujerdi M, Davis PJ, Mousa SA. Macrovesicle removal of anticancer drugs contributes to drug resistance in human pancreatic cancer cells. Oncotarget. 7(31):50365-50379, 2016. Muralidharan-Chari V, Mousa SA. Heparin neutralize anticoagulant reversal agent. Drugs of the Future. 41(6):341-346, 2016. Rajabi M, Mousa SA. Lipid nanoparticles and their application in nanomedicine. Current Pharmaceutical Biotechnology. 17(8):662-672, 2016. Rajabi M, Sudha T, Darwish NH, Davis PJ, Mousa SA. Synthesis of MR-49, a deiodinated analog of tetraiodothyroacetic acid (tetrac), as a novel pro-angiogenesis modulator. Bioorganic & Medicinal Chemistry Letters. 26 (16):4112-4116, 2016. Sahli ZT, *Jo J, Mousa SA, Tarazi FI. Clinical management of restless legs syndrome in end-stage renal disease patients. CNS Spectrums. 1-8, 2016. Yang YC, Chin YT, Hsieh MT, Lai HY, Ke CC, Crawford DR, Lee OK, Fu E, Mousa SA, Grasso P, Liu LF, Chang HY, Tang HY, Lin HY, Davis PJ. Novel leptin OB3 peptide-induced signaling and progression in thyroid cancers: Comparison with leptin. Oncotarget. 7(19):27641-27654, 2016.

Shaker A. Mousa, Ph.D. CURRICULUM VITAE Page 22 of 92

Radak D, Katsiki N, Resanovic I, Jovanovic A, Sudar-Milovanovic E, Zafirovic S, Mousa SA, Isenovic ER. Apoptosis and acute brain ischemia in ischemic stroke. Current Vascular Pharmacology. [Epub ahead of print], Nov. 2016. Zappa C, Mousa SA. Non-small cell lung cancer: Current treatment and future advances. Translational Lung Cancer Research. 5(3):288-300, 2016. Zheng Y, Miao J, Zhang F, Cai C, Koh A, Simmons TJ, Mousa SA, Linhardt RJ. Surface modification of a polyethylene film for anticoagulant and anti-microbial catheter. Reactive and Functional Polymers. 100:142-150, 2016. El-Fawal HAN, Rembisz R, Alobaidi R, Mousa SA. Chemotherapy-mediated pain and peripheral neuropathy: impact of oxidative stress and inflammation. In: Oxidative Stress and Antioxidant Protection. John Wiley & Sons, Inc, pp 367-388. DOI:10.1002/9781118832431.ch24, 2016 Hariri W, Sudha T, Bharali DJ, Cui H, Mousa SA. Nano-Targeted Delivery of Toremifene, an Estrogen Receptor-alpha Blocker in Prostate Cancer. Pharmaceutical Research 32:2764-2774, 2016.

Alshaiban A, Muralidharan-Chari V, Nepo A, Mousa SA. Modulation of Sickle Red Blood Cell Adhesion and its Associated Changes in Biomarkers by Sulfated Non-anticoagulant Heparin Derivative. Clinical and Applied Thrombosis/Hemostasis 22:230-238, 2015.

Al-Sofiani ME, Jammah A, Racz M, Khawaja RA, Hasanato R, El-Fawal HA, Mousa SA, Mason DL. Effect of Vitamin D Supplementation on Glucose Control and Inflammatory Response in Type II Diabetes: A Double Blind, Randomized Clinical Trial. International Journal of Endocrinology and Metabolism 13: e22604, 2015. Alyahya R, Sudha T, Racz M, Stain SC, Mousa SA. Anti-metastasis efficacy and safety of non-anticoagulant heparin derivative versus low molecular weight heparin in surgical pancreatic cancer models. International Journal of Oncology 46:1225-1231, 2015. Alzahri MS, Mousa SA, Almomen AM, Hasanato RM, Polimeni JM, Racz MJ. Lactate dehydrogenase as a biomarker for early renal damage in patients with sickle cell disease. Saudi Journal of Kidney Diseases and Transplantation 26:1161-1168, 2015. Bani-Jaber A, Cui H, Elsaid A, Yalcin M, Sudha T, Mousa SA. Pegylated solid lipid nanoparticles reconstituted from high-density lipoprotein components for hepatic targeting. Science Letters Journal 4, 2015. Belousova V, Abd-Rabou AA, Mousa SA. Recent advances and future directions in the management of hepatitis C infections. Pharmacology & Therapeutics 145:92-102, 2015. Block RC, Abdolahi A, Tu X, Georas SN, Brenna JT, Phipps RP, Lawrence P, Mousa SA. The effects of aspirin on platelet function and lysophosphatidic acids depend on plasma concentrations of EPA and DHA. Prostaglandins Leukotrienes and Essential Fatty Acids 96:17-24, 2015. Darwish NHE, Mousa SA. Extrinsic Targeting Strategies against Acute Myeloid Leukemic Stem

Shaker A. Mousa, Ph.D. CURRICULUM VITAE Page 23 of 92

Cells. Integrative Cancer Science and Therapeutics 2. DOI 10.15761/ICST.1000134, 2015. Darwish NHE, Mousa SA. Intrinsic Targeting Strategies against Acute Myeloid Leukemic Stem Cells. Integrative Cancer Science and Therapeutics 2. DOI: 10.15761/ICST.1000135, 2015. Davis PJ, Glinsky GV, Lin HY, Leith JT, Hercbergs A, Tang HY, Ashur-Fabian O, Incerpi S, Mousa SA. Cancer Cell Gene Expression Modulated from Plasma Membrane Integrin alphavbeta3 by Thyroid Hormone and Nanoparticulate Tetrac. Front Endocrinol (Lausanne) 5:240, 2015. Davis PJ, Incerpi S, Lin HY, Tang HY, Sudha T, Mousa SA. Thyroid hormone and P-glycoprotein in tumor cells. BioMed Research International 2015:168427, 2015. Davis PJ, Sudha T, Lin HY, Mousa SA. Thyroid Hormone, Hormone Analogs, and Angiogenesis. Comprehensive Physiology 6:353-362, 2015. Ebright J, Mousa SA. Oral Anticoagulants and Status of Antidotes for the Reversal of Bleeding Risk. Clinical and Applied Thrombosis-Hemostasis 21:105-114, 2015. Hercbergs A, Johnson RE, Ashur-Fabian O, Garfield DH, Davis PJ, Mousa SA. Medically Induced Euthyroid Hypothyroxinemia May Extend Survival in Compassionate Need Cancer Patients: An Observational Study. The Oncologist 20:72-76, 2015. Hug KA, Anthony L, Eldeiry D, Benson J, Wheeler E, Mousa S, Shi B. Expression and Tissue Distribution of MicroRNA-21 in Malignant and Benign Breast Tissues. Anticancer Research 35:3175-3183, 2015. Lin HY, Glinsky GV, Mousa SA, Davis PJ. Thyroid hormone and anti-apoptosis in tumor cells. Oncotarget 6:14735-14743, 2015. Obradovic M, Zafirovic S, Jovanovic A, Milovanovic ES, Mousa SA, Labudovic-Borovic M, Isenovic ER. Effects of 17 beta-estradiol on cardiac Na+/K+-ATPase in high fat diet fed rats. Molecular and Cellular Endocrinology 416:46-56, 2015. Rajabi M, Hossaini Z, Khalilzadeh MA, Datta S, Halder M, Mousa SA. Synthesis of a new class of furo 3, 2-c coumarins and its anticancer activity. Journal of Photochemistry and Photobiology B-Biology 148:66-72, 2015. Safer AM, Afzal M, Hanafy N, Mousa S. Green tea extract therapy diminishes hepatic fibrosis mediated by dual exposure to carbon tetrachloride and ethanol: A histopathological study. Experimental and Therapeutic Medicine 9:787-794, 2015. Safer A-M, Sen A, Hanafy NA, Mousa SA. Quantification of the Healing Effect in Hepatic Fibrosis Induced by Chitosan Nano-Encapsulated Green Tea in Rat Model. Journal of Nanoscience and Nanotechnology 15:9918-9924, 2015. Safer A-MA, Hanafy NA, Bharali DJ, Cui H, Mousa SA. Effect of Green Tea Extract Encapsulated Into Chitosan Nanoparticles on Hepatic Fibrosis Collagen Fibers Assessed by Atomic Force Microscopy in Rat Hepatic Fibrosis Model. Journal of Nanoscience and Nanotechnology 15:6452-

Shaker A. Mousa, Ph.D. CURRICULUM VITAE Page 24 of 92

6459, 2015. Shirode AB, Bharali DJ, Nallanthighal S, Coon JK, Mousa SA, Reliene R. Nanoencapsulation of pomegranate bioactive compounds for breast cancer chemoprevention. International Journal of Nanomedicine 10:475-484, 2015. Srinivasan M, Rajabi M, Mousa SA. Multifunctional Nanomaterials and Their Applications in Drug Delivery and Cancer Therapy. Nanomaterials 5:1690-1703, 2015. Stanimirovic J, Obradovic M, Zafirovic S, Resanovic I, Bogdanovic N, Gluvic Z, Mousa SA, Isenovic ER. Effects of altered hepatic lipid metabolism on regulation of hepatic iNOS. Clinical Lipidology 10:167-175, 2015. Vogel R, Hussein EA, Mousa SA. Stem Cells in the Management of Heart Failure: What Have We Learned from Clinical Trials? Expert Review of Cardiovascular Therapy; 13(1):75-83, 2015. Tarazi FI, Sahli ZT, *Pleskow J, Mousa SA. Asperger's syndrome: diagnosis, comorbidity and therapy. Expert Review of Neurotherapeutics 15:281-293, 2015. Trpkovic A, Resanovic I, Stanimirovic J, Radak D, Mousa SA, Cenic-Milosevic D, Jevremovic D, Isenovic ER. Oxidized low-density lipoprotein as a biomarker of cardiovascular diseases. Critical Reviews in Clinical Laboratory Sciences 52:70-85, 2015. Vogel R, Hussein EA, Mousa SA. Stem cells in the management of heart failure: what have we learned from clinical trials? Expert Review of Cardiovascular Therapy 13:75-83, 2015. Yasin BR, El-Fawal HA, Mousa SA. Date (Phoenix dactylifera) Polyphenolics and Other Bioactive Compounds: A Traditional Islamic Remedy's Potential in Prevention of Cell Damage, Cancer Therapeutics and beyond. International Journal of Molecular Sciences 16:30075-30090, 2015. Alyahya R, Sudha T, Racz M, Stain SC, Mousa SA. Anti-metastasis efficacy and safety of non-anticoagulant heparin derivative versus low molecular weight heparin in surgical pancreatic cancer models. International Journal of Oncology. 46(3):1225-1231, 2015. Belousova V, Abd-Rabou AA, Mousa SA. Recent advances and future directions in the management of hepatitis C infections. Pharmacology & Therapeutics. 145C:92-102, 2015. Block RC, Abdolahi A, Tu X, Georas SN, Brenna JT, Phipps RP, Lawrence P, Mousa SA. The effects of aspirin on platelet function and lysophosphatidic acids depend on plasma concentrations of EPA and DHA. Prostaglandins, Leukotrienes, and Essential Fatty Acids. pii: S0952-3278(14) 00207-5, 2014. Abdolahi A, Georas SN, Brenna JT, Cai X, Thevenet-Morrison K, Phipps RP, Lawrence P, Mousa SA, Block RC. The effects of aspirin and fish oil consumption on lysophosphatidylcholines and lysophosphatidic acids and their correlates with platelet aggregation in adults with diabetes mellitus. Prostaglandins, Leukotrienes, and Essential Fatty Acids. 90(2-3):61-68, 2014.

Shaker A. Mousa, Ph.D. CURRICULUM VITAE Page 25 of 92

Bombard DS, 2nd, Mousa SA. Mayer-Rokitansky-Kuster-Hauser syndrome: complications, diagnosis and possible treatment options: a review. Gynecological Endocrinology. 30(9):618-623, 2014. Davis PJ, Glinsky GV, Lin HY, Leith JT, Hercbergs A, Tang HY, Ashur-Fabian O, Incerpi S, Mousa SA. Cancer cell gene expression modulated from plasma membrane integrin alphavbeta3 by thyroid hormone and nanoparticulate tetrac. Frontiers in Endocrinology. 5: 240, 2014. Trpkovic A, Resanovic I, Stanimirovic J, Radak D, Mousa SA, Cenic-Milosevic D, Jevremovic D, Isenovic ER. Oxidized low-density lipoprotein as a biomarker of cardiovascular diseases. Crit Rev Clin Lab Sci. 24: 1-16, 2014. El-Sayyad HI, Khalifa SA, El-Sayyad FI, Mousa SA, Mohammed EA. Analysis of fine structure and biochemical changes of retina during aging of Wistar albino rats. Clin Experiment Ophthalmol. 42(2):169-81, 2014. Davis PJ, Lin HY, Sudha T, Yalcin M, Tang HY, Hercbergs A, Leith JT, Luidens MK, Ashur-Fabian O, Incerpi S, Mousa SA. Nanotetrac targets integrin alphavbeta3 on tumor cells to disorder cell defense pathways and block angiogenesis. OncoTargets and Therapy. 7: 1619-1624, 2014. Khan N, Bharali DJ, Adhami VM, Siddiqui IA, Cui H, Shabana SM, Mousa SA, Mukhtar H. Oral administration of naturally occurring chitosan-based Nanoformulated green tea polyphenol EGCG effectively inhibits prostate cancer cell growth in a xenograft model. Carcinogenesis. 35(2):415-423, 2014. Mousa SA, Lin HY, Tang HY, Hercbergs A, Luidens MK, Davis PJ. Modulation of angiogenesis by thyroid hormone and hormone analogues: implications for cancer management. Angiogenesis. 17(3): 463-469, 2014. Siddiqui IA, Bharali DJ, Nihal M, Adhami VM, Khan N, Chamcheu JC, Khan MI, Shabana S, Mousa SA, Mukhtar H. Excellent anti-proliferative and pro-apoptotic effects of (-)-epigallocatechin-3-gallate encapsulated in chitosan nanoparticles on human melanoma cell growth both in vitro and in vivo. Nanomedicine: Nanotechnology, Biology, and Medicine. 10(8):1619-1626, 2014. Sudha T, Yalcin M, Lin HY, Elmetwally AM, Nazeer T, Arumugam T, Phillips P, Mousa SA. Suppression of pancreatic cancer by sulfated non-anticoagulant low molecular weight heparin. Cancer Letters. 350 (1-2):25-33, 2014. Sweezy T, Mousa SA. Genotype-guided use of oral antithrombotic therapy: a pharmacoeconomic perspective. Personalized Medicine; 11(2):223-235, 2014. Tarazi FI, Sahli ZT, *Wolny M, Mousa SA. Emerging Therapies for Parkinson's disease: From Bench to Bedside. Pharmacology & Therapeutics; 144(2):123-133, 2014. Yaturu S, Dier E, Cui H, Mousa, S. Aspirin resistance in young men with Type 2 diabetes. Journal of Diabetes Mellitus: 4:72-76, 2014. Bharali DJ, Armstrong D, Mousa SA, Hybrid polymeric nanoparticles: potential candidate for opthalmic delivery. Methods in molecular biology (Clifton, N.J.); 1028: 279-286, 2013.

Shaker A. Mousa, Ph.D. CURRICULUM VITAE Page 26 of 92

Bharali DJ, Mousa SA. Relevance of nanotechnology in modulating oxidative stress: an overview. Methods in molecular biology (Clifton, N.J.); 1028: 289-292, 2013. Bharali DJ, Yalcin M, Davis PJ, Mousa SA. Tetraiodothyroacetic acid-conjugated PLGA nanoparticles: a nanomedicine approach to treat drug-resistant breast cancer. Nanomedicine (London, England). Feb 28 2013. Davis PJ, Glinsky GV, Lin HY, et al. Molecular mechanisms of actions of formulations of the thyroid hormone analogue, tetrac, on the inflammatory response. Endocrine research; 38(2): 112-118, 2013. Debourdeau P, Farge D, Beckers M, et al. International clinical practice guidelines for the treatment and prophylaxis of thrombosis associated with central venous catheters in patients with cancer. Journal of thrombosis and haemostasis: JTH.; 11(1): 71-80, Jan 2013. El-Sayyad HI, Khalifa SA, El-Sayyad FI, Mousa SA, Mohammed EA. Analysis of fine structure and biochemical changes of retina during aging of Wistar albino rats. Clinical & experimental opthalmology. Apr 22, 2013. Farge D, Debourdeau P, Beckers M, et al. International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. Journal of thrombosis and haemostasis: JTH.; 11(1): 56-70, Jan 2013. Feng X, Tonnesen MG, Mousa SA, Clark RA. Fibrin and collagen differentially but synergistically regulate sprout angiogensis of human dermal microvascular endothelial cells in 3-dimensional matrix. International journal of cell biology.: 231279, 2013. Khushnud T, Mousa SA. Potential Role of Naturally Derived Polyphemols and Their Nanotechnology Delivery in Cancer. Molecular biotechnology. Feb 1 2013. Lin HY, Su YF, Hsieh MT, et al. Nuclear monomeric integrin alpha v in cancer cells is a coactivator regulated by thyroid hormone. FASEB journal: official publication of the Federation of American Societies for Experimental Biology. May 2 2013. Lugade AA, Bharali DJ, Pradhan V, Elkin G Mousa SA, Thanavala Y. Single low-does unadjuvanted HBsAg nanoparticle vaccine elicits robust, durable immunity. Nanomedicine: nanotechnology, biology, and medicine. Mar 27 2013. Rebbaa A, Patil G, Yalcin M, Sudha T, Mousa SA. OT-404, multi-targeted anti-cancer agent affecting tumor proliferation, chemo-resistance, and angiogenesis. Cancer letters.; 332(1): 55-62, May 10 2013. Thomas M, Mousa SS, Mousa SA. Comparative effectiveness of aflibercept for the treatment of patients with neovascular age-related macular degeneration. Clinical opthalmology (Auckland, N.Z.).;7:495-501, 2013. Yalcin M, Lin HY, Sudha T, Mousa SA. Response of human pancreatic cancer cell xenografts to tetraiodothyroacetic acid nanoparticles. Hormones & cancer.; 4(3): 176-185, Jun 2013.

Shaker A. Mousa, Ph.D. CURRICULUM VITAE Page 27 of 92

Pai, M. P., Chen, W. Z., Garba, A., Cui, H., Zaffo, B., El-Fawal, H. A., and Mousa, S. A. Effects of obesity and sex on antimicrobial pharmacokinetics and acute kidney injury: validation of a preclinical model, Antimicrob Agents Chemother 57, 716-722, 2013.

Mousa SA. Comparative Pharmacodynamic Assessment of the Antiangiogenesis Activity of Heparin and Low-Molecular-Weight Heparin Fractions: Structure-Function Relationship. Clin Appl Thromb Hemost. 19(1):48-54, 2013.

Yang C.W., Mousa S.A. The effect of red yeast rice (Monascus purpureus) in dyslipidemia and other disorders. Complementary therapies in medicine. Dec; 20(6): 466-474, 2012. Safer, A. M., Afzal, M., Nomani, A., Sosamma, O., and Mousa, S. A. Curative propensity of green tea extract towards hepatic fibrosis induced by CCl(4): A histopathological study, Exp Ther Med 3, 781-786, 2012. Stanekzai, J., Isenovic, E. R., and Mousa, S. A. Treatment options for diabetes: potential role of stem cells, Diabetes Res Clin Pract 98, 361-368, 2012.

Sudha T, Phillips P, Kanaan C, Linhardt RJ, Borsig L, Mousa SA. Inhibitory effect of non-anticoagulant heparin (S-NACH) on pancreatic cancer cell adhesion and metastasis in human umbilical cord vessel segment and in mouse model. Clin Exp Metastasis 29, 431-439, 2012.

Aman W, Mousa S, Shiha G, Mousa SA. Current Status and future directions in the management of chronic hepatitis C. Virol J. 9(1):57, 2012.

Pabani S, Mousa SA. Current and future treatment of pulmonary hypertension. Drugs Today (Barc). 48(2):133-47, 2012.

Rogers NJ, Mousa SA. The shortcomings of clinical trials assessing the efficacy of probiotics in irritable bowel syndrome. J Altern Complement Med. 18 (2):112-9, 2012.

Swanson D, Block R, Mousa SA. Omega-3 Fatty Acids EPA and DHA: Health Benefits Throughout Life. Adv Nutr. 3(1):1-7, 2012.

Mousa SA. The Future of Anticoagulant Therapy. Cardiovasc Ther 2012; 30, 255-256, 2012.

Miao J, Zhang F, Takieddin M, Mousa S, Linhardt RJ. Adsorption of Doxorubicin on Poly (methyl methacrylate)-Chitosan-Heparin-Coated Activated Carbon Beads. Langmuir. 28(9):4396-403, 2012.

Aljada A, Mousa SA. Metformin and neoplasia: implications and indications. Pharmacol Ther. 133(1): 108-15, 2012.

Mousa SA, Yalcin M, Bharali DJ, Meng R, Tang HY, Lin HY, Davis FB, Davis PJ. Tetraiodothyroacetic acid and its nanoformulation inhibit thyroid hormone stimulation of non-small cell lung cancer cells in vitro and its growth in xenografts. Lung Cancer 76, 39-45, 2012.

Shaker A. Mousa, Ph.D. CURRICULUM VITAE Page 28 of 92

Qari MH, Dier U, Mousa SA. Biomarkers of Inflammation, Growth Factor, and Coagulation Activation in Patients with Sickle Cell Disease. Clin Appl Thromb Hemost. 18, 195-200, 2012.

Ardawi, M. S., Rouzi, A. A., Al-Sibiani, S. A., Al-Senani, N. S., Qari, M. H., and Mousa, S. A. High serum sclerostin predicts the occurrence of osteoporotic fractures in postmenopausal women: the Center of Excellence for Osteoporosis Research Study, J Bone Miner Res 27, 2592-2602, 2012. Beidoe, G., and Mousa, S.A. Current primary open-angle glaucoma treatments and future directions, Clin Ophthalmol 6, 1699-1707, 2012. Block, R. C., Dier, U., Calderonartero, P., Shearer, G. C., Kakinami, L., Larson, M. K., Harris, W. S., Georas, S., and Mousa, S. A. The Effects of EPA+DHA and Aspirin on Inflammatory Cytokines and Angiogenesis Factors, World J Cardiovasc Dis 2, 14-19, 2012. Bridoux, A., Mousa, S. A., and Samama, M. M. Pro- and anti-angiogenic agents, J Mal Vasc 37, 132-139, 2012. Calderon Artero, P., Champagne, C., Garigen, S., Mousa, S., and Block, R. Fish oil metabolites: translating promising findings from bench to bedside to reduce cardiovascular disease, J Glycomics Lipidomics 2(1). pii: 1000106, 2012. Farge-Bancel, D., Debourdeau, P., Beckers, M., Baglin, C., Bauersachs, R., Brenner, B., Brilhante, D., Falanga, A., Gerotziafas, G., Kakkar, A. K., Khorana, A. A., Lecumberri, R., Mandala, M., Marty, M., Monreal, M., Mousa, S., Nissim, H., Noble, S., Pabinger, I., Prins, M., Qari, M., Streiff, M., Bounameaux, H., Buller, H. R., and Methodologic, I. W. G. I. Guidelines for antithrombotics in cancer patients, Thromb Res 129, S194-S194, 2012. Jayaraman, M. S., Bharali, D. J., Sudha, T., and Mousa, S. A. Nano chitosan peptide as a potential therapeutic carrier for retinal delivery to treat age-related macular degeneration, Mol Vis 18, 2300-2308, 2012. Lanza, D., Ma, J., Guest, I., Uk-Lim, C., Glinskii, A., Glinsky, G., Bharali, D., Mousa, S., and Sell, S. A pre-clinical breast cancer stem cell model based on MMTV-PyMT Mice for testing nanoparticle directed therapy, Tumor Biol 33, 62-62, 2012. Lin, H. Y., Tang, H. Y., Davis, F. B., Mousa, S. A., Incerpi, S., Luidens, M. K., Meng, R., and Davis, P. J. Nongenomic regulation by thyroid hormone of plasma membrane ion and small molecule pumps, Discov Med 14, 199-206, 2012.

Swanson D, Block R, Mousa SA: Omega-3 Fatty Acids Eicosahexaenoic acid and Docosahexaenoic acid: Health Benefits. Advances In Nutrition. 3(1):1-7, 2012. Yang CW, Mousa SA. The Effect of Red Yeast Rice (Monascus Purpureus). J. Complimentary Ther Med 20, 466-474, 2012. Pabani S, Mousa SA: Current and Future Treatment of Pulmonary Hypertension. Drugs Today (Barc). Feb; 48(2):133-47, 2012.

Shaker A. Mousa, Ph.D. CURRICULUM VITAE Page 29 of 92

Rogers NJ, Mousa SA: The Shortcomings of Clinical Trials Assessing the Efficacy of Probiotics in Irritable Bowel Syndrome. J Altern Complement Med. Feb; 18(2):112-9, 2012.

Meng R, Tang HY, Westfall J, London D, Cao JH, Mousa SA, Luidens M, Hercbergs A, Davis FB, Davis PJ, Lin HY. Crosstalk between integrin αvβ3 and estrogen receptor-α is involved in thyroid hormone-induced proliferation in human lung carcinoma cells. PLoS One. 6(11): e27547, 2011.

Haidara M, Mikhailidis DP, Yassin HZ, Dobutovic B, Smiljanic KT, Soskic S, Mousa SA, Rizzo M, Isenovic ER. Evaluation of the possible contribution of antioxidants administration in metabolic syndrome. Curr Pharm Des. 17(33):3699-712, 2011.

Xu Y, Masuko S, Takieddin M, Xu H, Liu R, Jing J, Mousa SA, Linhardt RJ, Liu J. Chemoenzymatic synthesis of homogeneous ultralow molecular weight heparins. Science. 334(6055):498-501, 2011.

Lin HY, Davis FB, Luidens MK, Mousa SA, Cao JH, Zhou M, Davis PJ. Molecular basis for certain neuroprotective effects of thyroid hormone. Front Mol Neurosci. 4:29, 2011.

Golub N, Geba D, Mousa SA, Williams G, Block RC. Greasing the wheels of managing overweight and obesity with omega-3 fatty acids. Med Hypotheses. 77(6):1114-20, 2011.

Alhaidar A, Abdel Gader AG, Mousa SA. The antiplatelet activity of camel urine. J Altern Complement Med. 17(9):803-8, 2011.

Ramli J, CalderonArtero P, Block RC, Mousa SA. Novel therapeutic targets for preserving a healthy endothelium: strategies for reducing the risk of vascular and cardiovascular disease. Cardiol J. 18(4): 352-63, 2011.

El-Sayyad HI, El-Sherbiny MA, Sobh MA, Abou-El-Naga AM, Ibrahim MA, Mousa SA. Protective effects of Morus alba leaves extract on ocular functions of pups from diabetic and hypercholesterolemic mother rats. Int J Biol Sci. 7(6):715-28, 2011.

Yang B, Weyers A, Baik JY, Sterner E, Sharfstein S, Mousa SA, Zhang F, Dordick JS, Linhardt RJ. Ultra-performance ion-pairing liquid chromatography with on-line electrospray ion trap mass spectrometry for heparin disaccharide analysis. Anal Biochem. 415(1):59-66, 2011.

Lin HY, Cody V, Davis FB, Hercbergs AA, Luidens MK, Mousa SA, Davis PJ. Identification and functions of the plasma membrane receptor for thyroid hormone analogues. Discov Med. 11(59):337-47, 2011.

Laurenzo D, Mousa SA. Mechanisms of drug resistance in Mycobacterium tuberculosis and status of rapid molecular diagnostic testing. Acta Trop. 119(1):5-10, 2011.

Wang Z, Yang B, Zhang Z, Ly M, Takieddin M, Mousa S, Liu J, Dordick JS, Linhardt RJ. Control of the heparosan N-deacetylation leads to an improved bioengineered heparin. Appl Microbiol Biotechnol. 91(1):91-9, 2011.

Shaker A. Mousa, Ph.D. CURRICULUM VITAE Page 30 of 92

Clayton S, Mousa SA. Therapeutics formulated to target cancer stem cells: Is it in our future? Cancer Cell Int. 11:7, 2011.

Beaudet JM, Weyers A, Solakyildirim K, Yang B, Takieddin M, Mousa S, Zhang F, Linhardt RJ. Impact of autoclave sterilization on the activity and structure of formulated heparin. J Pharm Sci. 100(8):3396-404, 2011.

Bridoux A, Khan RA, Chen C, Chevé G, Cui H, Dyskin E, Yasri A, Mousa SA. Design, synthesis, and biological evaluation of bifunctional thyrointegrin inhibitors: new anti-angiogenesis analogs. J Enzyme Inhib Med Chem. 26(6):871-82, 2011.

Phillips PG, Yalcin M, Cui H, Abdel-Nabi H, Sajjad M, Bernacki R, Veith J, Mousa SA. Increased tumor uptake of chemotherapeutics and improved chemoresponse by novel non-anticoagulant low molecular weight heparin. Anticancer Res. Feb; 31(2):411-9, 2011.

Davis PJ, Lin HY, Mousa SA, Luidens MK, Hercbergs AA, Wehling M, Davis FB. Overlapping nongenomic and genomic actions of thyroid hormone and steroids. Steroids. Aug; 76(9):829-33, 2011.

Lin HY, Landersdorfer CB, London D, Meng R, Lim CU, Lin C, Lin S, Tang HY, Brown D, Van Scoy B, Kulawy R, Queimado L, Drusano GL, Louie A, Davis FB, Mousa SA, Davis PJ. Pharmacodynamic modeling of anti-cancer activity of tetraiodothyroacetic acid in a perfused cell culture system. PLoS Comput Biol. Feb 3; 7(2):e1001073, 2011.

Davis PJ, Davis FB, Mousa SA, Luidens MK, Lin HY. Membrane receptor for thyroid hormone: physiologic and pharmacologic implications. Annu Rev Pharmacol Toxicol. Feb 10; 51:99-115, 2011.

Bharali DJ, Siddiqui IA, Adhami VM , Chamcheu JC, Aldahmash AM, Mukhtar H, Mousa SA: Nanoparticle Delivery of Natural Products in the Prevention and Treatment of Cancers: Current Status and Future Prospects. Cancers (Basel). Oct 26;3(4):4024-45, 2011.

Lin HY, Davis FB, Luidens MK, Mousa SA, Cao JH, Zhou M, Davis PJ: Molecular basis for certain neuroprotective effects of thyroid hormone. Front Mol Neurosci.; 4: 29. Epub 2011 Oct 14, 2011. Mousa SA, Manna M: Differences among Unfractionated Heparin and Low Molecular Weight Heparins: Impact in Patients with Renal Impairment. Editors: D. E. Piyathilake, Rh. Liang, pp., Nova Science Publishers, Inc. Chapter VIII. In: Heparin: Properties, Uses and Side Effects, 2011. Golub N, Geba D, Mousa SA, Williams G, Block RC. Greasing the wheels of managing overweight and obesity with omega-3 fatty acids. Med Hypotheses. Dec; 77(6):1114-20, 2011.

Aljada A, Mousa SA: Metformin and neoplasia: Implications and indications. Pharmacol Ther. Sep 6. [Epub ahead of print], 2011.

Qari MH, Dier U, Mousa SA. Biomarkers of Inflammation, Growth Factor, and Coagulation Activation in Patients with Sickle Cell Disease. Clin Appl Thromb Hemost. Sep 23. [Epub ahead of print], 2011.

Shaker A. Mousa, Ph.D. CURRICULUM VITAE Page 31 of 92

Ramli J, CalderonArtero P, Block RC, Mousa SA: Novel therapeutic targets for preserving a healthy endothelium: strategies for reducing the risk of vascular and cardiovascular disease. Cardiol J.; 18(4):352-63, 2011.

Mousa SA, Bharali DJ: Nanotechnology-Based Detection and Targeted Therapy in Cancer: Nano-Bio Paradigms and Applications. Cancers 3, 2888-2903; doi: 10.3390 / cancers 3032888, 2011. Davis PJ, Davis FB, Mousa SA, Luidens MK, Lin HY. Membrane receptor for Thyroid hormone: physiologic and pharmacologic implications. Annu Rev Pharmacol Toxicol.; 51:99-115. PubMed PMID: 20868274, 2011. Davis PJ, Lin HY, Mousa SA, Luidens MK, Hercbergs AA, Wehling M, Davis FB. Overlapping nongenomic and genomic actions of thyroid hormone and steroids. Steroids. Feb 25. [Epub ahead of print] PubMed PMID: 21354437, 2011. Bharali DJ, Mousa SA. Emerging nanomedicine for early cancer detection and improved treatment: current perspective and future promise. Pharmacol Ther. Nov; 128(2):324-35, 2010. Trpkovic A, Stokic E, Radak D, Mousa S, Mikhailidis DP, Isenovic ER. Chronic hepatitis C, insulin resistance and vascular disease. Curr Pharm Des.; 16(34):3823-9. PubMed PMID: 21128893, 2010.

Aljada A, Dong L, Mousa SA. Sirtuin-targeting drugs: Mechanisms of action and potential therapeutic applications. Curr Opin Investig Drugs. Oct; 11(10):1158-68, 2010.

Mousa SA, Al Momen A, Al Sayegh F, Al Jaouni S, Nasrullah Z, Al Saeed H, Alabdullatif A, Al Sayegh M, Al Zahrani H, Hegazi M, Al Mohamadi A, Alsulaiman A, Omer A, Al Kindi S, Tarawa A, Al Othman F, Qari M. Management of painful vaso-occlusive crisis of sickle-cell anemia: consensus opinion. Clin Appl Thromb Hemost. ; 16(4):365-76, Aug 2010.

Bridoux A, Cui H, Dyskin E, Schmitzer AR, Yalcin M, Mousa SA. Semi-synthesis and pharmacological activities of thyroxine analogs: Development of new angiogenesis modulators. Bioorg Med Chem Lett. 2010 Jun 1; 20(11):3394-8. Epub 2010 Apr 11. Erratum in: Bioorg Med Chem Lett. Sep 15; 20(18):5585, 2010.

Mousa SA, Qari MH. Diagnosis and management of sickle cell disorders. Methods Mol Biol; 663:291-307. Review. PubMed PMID: 20617425, 2010. Mousa SA. Pharmacogenomics in thrombosis. Methods Mol Biol; 663:277-89. Review. PubMed PMID: 20617424, 2010. Mousa SA. Adhesion molecules: potential therapeutic and diagnostic implications. Methods Mol Biol; 663:261-76. PubMed PMID: 20617423, 2010. Amirkhosravi A, Mousa SA, Amaya M, Meyer T, Davila M, Robson T, Francis JL. Assessment of anti-metastatic effects of anticoagulant and antiplatelet agents using animal models of experimental lung metastasis. Methods Mol Biol; 663:241-59. PubMed PMID: 20617422, 2010.

Shaker A. Mousa, Ph.D. CURRICULUM VITAE Page 32 of 92

Mousa SA. Antithrombotic effects of naturally derived products on coagulation and platelet function. Methods Mol Biol; 663:229-40. Review. PubMed PMID: 20617421, 2010. Mousa SA, Jeske WP, Fareed J. Prasugrel: a novel platelet ADP P2Y (12) receptor antagonist. Methods Mol Biol; 663:221-8. Review. PubMed PMID: 20617420, 2010. Mousa SA. Antiplatelet therapies: drug interactions in the management of vascular disorders. Methods Mol Biol; 663:203-19. Review. PubMed PMID: 20617419, 2010. Mousa SA. Oral direct factor Xa inhibitors, with special emphasis on rivaroxaban. Methods Mol Biol; 663:181-201. Review. PubMed PMID: 20617418, 2010. Mousa SA. Novel anticoagulant therapy: principle and practice. Methods Mol Biol; 663:157-79. Review. PubMed PMID: 20617417, 2010. Mousa SA. Heparin and low-molecular weight heparins in thrombosis and beyond. Methods Mol Biol; 663:109-32. Review. PubMed PMID: 20617415, 2010. Mousa SA. In vivo models for the evaluation of antithrombotic and thrombolytic. Methods Mol Biol; 663:29-107. PubMed PMID: 20617414, 2010. Mousa SA. In vitro methods of evaluating antithrombotic and thrombolytic. Methods Mol Biol; 663:1-28. PubMed PMID: 20617413, 2010. Aderinwale OG, Ernst HW, Mousa SA. Current therapies and new strategies for the management of Alzheimer's disease. Am J Alzheimer’s Dis Other Demen. 2010 Aug; 25(5):414-24. Epub Jul 2. Review. PubMed PMID: 20601643, 2010. Mousa SA, Al Momen A, Al Sayegh F, Al Jaouni S, Nasrullah Z, Al Saeed H, Alabdullatif A, Al Sayegh M, Al Zahrani H, Hegazi M, Al Mohamadi A, Alsulaiman A, Omer A, Al Kindi S, Tarawa A, Al Othman F, Qari M. Management of painful vaso-occlusive crisis of sickle-cell anemia: consensus opinion. Clin Appl Thromb Hemost.; 16(4):365-76. Epub 2010 Jun 7. Review. PubMed PMID: 20530056, Aug 2010. Bridoux A, Cui H, Dyskin E, Schmitzer AR, Yalcin M, Mousa SA. Semi synthesis and pharmacological activities of thyroxine analogs: Development of new angiogenesis modulators. Bioorg Med Chem Lett. 2010 Jun 1; 20(11):3394-8. Epub Apr 11. Erratum in: Bioorg Med Chem Lett. Sep 15; 20(18):5585, 2010. Usoro OB, Mousa SA. Vitamin E forms in Alzheimer's disease: a review of controversial and clinical experiences. Crit Rev Food Sci Nutr. May; 50(5):414-9, 2010. Lin Y, Mousa SS, Elshourbagy N, Mousa SA. Current status and future directions in lipid management: emphasizing low-density lipoproteins, high-density lipoproteins, and triglycerides as targets for therapy. Vasc Health Risk Manag.; 6:73-85, 2010. Mousa SA, Mousa SS. Current status of vascular endothelial growth factor inhibition in age-related macular degeneration. BioDrugs.; 24(3):183-94. doi: 10.2165/11318550, 2010.

Shaker A. Mousa, Ph.D. CURRICULUM VITAE Page 33 of 92

Mousa SA, Jeske WP, Fareed J. Antiplatelet therapy prasugrel: a novel platelet ADP P2Y12 receptor antagonist. Clin Appl Thromb Hemost. Apr; 16(2):170-6, 2010.

Luidens MK, Mousa SA, Davis FB, Lin HY, Davis PJ. Thyroid hormone and angiogenesis. Vascul Pharmacol. Mar-Apr; 52(3-4):142-5, 2010.

Mousa SA, Sudha T, Dyskin E, Dier U, Gallati C, Hanko C, Chittur SV, Rebbaa A. Stress resistant human embryonic stem cells as a potential source for the identification of novel cancer stem cell markers. Cancer Lett. Mar 28; 289(2):208-16, 2010.

Lin Y*, Mousa SS, Elshourbagy N, Mousa SA. Current status and future directions in lipid management: emphasizing low-density lipoproteins, high-density lipoproteins, and triglycerides as targets for therapy. Vasc Health Risk Manag. Mar 3; 6:73-85, 2010.

Yalcin M, Bharali DJ, Dyskin E, Dier E, Lansing L, Mousa SS, Davis FB, Davis PJ, Mousa SA. Tetraiodothyroacetic acid and tetraiodothyroacetic acid nanoparticle effectively inhibit the growth of human follicular thyroid cell carcinoma. Thyroid. Mar; 20(3):281-6, 2010.

Block RC, Duff R, Lawrence P, Kakinami L, Brenna JT, Shearer GC, Meednu N, Mousa S, Friedman A, Harris WS, Larson M, Georas S. The effects of EPA, DHA, and aspirin ingestion on plasma lysophospholipids and autotaxin. Prostaglandins Leukot Essent Fatty Acids. Feb-Mar; 82(2-3):87-95, 2010.

Davis PJ, Zhou M, Davis FB, Lansing L, Mousa SA, Lin HY. Mini-review: Cell surface receptor for thyroid hormone and nongenomic regulation of ion fluxes in excitable cells. Physiol Behav. Feb 9; 99(2):237-9, 2010.

Yalcin M, Dyskin E, Lansing L, Bharali DJ, Mousa SS, Bridoux A, Hercbergs AH, Lin HY, Davis FB, Glinsky GV, Glinskii A, Ma J, Davis PJ, Mousa SA. Tetraiodothyroacetic Acid (Tetrac) and Nanoparticulate Tetrac Arrest Growth of Medullary Carcinoma of the Thyroid. J Clin Endocrinol Metab. 95(4):1972-80, 2010.

Jacoby DB, Dyskin E, Yalcin M, Kesavan K, Dahlberg W, Ratliff J, Johnson EW, Mousa SA. Potent pleiotropic anti-angiogenic effects of TM601, a synthetic chlorotoxin peptide. Anticancer Res.Jan; 30(1):39-46, 2010.

Mousa SS, Davis FB, Davis PJ, Mousa SA. Human Platelet Aggregation and Degranulation Is Induced In Vitro by L-Thyroxine, but Not by 3,5,3'-Triiodo-L-Thyronine or Diiodothyropropionic Acid (DITPA). Clin Appl Thromb Hemost. Jun; 16(3):288-93, 2010.

Assimon MM, Mousa S, Shaker O, Pai AB. The effect of sevelamer hydrochloride and calcium-based phosphate binders on mortality in hemodialysis patients: a need for more research. Consult Pharm. Jan; 25(1):41-54, 2010.

Mousa SS, Mousa SA: Current status of vascular endothelial growth factor inhibition in age-related

macular degeneration. BioDrugs. Jun; 24(3):183-94, 2010.

Shaker A. Mousa, Ph.D. CURRICULUM VITAE Page 34 of 92

Abdel-Majeed S, Mohammad A, Shaima AB, Mohammad R, Mousa SA. Inhibition property of green tea extract in relation to reserpine-induced ribosomal strips of rough endoplasmic reticulum (rER) of the rat kidney proximal tubule cells. J Toxicol Sci. Dec; 34(6):637-45, 2009.

Mousa SA, Gallati C, Simone T, Dier E, Yalcin M, Dyskin E, Thangirala S, Hanko C, Rebbaa A. Dual targeting of the antagonistic pathways mediated by Sirt1 and TXNIP as a putative approach to enhance the efficacy of anti-aging interventions. Aging (Albany NY) Mar 31; 1(4):412-24, 2009.

Davis PJ, Davis FB, Lin HY, Mousa SA, Zhou M, Luidens MK. Translational implications of nongenomic actions of thyroid hormone initiated at its integrin receptor. Am J Physiol Endocrinol Metab. Dec; 297(6):E1238-46, 2009.

Katrych O, Simone TM, Azad S, Mousa SA. Disease-modifying agents in the treatment of multiple sclerosis: a review of long-term outcomes. CNS Neurol Disord Drug Targets. Dec; 8(6):512-9, 2009.

Rebbaa A, Chu F, Sudha T, Gallati C, Dier U, Dyskin E, Yalcin M, Bianchini C, Shaker O, Mousa SA. The anti-angiogenic activity of NSITC, a specific cathepsin L inhibitor. Anticancer Res. Nov; 29(11):4473-81, 2009.

Dennis T, Fanous M, Mousa S. Natural products for chemopreventive and adjunctive therapy in oncologic disease. Nutr Cancer.; 61(5):587-97, 2009.

Kemp MM, Kumar A, Mousa S, Dyskin E, Yalcin M, Ajayan P, Linhardt RJ, Mousa SA. Gold and silver nanoparticles conjugated with heparin derivative possess anti-angiogenesis properties. Nanotechnology. Nov 11; 20(45):455104, 2009.

Yalcin M, Bharali DJ, Lansing L, Dyskin E, Mousa SS, Hercbergs A, Davis FB, Davis PJ, Mousa SA. Tetraiodothyroacetic acid (tetrac) and tetrac nanoparticles inhibit growth of human renal cell carcinoma xenografts. Anticancer Res. Oct; 29(10):3825-31, 2009.

Duong A, Mousa SA. Status of nucleoside antivirals in chronic hepatitis B. Drugs Today (Barc). Oct; 45(10):751-61, 2009.

Davis PJ, Davis FB, Mousa SA. Thyroid hormone-induced angiogenesis. Curr Cardiol Rev.; 5(1):12-6, 2009.

Tran K, Levin RM, Mousa SA. Behavioral Intervention versus Pharmacotherapy or Their Combinations in the Management of Overactive Bladder Dysfunction. Adv Urol.:345324, 2009.

Aljada A, Shah KA, Mousa SA. Peroxisome proliferator-activated receptor agonists: do they increase cardiovascular risk? PPAR Res.:460764, 2009.

Mousa SA, Petersen LJ. Anti-cancer properties of low-molecular-weight heparin: preclinical evidence. Thromb Haemost. Aug; 102(2):258-67, 2009.

Kemp MM, Kumar A, Clement D, Ajayan P, Mousa S, Linhardt RJ. Hyaluronan- and heparin-reduced silver nanoparticles with antimicrobial properties. Nanomedicine (Lond); 4 (4):421-9, 2009.

Shaker A. Mousa, Ph.D. CURRICULUM VITAE Page 35 of 92

Martin JW*, Mousa SS, Shaker O, Mousa SA. The multiple faces of nicotine and its implications in tissue and wound repair. Exp Dermatol.; 18(6):497-505, 2009.

Suwan J, Zhang Z, Li B, Vongchan P, Meepowpan P, Zhang F, Mousa SA, Mousa S, Premanode B, Kongtawelert P, Linhardt RJ. Sulfonation of papain-treated chitosan and its mechanism for anticoagulant activity. Carbohydr Res. Jul 6; 344(10):1190-6, 2009.

Lin HY, Davis PJ, Tang HY, Mousa SA, Luidens MK, Hercbergs AH, Davis FB. The pro-apoptotic action of stilbene-induced COX-2 in cancer cells: convergence with the anti-apoptotic effect of thyroid hormone. Cell Cycle; 8(12):1877-82, 2009.

Bridoux A, Cui H, Dyskin E, Yalcin M, Mousa SA. Semisynthesis and pharmacological activities of Tetrac analogs: angiogenesis modulators. Bioorg Med Chem Lett. 15; 19 (12):3259-63, 2009.

Alsayegh F, Al-Rasheed M, Al-Muhaini A, Al-Humoud E, Al-Ostaz M, Mousa SA. Heparin anticoagulation responsiveness in a coronary care unit: a prospective observational study. Cardiovasc Ther. Summer; 27 (2):77-82, 2009.

Bharali DJ, Khalil M*, Gurbuz M*, Simone TM, Mousa SA. Nanoparticles and cancer therapy: a concise review with emphasis on dendrimers. Int J Nanomedicine; 4:1-7, 2009.

Arias HR, Richards VE, Ng D, Ghafoori ME, Le V, Mousa SA. Role of non-neuronal nicotinic acetylcholine receptors in angiogenesis. Int J Biochem Cell Biol. Jul; 41(7):1441-51, 2009.

LaRocque J*, Bharali DJ, Mousa SA. Cancer detection and treatment: the role of nanomedicines. Mol Biotechnol. Jul; 42(3):358-66, 2009.

Glinskii AB, Glinsky GV, Lin HY, Tang HY, Sun M, Davis FB, Luidens MK, Mousa SA, Hercbergs AH, Davis PJ. Modification of survival pathway gene expression in human breast cancer cells by tetraiodothyroacetic acid (tetrac). Cell Cycle. Nov 1; 8(21):3554-62, 2009.

Bharali DJ, Khalil M, Gurbuz M, Simone TM, Mousa SA. Nanoparticles and cancer therapy: a concise review with emphasis on dendrimers. Int J Nanomedicine ; 4(1):1-7, 2009.

Barone C, Mousa SS, Mousa SA. Pharmacoeconomics in cardiovascular disorders: Steps in approaching personalized medicine in cardiovascular medicine. Pharmacogenomics and Personalized Medicine:2 1-9, 2009.

Greene R, Mousa SS, Ardawi M, Qari M, Mousa SA. Pharmacogenomics in osteoporosis: Steps toward personalized medicine. Pharmacogenomics and Personalized Medicine:2 1-10, 2009.

Clarke H, Mousa SA. The implications of pharmacogenomics in the treatment of HIV-1-infected patients of African descent. Pharmacogenomics and Personalized Medicine:2 93-99, 2009.

Avery P, Mousa SS, Mousa SA. Pharmacogenomics in type II diabetes mellitus management: Steps toward personalized medicine. Pharmacogenomics and Personalized Medicine:2 1-13, 2009.

Shaker A. Mousa, Ph.D. CURRICULUM VITAE Page 36 of 92

Alasfoor K, Alrasheed M, Alsayegh F, Mousa SA. Rituximab in the treatment of idiopathic thrombocytopenic purpura (ITP). Ann Hematol; 88(3):239-43, 2009.

Zheng X, Chu F, Chou PM, Gallati C, Dier U, Mirkin BL, Mousa SA, Rebbaa A. Cathepsin L inhibition suppresses drug resistance in vitro and in vivo: a putative mechanism. Am J Physiol Cell Physiol. Jan; 296 (1):C65-74, 2009.

Park BC, Park SY, Lee JS, Mousa SA, Kim JT, Kwak MK, Kang KW, Lee ES, Choi HG, Yong CS, Kim JA The anti-angiogenic effects of 1-furan-2-yl-3-pyridin-2-yl-propenone are mediated through the suppression of both VEGF production and VEGF-induced signaling. Vascul Pharmacol; 50(3-4):123-31, 2009.

Lin HY, Sun M, Tang HY, Lin C, Luidens MK, Mousa SA, Incerpi S, Drusano GL, Davis FB, Davis PJ.L-Thyroxine vs. 3,5,3'-Triiodo-L-Thyronine and Cell Proliferation: Activation of Mitogen-Activated Protein Kinase and Phosphatidylinositol 3-Kinase. Am J Physiol Cell Physiol; 296(5):C980-91, 2009.

Kemp MM, Kumar A, Mousa S, Park TJ, Ajayan P, Kubotera N, Mousa SA, Linhardt RJ. Synthesis of Gold and Silver Nanoparticles Stabilized with Glycosaminoglycans Having Distinctive Biological Activities. Biomacromolecules; 10(3):589-95, 2009.

Al-Bloushi S, Safer AM, Afzal M, Mousa SA: Green tea modulates reserpine toxicity in animal models. J Toxicol Sci. Feb; 34(1):77-87, 2009.

Alsayegh F, Fakeir A, Alhumood S, Abdumalek K, Matar H, Samaul I, Nampoory N, Kabalawi H, Mousa SA. Use of Recombinant Activated Factor VII to Arrest Uncontrolled Bleeding: A Case Series. Clin Appl Thromb Hemost. Mar-Apr; 15(2):225-32, 2009.

Norey E, Simone TM, Mousa SA.The Impact of Direct-to-Consumer Advertised Drugs on Drug Sales in the US and New Zealand. Appl Health Econ Health Policy; 6 (2-3):93-102, 2008.

Park TJ, Lee SH, Simmons TJ, Martin JG, Mousa SA, Snezhkova EA, Sarnatskaya VV, Nikolaev VG, Linhardt RJ. Heparin-cellulose-charcoal composites for drug detoxification prepared using room temperature ionic liquids. Chem Commun (Camb). Oct 28; (40):5022-4, 2008.

Aljada A, O'Connor L, Fu YY, Mousa SA. PPAR gamma ligands, rosiglitazone and pioglitazone, inhibit bFGF- and VEGF-mediated angiogenesis. Angiogenesis; 11(4):361-7, 2008.

Zheng X, Chu F, Mirkin BL, Sudha T, Mousa SA, Rebbaa A. Role of the proteolytic hierarchy between cathepsin L, cathepsin D and caspase-3 in regulation of cellular susceptibility to apoptosis and autophagy. Biochim Biophys Acta. Dec; 1783(12):2294-300, 2008.

Bawarski WE, Chidlowsky E, Bharali D, Mousa SA: Emerging NanoPharmaceuticals. Nanomedicine. Dec; 4(4):273-82, 2008.

Santulli RJ, Kinney WA, Ghosh S, Decorte BL, Liu L, Tuman RW, Zhou Z, Huebert N, Bursell SE, Clermont AC, Grant MB, Shaw LC, Mousa SA, Galemmo RA, Jr., Johnson DL, Maryanoff BE, Damiano BP: Studies with an orally bioavailable alphaV integrin antagonist in animal models of ocular

Shaker A. Mousa, Ph.D. CURRICULUM VITAE Page 37 of 92

vasculopathy: retinal neovascularization in mice and retinal vascular permeability in diabetic rats. The Journal of Pharmacology and Experimental Therapeutics; 324(3):894-901, 2008.

Mousa SA: Cell adhesion molecules: potential therapeutic & diagnostic implications. Molecular Biotechnology; 38(1):33-40, 2008.

Fares RR, Lansing LS, Gallati CA, Mousa SA: Antiplatelet therapy with clopidogrel and aspirin in vascular diseases: clinical evidence for and against the combination. Expert Opinion on Pharmacotherapy; 9(3):377-386, 2008.

Mousa SA, Bergh JJ, Dier E, Rebbaa A, O'Connor LJ, Yalcin M, Aljada A, Dyskin E, Davis FB, Lin HY, Davis PJ. Tetraiodothyroacetic acid, a small molecule integrin ligand, blocks angiogenesis induced by vascular endothelial growth factor and basic fibroblast growth factor. Angiogenesis; 11(2):183-90, 2008.

Qari MH, Aljaouni SK, Alardawi MS, Fatani H, Alsayes FM, Zografos P, Alsaigh M, Alalfi A, Alamin M, Gadi A, Mousa SA: Reduction of painful vaso-occlusive crisis of sickle cell anemia by tinzaparin in a double-blind randomized trial. Thrombosis and Haemostasis; 98(2):392-396, 2007.

Puskas A, Balogh Z, Hadadi L, Imre M, Orban E, Kosa K, Brassai Z, Mousa SA: Spontaneous recanalization in deep venous thrombosis: a prospective duplex ultrasound study. Int Angiol; 26(1):53-63, 2007.

Powell JA, Jr., Mousa SA: Neutrophil-activating protein-2- and interleukin-8-mediated angiogenesis. Journal of Cellular Biochemistry; 102(2):412-420, 2007.

Murugesan S, Mousa SA, O'Connor L J, Lincoln DW, 2nd, Linhardt RJ: Carbon inhibits vascular endothelial growth factor- and fibroblast growth factor-promoted angiogenesis. FEBS Letters; 581(6):1157-1160, 2007.

Mousa SA, Zhang F, Aljada A, Chaturvedi S, Takieddin M, Zhang H, Chi L, Castelli MC, Friedman K, Goldberg MM, Linhardt RJ: Pharmacokinetics and pharmacodynamics of oral heparin solid dosage form in healthy human subjects. Journal of Clinical Pharmacology; 47(12):1508-1520, 2007.

Mousa SA, O'Connor L, Rossman TG, Block E: Pro-angiogenesis action of arsenic and its reversal by selenium-derived compounds. Carcinogenesis; 28(5):962-967, 2007.

Mousa SA, Goncharuk O, Miller D: Recent advances of TNF-alpha antagonists in rheumatoid arthritis and chronic heart failure. Expert Opinion on Biological Therapy; 7(5):617-625, 2007.

Mousa SA: In-vitro efficacy of different platelet glycoprotein IIb/IIIa antagonists and thrombolytic on platelet/fibrin-mediated clot dynamics in human whole blood using thrombelastography. Blood Coagul Fibrinolysis. 18(1):55-60, 2007.

Mousa SA, Bharali DJ, Armstrong D: From nutraceuticals to pharmaceuticals to NanoPharmaceuticals: a case study in angiogenesis modulation during oxidative stress. Molecular Biotechnology; 37(1):72-80, 2007.

Shaker A. Mousa, Ph.D. CURRICULUM VITAE Page 38 of 92

Mousa SA, Ahmad S: Platelet GPIIb/IIIa antagonist, XV459, in heparin-induced thrombocytopenia. American Journal of Hematology; 82(4):276-282, 2007.

Mousa SA: Heparin, low molecular weight heparin, and derivatives in thrombosis, angiogenesis, and inflammation: emerging links. Seminars in Thrombosis and Hemostasis; 33(5):524-533, 2007.

Hantgan RR, Stahle MC, Connor JH, Connor RF, Mousa SA: AlphaIIbbeta3 priming and clustering by orally active and intravenous integrin antagonists. J Thromb Haemost; 5(3):542-550, 2007.

Cloonan ME, DiNapoli M, Mousa SA: Efficacy of anticoagulants and platelet inhibitors in cancer-induced thrombosis. Blood Coagul Fibrinolysis; 18(4):341-345, 2007.

Bharali DJ, Mousa SA, Thanavala Y: Micro- and nanoparticle-based vaccines for hepatitis B. Advances in Experimental Medicine and Biology; 601: 415-421, 2007.

Amirkhosravi A, Meyer T, Amaya M, Davila M, Mousa SA, Robson T, Francis JL: The role of tissue factor pathway inhibitor in tumor growth and metastasis. Seminars in Thrombosis and Hemostasis; 33(7):643-652, 2007.

Mousa SA, O'Connor L, Davis FB, Davis PJ: Proangiogenesis action of the thyroid hormone analog 3, 5-diiodothyropropionic acid (DITPA) is initiated at the cell surface and is integrin mediated. Endocrinology; 147(4):1602-1607, 2006.

Mousa SA, Linhardt R, Francis JL, Amirkhosravi A: Anti-metastatic effect of a non-anticoagulant low-molecular-weight heparin versus the standard low-molecular-weight heparin, enoxaparin. Thrombosis and Haemostasis; 96(6):816-821, 2006.

Mousa SA, Feng X, Xie J, Du Y, Hua Y, He H, O'Connor L, Linhardt RJ: Synthetic oligosaccharide stimulates and stabilizes angiogenesis: structure-function relationships and potential mechanisms. Journal of Cardiovascular Pharmacology; 48(2):6-13, 2006.

Mousa SA, Davis FB, Mohamed S, Davis PJ, Feng X: Pro-angiogenesis action of thyroid hormone and analogs in a three-dimensional in vitro microvascular endothelial sprouting model. Int Angiol; 25(4):407-413, 2006.

Mousa SA: Inhibitory effect of C-reactive protein on the release of tissue factor pathway inhibitor from human endothelial cells: reversal by low molecular weight heparin. Int Angiol; 25(1):10-13, 2006.

Mousa SA: Role of current and emerging antithrombotic in thrombosis and cancer. Drugs Today (Barc); 42(5):331-350, 2006.

Mousa SA: Role of current and emerging antithrombotic in thrombosis and cancer. Timely Topics in Medicine; 10: E19, 2006.

Mousa S, Mousa SA: Cellular and molecular mechanisms of nicotine's pro-angiogenesis activity and its potential impact on cancer. Journal of Cellular Biochemistry; 97(6):1370-1378, 2006.

Shaker A. Mousa, Ph.D. CURRICULUM VITAE Page 39 of 92

Davis FB, Tang HY, Shih A, Keating T, Lansing L, Hercbergs A, Fenstermaker RA, Mousa A, Mousa SA, Davis PJ, Lin HYL: Acting via a cell surface receptor, thyroid hormone is a growth factor for glioma cells. Cancer Research; 66(14):7270-7275, 2006.

Stoller GL, Mousa SA: Angiogenesis, choroidal neovascularization, and the coagulation system. Retina Philadelphia, Pa; 25(1):19-25, 2005.

Sehgal LR, Wong J, He J, Wood T, Takagi I, Eldibany M, Caprini J, Mousa SA: Novel in vitro perfusion model to study the interaction between coagulation and blood-borne metastasis. Journal of Cellular Biochemistry; 96(4):700-708, 2005.

Mousa SS, Mousa SS, Mousa SA: Effect of resveratrol on angiogenesis and platelet/fibrin-accelerated tumor growth in the chick chorioallantoic membrane model. Nutrition and Cancer; 52(1):59-65, 2005.

Mousa SA, O'Connor LJ, Bergh JJ, Davis FB, Scanlan TS, Davis PJ: The proangiogenic action of thyroid hormone analogue GC-1 is initiated at an integrin. Journal of Cardiovascular Pharmacology; 46(3):356-360, 2005.

Mousa SA, Mohamed S, Wexler EJ, Kerr JS: Anti-angiogenesis and anticancer efficacy of TA138, a novel alphavbeta3 antagonist. Anticancer Research; 25(1A):197-206, 2005.

Mousa SA, Mohamed S: Human alphavbeta3 integrin potency and specificity of TA138 and its DOTA conjugated form (89) Y-TA138. Journal of Cardiovascular Pharmacology; 45(2):109-113, 2005.

Mousa SA, Johansen K: Pharmacodynamic effects of low molecular weight heparin in obese subjects following subcutaneous administration of 75 IU/kg on plasma tissue factor pathway inhibitor and nitric oxide. Int Angiol; 24(1):40-42, 2005.

Mousa SA, Bozarth JM, Seiffert D, Feuerstein GZ: Using thrombelastography to determine the efficacy of the platelet glycoprotein IIb/IIIa antagonist, roxifiban, on platelet/fibrin-mediated clot dynamics in humans. Blood Coagul Fibrinolysis; 16(3):165-171, 2005.

Mousa SA, Abdel-Razeq HN: Ximelagatran, the new oral anticoagulant: would warfarin survive the challenge? Cardiovascular Drug Reviews; 23(4):331-344, 2005.

Mousa SA: Effect of low molecular weight heparin and different heparin molecular weight fractions on the activity of the matrix-degrading enzyme aggrecanase: structure-function relationship. Journal of Cellular Biochemistry; 95(1):95-98, 2005.

Mousa SA: Alpha v integrin affinity/specificity and antiangiogenesis effect of a novel tetraaza cyclic peptide derivative, SU015, in various species. Journal of Cardiovascular Pharmacology; 45(5):462-467, 2005.

Mousa SA: Emerging links between thrombosis, inflammation and cancer: role of heparin. Acta Chirurgica Belgica; 105(3):237-248, 2005.

Shaker A. Mousa, Ph.D. CURRICULUM VITAE Page 40 of 92

Mousa SA: Elevation of plasma von Willebrand factor and tumor necrosis factor-a in obese subjects and their reduction by the low molecular weight heparin tinzaparin. Int Angiol; 24(3):278-281, 2005.

Mousa SA: Antithrombotics in thrombosis and cancer. Hamostaseologie; 25(4):380-386, 2005.

Mousa SA: Anti-thrombotics in thrombosis and cancer. Future Oncology (London, England); 1(3):395-403, 2005.

Mousa AS, Mousa SA: Anti-angiogenesis efficacy of the garlic ingredient alliin and antioxidants: role of nitric oxide and p53. Nutrition and Cancer; 53(1):104-110, 2005.

Smallheer JM, Weigelt CA, Woerner FJ, Wells JS, Daneker WF, Mousa SA, Wexler RR, Jadhav PK: Synthesis and biological evaluation of nonpeptide integrin antagonists containing spirocyclic scaffolds. Bioorganic & Medicinal Chemistry Letters; 14(2):383-387, 2004.

Shaqura MA, Zollner C, Mousa SA, Stein C, Schafer M: Characterization of mu opioid receptor binding and G protein coupling in rat hypothalamus, spinal cord, and primary afferent neurons during inflammatory pain. The Journal of Pharmacology and Experimental Therapeutics; 308(2):712-718, 2004.

Pawar P, Shin PK, Mousa SA, Ross JM, Konstantopoulos K: Fluid shear regulates the kinetics and receptor specificity of Staphylococcus aureus binding to activated platelets. J Immunol; 173(2):1258-1265, 2004.

Mousa SA, Shakibaei M, Sitte N, Schafer M, Stein C: Subcellular pathways of beta-endorphin synthesis, processing, and release from immunocytes in inflammatory pain. Endocrinology; 145(3):1331-1341, 2004.

Mousa SA, Mousa AS: Angiogenesis inhibitors: current & future directions. Current Pharmaceutical Design; 10(1):1-9, 2004.

Mousa SA, Mohamed S: Inhibition of endothelial cell tube formation by the low molecular weight heparin, tinzaparin, is mediated by tissue factor pathway inhibitor. Thrombosis and Haemostasis; 92(3):627-633, 2004.

Mousa SA, Mohamed S: Anti-angiogenic mechanisms and efficacy of the low molecular weight heparin, tinzaparin: anti-cancer efficacy. Oncology Reports; 12(4):683-688, 2004.

Mousa SA, Fareed J, Iqbal O, Kaiser B: Tissue factor pathway inhibitor in thrombosis and beyond. Methods in Molecular Medicine; 93: 133-155, 2004.

Mousa SA: Highlights of latest advances in antithrombotic. Methods in Molecular Medicine; 93: 1-7, 2004.

Mousa SA: Heparin and low molecular weight heparin in thrombosis, cancer, and inflammatory diseases. Methods in Molecular Medicine; 93:35-48, 2004.

Shaker A. Mousa, Ph.D. CURRICULUM VITAE Page 41 of 92

Mousa SA: Expression of adhesion molecules during cadmium hepatotoxicity. Life Sciences; 75(1):93-105, 2004.

Mousa SA: Are low molecular weight heparins the same? Methods in Molecular Medicine; 93: 49-59, 2004.

Mousa SA: Low-molecular-weight heparin in thrombosis and cancer. Seminars in Thrombosis and Hemostasis; 30 Suppl 1:25-30, 2004.

Mousa SA: Tissue factor/VIIa in thrombosis and cancer. Methods in Molecular Medicine; 93: 119-132, 2004.

Mousa SA: Cell adhesion molecules: potential therapeutic and diagnostic implications. Methods in Molecular Medicine; 93: 157-174, 2004.

Mousa SA: Arixtra (fondaparinux sodium). Methods in Molecular Medicine; 93: 239-246, 2004.

Shahan TA, Grant D, Tootell M, Ziaie Z, Ohno T, Mousa SA: Oncothanin, a peptide from alpha3 chain of type IV Collagen, inhibits tumor growth by inhibiting angiogenesis. Connect Tissue Res.; 45(3):151-63, 2004.

Mousa SA: Oral thrombin inhibitor ximelagatran. Methods in Molecular Medicine. 2004; 93: 247-251, 2004.

Mousa SA: Low-molecular-weight heparins in thrombosis and cancer: emerging links. Cardiovascular Drug Reviews; 22(2):121-134, 2004.

McCarty OJ, Abulencia JP, Mousa SA, Konstantopoulos K: Evaluation of platelet antagonists in in vitro flow models of thrombosis. Methods in Molecular Medicine; 93: 21-34, 2004.

Iqbal O, Mousa SA: Antiplatelet, anticoagulant, and thrombolytic drug interactions. Methods in Molecular Medicine; 93: 9-20, 2004.

Davis FB, Mousa SA*, O'Connor L, Mohamed S, Lin HY, Cao HJ, Davis PJ: Proangiogenic action of thyroid hormone is fibroblast growth factor-dependent and is initiated at the cell surface. Circulation Research; 94(11):1500-1506. (Equal Contributor), 2004.

Mousa SA, Mousa, AS: Angiogenesis Inhibitor Strategies & Future Directions. Curr Pharm Des.; 10(1):1-9, 2004.

Abdel-Razeq H, Qari M, Kristensen J, Alizeidah H, Al-Sayegh F, Marashi M, Alzeer A, Al-Amoudi O, Qutub H, Al-Humiadi AA, Husted S, Mousa SA: Guidelines for diagnosis and treatment of deep venous thrombosis and pulmonary embolism. Methods in Molecular Medicine; 93: 267-292, 2004.

Naik MU, Mousa SA, Parkos CA, Naik UP: Signaling through JAM-1 and alphavbeta3 is required for the angiogenic action of bFGF: dissociation of the JAM-1 and alphavbeta3 complex. Blood; 102(6):2108-2114, 2003.

Shaker A. Mousa, Ph.D. CURRICULUM VITAE Page 42 of 92

Mousa SA: Alpha v Vitronectin receptors in vascular-mediated disorders. Medicinal Research Reviews; 23(2):190-199, 2003.

Mousa SA: Antiplatelet therapies: platelet GPIIb/IIIa antagonists and beyond. Current Pharmaceutical Design; 9(28):2317-2322, 2003.

Mousa SA: Antithrombotics in thrombosis and cancer. Expert Review of Cardiovascular Therapy; 1(2):283-291, 2003.

Colman RW, Pixley RA, Sainz IM, Song JS, Isordia-Salas I, Muhamed SN, Powell JA, Jr., Mousa SA: Inhibition of angiogenesis by antibody blocking the action of proangiogenic high-molecular-weight kininogen. J Thromb Haemost; 1 (1):164-170, 2003.

Marcinkiewicz C, Weinreb PH, Calvete JJ, Kisiel DJ, Mousa SA, Tuszynski JP, Lobb RR: Obtustatin, a potent selective inhibitor of alpha1/Beta1 integrin in vitro and angiogenesis in vivo. Cancer Research 63: 2020-2023, 2003.

Mousa SA: Antithrombotics in thrombosis and cancer. Expert Rev. Cardiovascular Thera. 1 (2): 89-96, 2003.

Amirkhosravi A, Mousa SA, Amaya M, Frances JL: Antimetastatic effect of tinzaparin, a Low molecular weight Heparin. J Thrombosis and Haemostasis, 1(9): 1972-1976, 2003.

Mousa SA, Bozarth JM, Barrett JS: Pharmacodynamic properties of the Low Molecular weight Heparin, Tinzaparin: Effect of Molecular weight Distribution on plasma tissue factor pathway inhibitor in healthy human subjects. J. Clinical Pharmacology & Therapeutics, 43 (7): 727-734, 2003.

Amirkhosravi A, Mousa SA, Amaya M, Frances JL: Inhibition of tumor cell-induced platelet aggregation and lung metastasis by the oral GpIIb/IIIa antagonist XV454. Thrombosis and Haemostasis, 90 (3): 549-554, 2003.

Naik MU, Mousa SA, Parkos CA, Naik UP. Signaling through JAM-1 and alphav-beta3 is required for the angiogenic action of bFGF: dissociation of the JAM-1 and alphav-beta3 complex. Blood 102: 2108-2114, 2003.

Qari M, Abdel-Razaq H, Alzeer A, Alizadeh H, Mousa, SA: Recent advances in the diagnosis and treatment of deep vein thrombosis: A regional consensus. Cur Opin Investig Drugs 4 (3): 301-315, 2003.

Mousa SA: Antiplatelet Therapies: Platelet GPIIb/IIIa antagonists and beyond. Current Pharmaceutical Design 9 (28): 2317-2322, 2003.

Mousa SA, Forsythe MS, Bozarth JM. Differential efficacy of different platelet glycoprotein IIb/IIIa antagonists on Platelet/fibrin-mediated clot dynamics under different conditions using Thrombelastography: the critical need for anticoagulant. Coronary Artery Disease 13(4):243-8, 2002.

Shaker A. Mousa, Ph.D. CURRICULUM VITAE Page 43 of 92

Mousa SA. Anti-integrin as novel drug-discovery targets: potential therapeutic and diagnostic implications. Cur Opin Chem Biol 6(4):534-41, 2002.

Kerr JS, Slee AM, Mousa SA. The alpha (v) integrin antagonists as novel anticancer agents: an update. Expert Opin Investig Drugs 11(12):1765-74, 2002.

Mousa SA. The low molecular weight heparin, tinzaparin, in thrombosis and beyond. Cardiovascular Drug Rev Fall; 20(3):199-216, 2002.

West SG, Hilpert KF, Juturu V, Bordi PL, Lampe JW, Mousa SA, Kris-Etherton PM: Effects of including soy protein in a blood cholesterol-lowering diet on markers of cardiac risk in men and in postmenopausal women with and without hormone replacement therapy. Journal of Women's Health; 14(3):253-262, 2002.

Mousa SA. Vitronectin receptors in vascular disorders. Cur Opin Investig Drugs 3(8):1191-5, 2002.

Mousa SA. Heparin and low molecular weight heparin in thrombosis and beyond. Cur Opin Investig Drugs 3(8):1181-6, 2002.

Mousa SA, Iqbal O, Fareed J. Antithrombotics and thrombolytics in stroke. Cur Opin Investig Drugs 3(6): 878-85, 2002.

Caron A, Theoret JF, Mousa SA, Merhi Y. Anti-platelet effects of GPIIb/IIIa and P-selectin antagonism, platelet activation, and binding to neutrophils. J Cardiovascular Pharmacology 40(2):296-306, 2002.

Mousa SA. Anticoagulants in thrombosis and cancer: the missing link. Expert Rev Anticancer Ther 2(2):227-33, 2002.

Mousa S: Angiogenesis, Coagulation activation, and malignant dissemination. Seminar in Thrombosis & Hemostasis, 28(1):45-52, 2002. Mousa S: Anti-integrin as novel drug discovery targets: Potential therapeutic and diagnostic implication. Current Opinion in Chemical Biology, 6: 534-541, 2002.

Elhadj S, Mousa SA, Forsten-Williams K. Chronic pulsatile shear stress impacts synthesis of proteoglycans by endothelial cells: effect on platelet aggregation and coagulation. J Cell Biochem 86(2): 239-50, 2002.

Dupont E, Falardeau P, Mousa SA, Dimitriadou V, Pepin MC, Wang T, Alaoui-Jamali MA. Antiangiogenic and antimetastatic properties of Neovastat (AE-941), an orally active extract derived from cartilage tissue. Clin Exp Metastasis 19(2):145-53, 2002.

Mousa SA, Abulencia JP, McCarty OJ, Turner NA, Konstantopoulos K. Comparative efficacy between the glycoprotein IIb/IIIa antagonist’s roxifiban and orbofiban in inhibiting platelet responses in flow models of thrombosis. J Cardiovascular Pharmacology 39(4):552-60, 2002.

Shaker A. Mousa, Ph.D. CURRICULUM VITAE Page 44 of 92

Mousa SA. Anticoagulants in thrombosis and cancer: the missing link. Semin Thromb Haemost 28(1):45-52, 2002.

Mousa SA: Antithrombotic and cancer. Thrombosis in Oncology 5 (4): 5-7, 2002.

Kerr JS, Slee AM, Mousa SA: The alpha v integrin antagonists as novel anticancer agents: an update. Expert Opin Investig Drugs. 11(12):1765-1774, 2002.

Mousa S: Heparin in thrombosis & cancer: the missing Link. Expert Rev Anticancer Cancer, 2 (2):89-95, 2002.

Mousa S: Novel Therapeutic Developments. Exp. Opinion Invest. Drugs, 10 (2): 387-391, 2001.

Ali S, O’Dounell A, Balu D, Pohl M, Seyler M, Mohamed S, Mousa S, Dandona P: High levels of estrogen receptor-a in tumorigenesis: Inhibition of cell growth and angiogenic factors. Cell Proliferation, 34: 223-231, 2001.

Fenton J, Mousa S: Statin as cellular antithrombotic and prothrombolytic agents. Acta Haemologica Polonica, 32, Suppl. 1, 60-62, 2001.

Konstantopoulos K, Mousa S: Antiplatelet Therapies: Platelet GPIIb/IIIa antagonists & beyond. Current Opin. Invest. Drugs, 2 (8): 1086-1092, 2001.

Mousa S, Fareed J: From Heparin to Low Molecular weight Heparin: Beyond Anticoagulation. Current. Opin. Invest. Drugs: 2 (8): 1077-1080, 2001. Mousa S, Fareed J: Advances in Anticoagulant, Antithrombotic and Thrombolytic Drugs: Exp. Opin. Invest. Drugs: 10 (1): 157-162, 2001.

Bennett J, Mousa S: Platelet Function Inhibitors in the Year 2000. Thrombosis Hemostasis, 85:1-6, 2001.

Wilson MF, Blum R, Dandona P, Mousa S: Effects of intravenously administered endotoxin on soluble adhesion molecule and inflammatory markers: A model of human diseases. Clinical & Experimental Pharmacology and Physiology. 28: 1-5, 2001.

Abulencia JA, Tien N, McCarty OJT, Mousa SA, Konstantopoulos K: Antiplatelet Efficacy of a Novel Non-Peptide GPIIb-IIIa Antagonist, XV454, in In Vitro Flow Models of Thrombosis: Comparison with c7E3. Arteriosclerosis, Thrombosis & Vascular Biology, 21(1): 149-163, 2001. Bishop G, McPherson JA, Sanders J, Hesselbacher S, Feldman ML, Gimple LW, Powers E, Mousa SA, Sarembock IJ: Vitronectin ( v 3) receptor blockade reduces restenosis and intramural macrophage infiltration associated with a reduction in cellular adhesion molecule expression following balloon angioplasty of the atherosclerotic rabbit femoral artery. Circulation, 103: 1906-1911, 2001. Mousa S, Bozarth J, Naik U, Slee, A: Platelet GPIIb/IIIa binding characteristics of small molecule RGD mimetic: Distinct binding profile for roxifiban. Br. J. Pharamcology, 133: 331-336, 2001.

Shaker A. Mousa, Ph.D. CURRICULUM VITAE Page 45 of 92

Mousa S, Forsythe M: Comparative efficacy for different platelet GPIIb/IIIa antagonists on the dynamics of platelet/fibrin-mediated clot strength induced by different stimulus using thrombelastography. Thrombosis Research, 104 (1): 49-56, 2001.

Kerr J, Mousa S, Slee A: Anti-integrins as a target for angiogenesis & restenosis. Drug News Perspect Emerging Therapeutic Targets, Ashley Publications Ltd, 14 (3): 1-8, 2001.

Colman RW, Jameson BA, Lin Y, Mousa S: Inhibition of Angiogenesis by Kininogen Domain 5. Blood, 95 (2): 543-550, 2000.

Wong MK, Prudovsky I, Vary C, Booth C, Liaw L, Mousa S, Maciag T: Jagged-1 regulates the formation of matrix-dependent chord-like structure in vitro and angiogenesis in vivo. Biochemical and Biophysical Research Comm., 268 (3): 853-859, 2000.

Ali S, O’Dounell A, Balu D, Pohl M, Seyler M, Mohamed S, Mousa S, Dandona P: Estrogen receptor-alpha in the inhibition of cancer growth and angiogenesis. Cancer Research, 60: 7094-7098, 2000.

Van Waes I, Enamorado D, Hecht L, Sulica Z, Chen G, Batt D, Mousa S: Effects of the novel v integrin antagonist SM256 and cis-platinum on growth of murine squamous cell carcinoma PAMLY8. Int. Journal of Oncology, 16 (6):1189-1195, 2000.

Mousa S: Potential role of platelet glycoprotein IIb/IIIa antagonists in cerebrovascular disorders. CNS Drugs, 13 (3): 155-160, 2000.

Mousa S: Anti-Integrins as a novel drug discovery targets: Therapeutic & Diagnostic Implications. Emerging Therapeutic Targets, Ashley Publications Ltd, 4 (2): 143-153, 2000.

Powell JA, Mohamed S, Kerr J, Mousa S: Anti-angiogenesis efficacy of nitric oxide donors. J. Cellular Biochemistry, 80: 104-114, 2000.

McCarty OJ, Mousa SA, Bray PF, Konstantopoulos K: Immobilized Platelet Support Human Colon Carcinoma Cell Tethering, Rolling and Firm Adhesion under Dynamic Flow Conditions. Blood, 96 (5):1789-1797, 2000.

Kim S, Mousa S, Varner J: Requirement of integrin alpha 5/ beta 1 and its ligand fibronectin in angiogenesis. American J. Pathology, 156: 1345-1362, 2000.

Suich D, Mousa S, Singh G, Liapakis G, Reisine T, DeGrado W: Novel template-constrained cyclic peptide analogs of Somatostatin: subtype Selective binding to Somatostatin receptors and anti-angiogenic efficacy. Bioorganic and Medicinal Chemistry, 8/9, 2229-2241, 2000.

Helluin O, Chan C, Vilaire G, Mousa S, DeGrado W, Bennett J: The activation state of alpha v/ beta3 regulates platelet and lymphocyte adhesion to intact and thrombin-cleaved osteopontin. J. Biol Chem. 275 (24): 18337-18343, 2000.

Mousa S: Alpha v/ Beta 3 Integrin blockade in interventional coronary restenosis. Int J. Cardiovascular Medicine and Science, 2 (3/4), 127-131, 2000.

Shaker A. Mousa, Ph.D. CURRICULUM VITAE Page 46 of 92

Batt D, Petraitis J, Houghton D, Modi G, Cain P, Bouchard M, Forsythe P, Corjay HM, Mousa S, et al: Disubstituted Indazoles as potent antagonists for the integrin av/b3. J. Medicinal Chemistry, 43 (1): 41-58, 2000.

Pitts W, Wityak J, Smallheer J, Tobin E, Jetter J, Buynitzky J, Harlow P, Corjay M, Mousa S, Wexler R, Jadhav P: Isoxazolines as potent antagonists for the integrin av/b3. J. Medicinal Chemistry, 43 (1): 27-40, 2000.

Somasundaram P, Sung BH, Mousa S, Wilson M: Acute Congestive Heart failure and tumor necrosis factor alpha. American Journal of Geriatric Cardiology, 9 (2): 76-80, 2000.

Mousa SA, Bozarth J, Forsythe M, Slee, A: Differential antiplatelet efficacy for various GPIIb/IIIa Antagonists: Role of Plasma Calcium Levels. Cardiovascular research, 47 (4): 819-826, 2000.

Sielckli T, Wityak J, Liu L, Mousa S, Thoolen M, Wexler R: Ring constrained analogs of alpha-alanine containing GPIIb/IIIa receptor antagonists. Biorganic and Med Chem Lett., 10 (5): 449-452, 2000.

Cue D, Southern S, Southern P, Prabhakar J, Lorelli W, Smallhear J, Mousa S, Cleary P: A nonpeptide integrin antagonist can inhibit epithelial cell ingestion of streptococcus pyogenes by blocking alpha 5/Beta 1-fibronectin-M1 protein complexes. Proceeding National Academy of Sciences, 97 (6): 2858-2863, 2000.

Mousa SA: Comparative Efficacy among Different Low Molecular weight Heparins (LMWHs) & Drug Interaction: Implications in the Management of Vascular Disorders. Thrombosis & Hemostasis, 26 (1): Suppl. 1, 39-46, 2000.

Walton HL, Corjay M, Mohamed S, Mousa S, Reilly T: Hypoxia induces expression of the integrin receptor alpha v/ beta 3 in cultured human endothelial cells. J. Cellular Biochem. 78: 674-680, 2000.

Mousa SA, S. Khurana, Forsythe M: Comparative in Vitro efficacy of different platelet GPIIb/IIIa antagonists on platelet-mediated clot retraction using tissue factor-thrombelastography: Distinct classes of GPIIb/IIIa antagonists. Arteriosclerosis, Thrombosis & Vascular Biology, 20:1162-1167, 2000.

Mousa SA, Forsythe M, Bozarth J, Lorelli W, Jin F, Confalone PN: Human platelet GPIIb/IIIa Integrin Binding affinity & specificity of SJ874: Antiplatelet efficacy versus Aspirin. Coronary Artery Diseases, 11: 563-570, 2000.

Mousa S: Role of Antiplatelet agents in stroke. Current Opinion in Investigational Drugs, 1 (4): 464-467, 2000.

Kerr J, Slee A, Mousa SA: Small Molecule alpha v Integrin Antagonists: novel Anti-Cancer Agents. Submitted Expert Opinion Investigational Drugs, Ashley Publications Ltd, 9 (6): 1271-1279, 2000.

Mousa S, Lorelli W, Mohamed S, Batt D, Jadhav PK, Reilly TM: Alpha v/ Beta 3 Integrin binding affinity and specificity of SM256 in various species. J. Cardiovascular Pharmacology, 33: 641-646, 1999.

Shaker A. Mousa, Ph.D. CURRICULUM VITAE Page 47 of 92

Mousa S: Anti-Integrin in Angiogenesis. Expert opinion, Ther. Patents, Ashley Publications Ltd, 9 (9): 1237-1248, 1999.

Rockwell A, Rafalski M, Pitts W, Batt D, Petraitis J, DeGrado W, Mousa S, Jadhav P: Rapid synthesis of RGD mimetics with isoxazoline scaffold on solid phase: Identification of alp v/ beta 3 antagonist lead compounds. Biorganic and Med Chem Lett., 9, 937-942, 1999.

Chen Z, Malhotra P, Thomas G, Ondrey F, Duffey D, Smith C, Enamorada D, Yeh N, Kroog G, Rudy S, McCullagh L, Mousa S et al: Expression of proinflammatory and proangiogenic cytokines in patients with head and neck cancer. Clinical Cancer Res, (5): 1369-1379, 1999.

Mousa SA, Lorelli W, Campochiaro PA: Role of hypoxia and extracellular matrix-integrin binding in the modulation of angiogenic growth factors secretion by retinal pigmented epithelial cells. J. Cellular Biochemistry, 74 (1): 135-143, 1999.

Ali SH, O’Donnell AL, Mohamed S, Mousa S, Dondona P: Stable over-expression of estrogen receptor-alpha in ECV304 cells inhibits proliferation, endothelin-1 and vascular endothelial growth factor. Molecular and Cellular Endocrinology, 152 (1-2): 1-9, 1999.

Mousa SA, Kapil R, Mu D: Intravenous and Oral antithrombotic efficacy of Roxifiban (DMP754) & its free acid form, XV459. Atherosclerosis Thrombosis & Vascular Biology, 19: 2535-2541, 1999.

Wityak J, Tobin E, Mousa S, Wexler R, Olson R: Novel isoxazoline GPIIb/IIIa antagonists bearing a phosphoramidate moiety. Biorganic and Med Chem Lett., 9 (2): 123-126, 1999.

Mousa S, Wilson M, Taheri S: Soluble adhesion molecules as potential diagnostic markers of disease states. The Medical Examiner, Vol. 1, 1-3, 1999.

Olson R, Sielecki TM, Wityak J, Pinto D, Batt D, Frietze W, Liu J, Tobin E, Orwat M, DiMeo SV, Lalka G, Mousa S, et al.: Orally active isoxazoline glycoprotein IIb/IIIa antagonists with extended duration of action. J. Med. Chem., 42 (7): 1178-1192, 1999.

Mousa S: Antithrombotics and Hematological disorders. Current Opinion in Cardiovascular, Pulmonary & Renal Investigational drugs. Vol. 1 (1), 9-12, 1999.

Taheri S, Shenoy S, Murawski S, Divan K, Gullin J, Mousa SA: Diagnosis of pulmonary embolism by use of TNF-alpha and its TNF receptor I. Angiology 50 (9): 703-706, 1999. Mousa S: Antiplatelet Therapies: From Aspirin to Platelet GPIIb/IIIa Antagonists & Beyond. Drug Discovery Today, 4 (12): 552-561, 1999.

Mohamed S, Forsythe M, Mousa S: Effect of platelet specific integrin alpha IIb/ Beta 3 antagonists on platelet stimulated -granular secretion of PDGF. Biochem. Archives, 15: 89-97, 1999.

Confalone PN, Jin FQ, Mousa SA : Platelet glycoprotein IIb/IIIa receptor antagonists derived from isoxazolines. Biorganic & Medicinal Chemistry Letters, 9 (1): 55-58, 1999.

Shaker A. Mousa, Ph.D. CURRICULUM VITAE Page 48 of 92

Wityak J, Tobin AE, Mousa SA, Wexler RR, Olson RE: Isoxazoline GPIIb/IIIa antagonists bearing a phosphoramidate. Bioorganic Med Chem Lett 9 (2): 123-126, 1999.

Olson R, Sielecki T, Wityak J, Pinto D, Batt D, Mousa S et al: Isoxazoline glycoprotein IIb/IIIa antagonists with extended duration of action. Actual. Chem Ther. 25: 19-32, 1999.

Barrett J, Yu J, Kapil R, Padovani P, Brown F, Ebling W, Corjay M, Reilly T, Bozarth J, Mousa S, Pieniaszek H: Disposition and exposure of the fibrinogen receptor antagonists XV459 on alpa IIb/beta 3 binding sites in the guinea pig. Biopharmaceutical & Drug Disposition. Xx, 1-17, 1999.

Mousa S, Bozarth J, Edward S, Carroll T, Barrett J: Novel Technetium-99m Labeled Platelet GPIIb/IIIa Receptor Antagonists for Imaging Venous & Arterial Thrombosis. Coronary Artery Disease, 9 (2/31): 1-11, 1998.

Mousa S: Angiogenesis: Regulation & Dysfunction. Molecular Medicine Today, 4 (3)101, 1998.

Mousa S, Forsythe MS, Bozarth JM, Youssef A, Wityak J, Olson RE, Sielecki TM: XV454, a novel non-peptide small molecule platelet GPIIb/IIIa antagonist with comparable platelet aIIbb3-binding kinetics to c7E3. Journal Cardiovascular Pharmacology, 32 (5):736-744, 1998.

Xue CB, Roderick J, Mousa S, Olson R, DeGrado W: Synthesis and antiplatelet effects of an isoxazole series of glycoprotein IIb/IIIa antagonists. Biorganic & Medicinal Chemistry Letters, 8 (24): 3499-3504, 1998.

Mousa S, Kerr J, Ho A: Angiogenesis in Vascular Disorders. Current Drugs, Current Research in Vascular Diseases, 3(1): 1-5, 1998.

Mousa S, Bozarth J, Youssef A, Levine B: Oral antiplatelet efficacy of the platelet GPIIb/IIIa antagonist, DMP754 in non-human primates. Thrombosis Research, 89: 217-225, 1998.

Mousa S, Mu D, M. Hussain: Intranasal antiplatelet / antithrombotic efficacy of a novel platelet GPIIb/IIIa antagonist, DMP755 in non-human primates. Thrombosis Research, 92 (3): 115-124, 1998.

Michaelis W, Turlapaty P, Kornhauser D, Gray J, Fiske W, Faulkner E, Mousa S: Pharmacodynamics and pharmacokinetics of DMP728, a platelet GPIIb/IIIa antagonist in healthy subjects. Clinical Pharmacol & Therapeutics, 63: 384-392, 1998.

Mousa S: Angiogenesis: Potential Therapeutic Applications. Drugs of the Future 23 (1): 51-60, 1998.

Van Waes C, Hecht D, Mousa S: Tumor Remodeling In Cancer & Anti-cancer Therapy. Biochem. Arch., (14): 71-91, 1998.

Mousa S, Wityak J: Orally Active Isoxazoline Platelet GPIIb/IIIa Antagonists. Cardiovascular Drug Review, 16 (1): 48-61, 1998.

Mousa S, Olson RE, Bozarth JM, Lorelli W, Forsythe MS, Racanelli A, Gibbs S, Schlingman K, Bozarth T, Kapil R, Wityak J, Sielecki TM, Wexler R, Thoolen MJ, Slee A, Reilly TM, Anderson PS,

Shaker A. Mousa, Ph.D. CURRICULUM VITAE Page 49 of 92

Friedman PA: Oral Antiplatelet Efficacy and Specificity of A Novel Non- Peptide Platelet GPIIb/IIIa Receptor Antagonist, DMP 802. Journal Cardiovascular Pharmacology, 32 (2):169-176, 1998.

Mousa S, Wityak J, Forsythe M, Bozarth J, Lorelli W, Mu D: Oral Antiplatelet and Antithrombotic Efficacy & Specificity of XR300, a novel Platelet GPIIb/IIIa Receptor Antagonist. J. Cardiovascular Pharmacology, 31:441-448, 1998.

Hantgan RR, Mousa SA: Inhibition of platelet -mediated clot retraction by integrin antagonists. Thrombosis Research, 89: 271-279, 1998.

Mousa S, Bozarth JM, Lorelli W, Forsythe MS, Martin Thoolen, Slee A, Reilly TM, Friedman PA: Discovery of Novel Orally Active Non-Peptide Platelet GPIIb/IIIa Receptor Antagonist, DMP754: Comparative Platelet Binding Profiles with c7E3. Journal Pharmacol & Exp. Thera., 286 (3): 1277-1284, 1998.

Taheri S, Mousa S: Diagnosis of deep vein thrombosis using soluble tissue necrosis factor receptor (s-TNFR). Angiology: J. of Vascular Diseases, 49 (7): 1-5, 1998.

Pedicord D, Thomas B, Mousa S, Dicker I: GPIIb/IIIa receptor antagonists inhibit the development of platelet procoagulant activity: Mechanistic analysis. Thrombosis Research, 90: 247-258, 1998.

Mousa SA, Forsythe M, Bozarth J, Youssef A, Wityak J, Olson R, Sielecki T. XV454, A Novel Non-Peptide Small Molecule Platelet GPIIB/IIIA Antagonist with Comparable Platelet AIIBB3 Binding Kinetics toc7E3. J. Cardiovascular Pharmacology, 32 (5): 1-9, 1998.

Xue CB, Mousa S: DMP754: Roxifiban. Antiplatelet/Antithrombotic Glycoprotein IIb/IIIa Antagonist. Drugs of the Future, 23 (7): 707-711, 1998.

Bozarth J, Penno M, Mousa S: An improved method for the quantitation of cellular migration: Role of avb3 integrin in endothelial and smooth muscle cell migration. Methods in Cell Science, 19 (3): 179-187, 1997.

Mousa S, Srivatsa SS: Vascular and Tissue Remodeling. Current Drugs in Atherosclerosis, 2 (7): 293-303, 1997.

Penno MB, Mousa S, Bozarth J, Hart JC: Rapid and quantitative measurement of chemotaxis & invasion. J. Method in Cell Science, 19 (3): 189-195, 1997.

Mousa S: Antiplatelet Therapies: Platelet Glycoprotein IIb/IIIa Receptor Antagonists. Drug & Market Development, 8 (10): 223-226, 1997.

Mousa S: Angiogenesis: Potential Therapeutic Applications. Drug & Market Development, Sept. Issue, 44-51, 1997.

Bennett JS, Chan C, Vilaire G, Mousa S, DeGrado W: Agonist-activated alpha v/ beta 3 on platelets and lymphocytes binds to the matrix protein osteopontin mediates platelet adhesion to the matrix protein osteopontin. J. Biol. Chem. 272 (13): 8137- 8140, 1997.

Shaker A. Mousa, Ph.D. CURRICULUM VITAE Page 50 of 92

Hussain MA, Aungst BJ, Kapil R, Mousa SA: Intranasal absorption of the platelet glycoprotein IIb/IIIa antagonist, DMP755, and the effect of anesthesia on nasal bioavailability. J. Pharm. Science, 86 (12): 1358-1360, 1997.

Mousa S, Cheresh D: Recent Advances in Cell Adhesion Molecule (CAM): Potential Clinical Utility. Drug Discovery Today, 2 (5): 9-21, 1997.

Xue CB, Roderick J, Jackson S, Rafalski M, Rockwell A, Mousa S, Olson R, DeGrado W: Design, Synthesis and in vitro activities of benzamide-core glycoprotein IIb/IIIa antagonists: 2,3- diaminopropionic acid derivatives as surrogates of aspartic acid. BioOrganic & Medicinal Chem., 5 (4): 693-705, 1997.

Kapil R, Emm T, Mousa S, Padovani P, Quon C, Lam G: Biological matrix-dependent pharmacokinetic and pharmacodynamic parameters of a novel antiplatelet agent, XU063, in beagle dogs. Thromb. Res. 86 (3): 221-232, 1997.

Wityak J, Sielecki T, Pinto D, Sze J, Liu J, Tobin E, Wang S, Jiang B, Emmett G, Ma P, Mousa S, Olson R, Wexler R. The discovery of potent Isoxazoline glycoprotein IIb/IIIa receptor antagonists. J. Med. Chem., 40: 50-60, 1997.

Tsao, PW, Forsythe, MS, Mousa S: Dissociation between the antiaggregatory and anti-secretory effects of platelet integrin aIIbb3 (GPIIb/IIIa) antagonists: c7E3 and DMP728. Thrombosis Research, 88 (2), 137-146, 1997.

Xue CB, Wityak J, Sielecki T, Pinto D, Batt D, Cain G, Sworin M, Rockwell A, Emmett G, Liu J, Wang S, Orwat M, Bostrom L, Higley CA, Tobin E, Frietze W, Lalka G, Sze J, Zhang LH, Ma P, Mousa S, et al.: The discovery of an orally active Isoxazoline GPIIb/IIIa receptor antagonists. J. Med. Chem., 40 (13): 2064-2084, 1997.

Mousa S, Mu D, Lucchesi B: Prevention of Carotid Artery Thrombosis by Oral Platelet GPIIb/IIIa Antagonist. STROKE, 28: 830-836, 1997.

Corbett JW, Gracini NR, Mousa SA, DeGrado WF. Solid-Phase Synthesis of a Selective v 3 Integrin Antagonist Library. Biorganic Med. Chem. Lett., 7 (11): 1371-1376, 1997.

Srivasata S, Tsao P, Reilly T, Shwartz R, Holmes D, Mousa S: Selective alpha v/ beta 3 integrin blockade limits neointima hyperplasia and lumen stenosis in stented porcine coronary artery injury in Pig. Cardiovascular Res., 36:408-428, 1997.

Mousa S, DeGrado W, Mu D, Kapil R, Lucchesi B, Reilly TM: Oral antiplatelet, Antithrombotic efficacy of a novel orally active platelet GPIIb/IIIa antagonist, DMP728 in dogs. Circulation, 93(3): 537-543, 1996.

Mousa S: Angiogenesis Promoters and Inhibitors: Potential Therapeutic Applications. Molecular Medicine Today, 2 (4): 140-142, 1996.

Bach AC, Espina R, Jackson S, Stouten P, Mousa S, DeGrado W: Type II to Type I Beta Turn Swap Changes Specificity for Integrins. J. Am. Chemical Society, 118: 293-294, 1996.

Shaker A. Mousa, Ph.D. CURRICULUM VITAE Page 51 of 92

Mousa S: Nitric Oxide and its role in vascular and other diseases, Part I. Drug & Market Development, 7 (3): 55-57, 1996.

Mousa S, Bennett J: Platelets in Health & Diseases: Platelet GPIIb/IIIa Structure and Function: Recent Advances in Anti-Platelet Therapy. Drugs of the Future, 21(11):1141-1154, 1996.

Burgess K, Lim D, Mousa S: Synthesis and Solution Conformation of Cyclo-[RGDRGD]: A Cyclic Peptide with Selectivity for The alpha v / beta 3 Receptor. J. Medicinal Chemistry, 39 (22): 4520-4526, 1996. Dondana P, Thusu K, Khurana U, Love J, Aljada A, Mousa S: Calcium, Calmodulin and protein kinase C dependence of platelet shape change. Thrombosis Research, 82 (2): 163-175, 1996.

Mousa S: Angiogenesis Modulators and vascular mediated disorders, Part 2. Drug & Market Development, 7 (2): 30-34, 1996.

Luna J, Tobe T, Mousa S, Reilly T, Campochiaro P: Antagonist of Integrin alpha v / beta 3 Inhibit Retinal Neovascularization in Murine Model. Lab. Investigation, 75 (4), 563-573, 1996.

Mousa S, Forsythe M, Lorelli W, Bozarth J, Xue CB, Wityak J, Sielecki T, Olson R, DeGrado W, Wexler R, Thoolen M, Reilly T: Discovery of Novel Nonpeptide Antiplatelet GPIIb/IIIa Receptor Antagonist, DMP754: Receptor Binding Affinity & Specificity. Coronary Artery Disease, 7 (10): 767-774, 1996.

Mousa S: Recent Advances in Cell Adhesion Molecules (CAM) Research & Development: Targeting CAM for Therapeutic and Diagnostic Applications. Drugs of the Future, 21(3): 283-289, 1996. Mousa S: Therapeutic & Diagnostic Implications of Cell Adhesion Molecule and Matrix Proteins. Drug & Market Development, 7 (9), 199-206, 1996.

Mousa S: Angiogenesis in Ocular, Cancer, Wound Healing & Cardiovascular Diseases: Potential Therapeutic Applications. Drug & Market Development, 7 (10): 226-230, 1996.

Mousa S: Vascular Remodeling. Drug & Market Development, 7 (8): 173-177, 1996.

Aungst B, Saitoh H, Burcham D, Huang SM, Mousa S, Hussain M: Enhancement of the intestinal absorption of peptides and non-peptides. J. Controlled Release, 41: 19-31, 1996.

Mousa S, Forsythe M, Reilly TM: Platelet-Endothelial cell interactions in mediating the release of plasminogen activator inhibitor type-1. Biochem Arch., 12, 43-53, 1996. Xue C, Rafalaski M, Roderick J, Eyermann J, Mousa S, Olson R, DeGrado W: Design, Synthesis and in vitro activities of a series of benzimidazole/benzoxazole glycoprotein IIb/IIIa inhibitors. Bioorganic and Med. Chem. Letters, 6, 339, 1996.

Mousa S: Cell Adhesion Molecule Research & Therapeutic Targets. Drugs & Market Development. 6 (1): 12-16, 1995.

Shaker A. Mousa, Ph.D. CURRICULUM VITAE Page 52 of 92

Tsao P, Mousa S: Thrombospondin mediates Calcium mobilization in fibroblasts via its Arg-Gly-Asp and carboxy-terminal domains. J. Biol. Chem., 270 (40): 23747-2375, 1995.

Mousa S: Update in Cell Adhesion Molecule (CAM) Research and Development: Targeting CAM for Therapeutic & Diagnostic Applications. Drug & Market Development. 6 (9): 201-205, 1995.

Tsao P, Bozarth J, Pierce S, Mousa S. Platelet GPIIb/IIIa receptor occupancy: Flow cytometric analysis. Thrombosis Research, 77 (6): 543-556, 1995.

Reilly TM, Mousa S, Racanelli A, Thoolen M, Flint S, Bozarth J, Mu D, Walton H: A monoclonal antibody which recognizes the GPIIb/IIIa antagonist DMP728: Reversal of DMP728's effects on platelet aggregation and bleeding time in dog. Arteriosclerosis & Thrombosis, 15 (12): 2195-2199, 1995.

Mousa S: Implications of Angiogenesis in Cancer (Part I). Drug & Market Development, 6 (10): 218-220, 1995.

Wityak J, Fevig J, Jackson S, Johnson A, Mousa S, Parthasarathy A, Wells G, DeGrado W, Wexler R: Synthesis and antiplatelet activity of DMP757 analogs. Bioorg. Med. & Chem. Letter, 5 (18): 2097-2100, 1995. Mousa S, Bozarth J, Forsythe M, Jackson S, Leamy A, Diemer M, Kapil R, Knabb R, Mayo M, Pierce S, De Grado W, Thoolen M, Reilly T: Antiplatelet, antithrombotic efficacy of DMP728, a novel platelet GPIIb/IIIa receptor antagonist. Circulation, 89: 3-12, 1994.

Mousa S, Hassell S, Pierce S, Lorelli W, De Grado W, Thoolen M, Reilly T: Intravenous anti-platelet efficacy and safety of the platelet GPIIb/IIIa antagonist, DMP728 in anesthetized dogs. Thromb. Res., 76 (2): 109-119, 1994.

Mousa S, Bozarth J, Forsythe M, Pease L, Reilly TM: Role of platelet GPIIb/IIIa receptors in the modulation of platelet plasminogen activator inhibitor type-1 (PAI-1 release). Life Sciences, 54 (16): 1155 - 1162, 1994.

Mousa S, DeGrado W, Reilly TM: Platelet GPIIb/IIIa antagonists: How safe is this antithrombotic approach? Am. J. Medicine, 96, 300, 1994.

Mousa S, Forsythe M, Diemer M, Thoolen M, Reilly TM. Thrombolytic antithrombotic, efficacy of the platelet GPIIb/IIIa antagonist DMP728. Coronary Artery Diseases, 5 (11): 919-927, 1994.

Jackson S, DeGrado WF, Dwivedi A, Parthasarathy A, Higley A, Krywko J, Rockwell A, Markwalder J, Wells G, Wexler R, Harlow R, Mousa S: Template-constrained cyclic peptides: design of high affinity ligand for the platelet GPIIb/IIIa receptors. J. Am. Chem. Soc., 116 (8): 3220-3230, 1994.

Rote W, Davis J, Mousa SA, Reilly TM, B. Lucchesi R: Antithrombotic effects of DMP 728, a platelet GPIIb/IIIa receptor antagonists, in a canine model of arterial thrombosis. Journal Cardiovascular Pharmacology, 23: 681-689, 1994.

Shaker A. Mousa, Ph.D. CURRICULUM VITAE Page 53 of 92

Reilly T, Mousa S, Seetharam R, Racanelli A: Recombinant plasminogen activator inhibitor type 1: A review of structural, functional, and biological aspects. Blood Coagulation & Fibrinolysis, 5: 73-81, 1994. O’Neil K, De Grado W, Mousa S, Ramachandran N, Hoess R : Identification of recognition sequences of adhesion molecules using phage display technology. Methods in Enzymology, 245: 370-386, 1994.

Mousa S, Forsythe M, Hassell S, Bozarth J and Reilly T: Effect of single oral dose of aspirin on human platelet functions and plasma levels of plasminogen activator inhibitor type-1. Cardiology, 83 (5-6): 367-373, 1993. Mousa S, Bozarth J, Forsythe M, Lorelli W, Jackson S, Ramachandran N, DeGrado W, Thoolen M, Reilly T: Antiplatelet efficacy and specificity of a novel platelet GPIIb/IIIa receptor antagonist, DMP728. Cardiology, 83 (5-6): 374-382, 1993.

Mousa S, Reilly TM: Pharmacological blockade of platelet GPIIb/IIIa and the inherited disorders of the platelet GPIIb/IIIa (Glanzmann's Thrombasthenia): How safe is this antithrombotic approach for both acute and chronic treatment of thromboembolic disorders? Cardiology, 83: 36-37, 1993.

Mousa S, Forsythe M, Dwivedi A, Reilly T: Protective effect of vitronectin on oxidant-induced inactivation of recombinant plasminogen activator inhibitor type 1 (rPAI-1): Structural and functional analysis. Biochemical Archives, 9: 205-216, 1993.

Pease L, Bozarth J, Robinson C, Gillies P, Reilly TM, Mousa S: Increased Platelet GPIIb/IIIa in genetically hypercholesterolemic rabbits. Biochem. Arch., 9 (4): 311-320, 1993.

Reilly TM, Forsythe MS, Racanelli AL, Spitz SM, Walton HL, Mousa, SA: Recombinant plasminogen activator inhibitor-1 protects platelet against the inhibitory effects of plasmin. Thrombosis Research. 71: 61-68, 1993.

O’Neil K, Hoess R, Jackson S, Ramachandran N, Mousa S: Identification of novel peptide antagonists for GPIIb/IIIa using a conformationally constrained peptide library. PROTEINS: Structure, Function and Genetics 14:509-515, 1992.

Reilly TM, Knabb R, Hassell S, Bozarth J, Forsythe M, Mayo M, Racanelli A, and Mousa S. Effect of Thrombin Inhibitors on Platelet Functions: Comparative Analysis of DuP 714 and Hirudin. Blood Coagulation and Fibrinolysis, 3:513-517, 1992.

Mousa SA, Cooney JM: Kinetics of TC-99m Sestamibi Versus TL201 in Transient Ischemic Animal Models: Insight into the "Redistribution" Phenomenon. Cardiology, 81 (3), 157-163, 1992.

Kerr J, Mackin W, Timmermans P, Mousa S: Azapropazone: New indications for an old drug. Drugs of Today, 28(5):299-301, 1992.

Reilly T, Forsythe M, Dwivedi A, Walton H, Mousa S. Vitronectin effects on recombinant plasminogen activator inhibitor-1: Structural and Functional analysis. Fibrinolysis, 6:167-171, 1992.

Shaker A. Mousa, Ph.D. CURRICULUM VITAE Page 54 of 92

Mousa SA, Ritger R: Effect of the duration of coronary artery occlusion on the recovery of regional myocardial Function post reperfusion in anesthetized swine. Biochem. Arch., 8,273-282, 1992.

Khaw BA, Mousa SA, Haber E: Comparative Assessment of Experimental Infarction with TC99m-Sestamibi, IN-111 Antimyosin and TL201. Nuclear Med. Comm. 12,853-863, 1992. Mousa SA, Ritger R: Leukocyte Infiltration into Regional Ischemic/Reperfused Myocardium. Biochem. Arch., 8,165-174, 1992.

Mousa SA, Ritger R, Smith RD: Myocardial cytoprotective efficacy and safety of deferoxamine conjugated to hydroxyethyl starch in a swine model of regional ischemia/reperfusion injury. J. Cardiovasc. Pharmacol 19,425-429, 1992. Reilly T, Racanelli A, Mousa S: Recombinant plasminogen activator inhibitor-1: Anti-fibrinolytic. Drugs of the Future 17(12):1091-1092, 1992.

Mousa S, Rainsford K, Timmmermans P: Pharmacology of Azapropazone. Cardiovas. Drug review. 10(3): 323-332, 1992.

Mousa SA, Patil G, Mayo MC, Tong TM: Myocardial anti-ischemic characteristics of a novel class of B-adrenoceptor blockers. Int. J.Clin.Pharmacol. &Tox. 30(3),103-106,1992.

Mousa SA, Carroll T, Morgan R: Effect of Commonly used Drugs in the Cardiac Care Unit and Myocardial Extraction Kinetics of TC-99m Sestamibi. Int. J. Clinical Pharmacol & Thera., 29(1), 14-18, 1991.

Mousa SA, Conney JM: Detection Sensitivity of Coronary Artery Stenosis by TC99m-Sestamibi and TL-201 IN Canine Model of Partial and Subcritical Stenosis. Cardiology 79 (2), 135-150, 1991. Chiu AT, Mousa S, Pease L, Roscoe WA, Bozarth J, Reilly TM, Smith RD, and Timmermans PB: Inhibition of the thrombin-platelet reactions by Dup 714. Biochem. Biophys. Res. Comm. 179(3), 1500-1508, 1991.

Mousa S: Animal Models in Radiotracer Design of a Tc-Labelled Myocardial Perfusion Agent. American Journal of Physiologic Imaging, 6 (1), 16-25, 1991.

Mousa SA, Cooney JM, Williams SJ: Relationship between Regional Myocardial Blood Flow and the Distribution of TC99m-Sestamibi in the Presence of Total Coronary Artery Occlusion. Am. Heart J., 119(4), 842-848, 1990.

Mousa SA, Brown R, Thoolen M, Smith RD: Evaluation of the effect of azapropazone on neutrophil migration in regional myocardial ischemia/reperfusion injury in rabbit. Br. J. Pharmacol. 100,379-382, 1990.

Mousa SA, Brown R, Chan Y, Hisch J, Smith RD: Evaluation of the effect of azapropazone on neutrophil migration in anesthetized swine using a multiblister suction technique. Br. J. Pharmacol., 99, 233-236, 1990.

Shaker A. Mousa, Ph.D. CURRICULUM VITAE Page 55 of 92

Mousa SA and Ritger R: Myocardial cytoprotective efficacy of azapropazone in a swine model of regional ischemia/reperfusion injury. Int. J.Clin. Pharmacol. 29(2), 51-58, 1990. Mousa SA, Williams SJ, Sands H. Characterization of In Vivo Chemistry of Cations in the Heart. J. Nuclear Medicine, 28(8), 1351-1357, 1989.

Mousa SA, Conney JM, Thoolen M, Timmermans P: Myocardial cytoprotective efficacy of Azapropazone in a canine model of regional ischemia/reperfusion. J. Cardiovasc. Pharmacol. 14, 542-548, 1989.

Mousa SA, Khalil MN, Hubner PJ: 99mTc Hexakis-t-butylisonitrile (TBI): An Agent for the Diagnosis of Coronary Artery Diseases. Int. J. Clinical Pharmacol. & Thera. 27(2), 66-75, 1989. CNS PHARMACOLOGY: Kiritsy JA, Mousa SA, Appel NM, Van Loon GR: Tolerance to nicotine-induced sympathoadrenal and cross-tolerance to stress: Differential central and peripheral mechanisms in rats. Neuropharmacology, 29 (6): 579-589, 1990.

Mousa SA, Aloyo VJ, Van Loon GR: "Tolerance to Nicotine or Tobacco Smoke-induced Analgesia". Biochem. Pharmacol. & Behav. 31 (2), 265-268, 1988. Aloyo VJ, Mousa S, VanLoon GR: "Stabilization of Methionine-Enkephalin in Human and Rat Blood", Life Science, 39, 21-28, 1986. Mousa S, Tijioe S, Couri D: Decreased Enkephalinase Activity Following Postnatal Treatment with Phenobarbital. Neuropharmacology, 24(1), 9-11, 1985. Mousa S, Van Loon GR: "Current Concepts", Measurements of Proenkephalin A - Derived Peptides in Biological Tissues by HPLC Coupled with Amperometric Electrochemical Detection. Life Sciences, 37, 1795-1802, 1985. Mousa S, Van Loon GR, Audi A, Hand P, Crooks A: "High-performance Liquid Chromatography with Electrochemical Detection For the π Determination of Nicotine and N-methyl nicothinium Ion", J. Chromatography, 347, 405-410, 1985.

McGivern RF, Clancy AN, Mousa S, Couri D, Noble EP: "Prenatal Alcohol Exposure Alters Enkephalin Levels, Without Affecting Ethanol Preference. Life Sciences, 34, 585-589, 1984. Mousa S, Miller CH, Couri D: "Dexamethasone and Stress Induced Analgesia in Rats", Psychopharmacology, 79, 194-202, 1983.

Mousa S, Couri D: "Adrenal-Pituitary Axis and the Opiate System". J. Substance and Alcohol Action/Misuse, 4(1), 1-18, 1983.

Shaker A. Mousa, Ph.D. CURRICULUM VITAE Page 56 of 92

Mousa S, Couri D: "Analysis of Enkephalins and B-endorphin by HPLC-EC Method: Implication in Metabolism of Opioid Peptides". J. Chromatography, 267, 191-198, 1983. K. Vaswani, Tejwani GA, Mousa S: "Stress-Induced Differential Intake of Various Diets and Water by Rats: The Role of the Opiate System", Life Sciences, 32, 17, 1983-1996, 1983. McGivern RF, Mousa S, Couri D, Bernston GG: "Chronic Stress Decreases Met- and Leu-enkephalin Levels in Brain with Concomitant Decreases in Pain Thresholds", Life Sciences, 33 (1), 47-54, 1983.

Mousa S, Dllet M, Couri D. "Sensitive and Specific High Performance Liquid Chromatographic Methods for Enkephalins", Life Sciences, 29(1), 51-68, 1981. Tejwani GA, Mousa S: "The Allosteric Property of the Rat Lung Phosphofructokinase: ENZYME, 26, 306-314, 1981. Mousa S, Miller CH, Couri D: "Corticosteroid Modulation and Stress Induced Analgesia", Neuroendocrinology, 33, 317-318, 1981. Mousa S, Miller CH, Couri D: "Dimethylsulfoxide and Pain Sensitivity in Rats", J. Substance and Alcohol Action-Misuse, 2, 241-248, 1981.

BOOK CHAPTERS

Bowen N, Mousa SA. Role of antiplatelet therapy in neurosurgery: Efficacy and safety profiles. In: Loftus CM, ed. Anticoagulation and hemostasis in neurosurgery. Switzerland: Springer; 65-89, 2016. El-Fawal HA, Rembisz R, Alobaidi R, Mousa SA. Chemotherapy-mediated pain and peripheral neuropathy: Impact of oxidative stress and inflammation. In: Armstrong D, Stratton RD, eds. Oxidative stress and antioxidant protection: The science of free radical biology and disease. Hoboken, New Jersey: John Wiley & Sons, Inc. 367-388, 2016. Rajabi M, Srinivasan M, Mousa SA. Nanobiomaterials in drug delivery. In: Grumezescu, A, ed. Nanobiomaterials in drug delivery: William Andrew Publishing; 1-37:2016. Srinivasan M, Rajabi M, A. Mousa SA. Nanobiomaterials in cancer therapy. In: Grumezescu, A, ed. Nanobiomaterials in cancer therapy: William Andrew Publishing; 57-89; 2016. Mousa SA, Davis, PJ. Angiogenesis and anti-angiogenesis strategies in cancer. In: Mousa SA, Davis PJ, eds. Anti-angiogenesis Strategies in Cancer Therapies. Elsevier, London: Academic Press; 1-19:2016.

Mousa SA, Yalcin M, Davis PJ. Models for assessing anti-angiogenesis agents: Appraisal of current techniques. In: Mousa SA, Davis PJ, eds. Anti-angiogenesis Strategies in Cancer Therapies. Elsevier, London: Academic Press; 21-38:2016. Mousa SA, Muralidharan-Chari V, Davis PJ. Interface between thrombosis-inflammation and

Shaker A. Mousa, Ph.D. CURRICULUM VITAE Page 57 of 92

angiogenesis. In: Mousa SA, Davis PJ, eds. Anti-angiogenesis Strategies in Cancer Therapies. Elsevier, London: Academic Press; 51-68:2016. Davis PJ, Leinung M, Mousa, SA. MicroRNAs and angiogenesis. In: Mousa SA, Davis PJ, eds. Anti-angiogenesis Strategies in Cancer Therapies. Elsevier, London: Academic Press; 69-84:2016. Mousa SA, Abutaleb M, Davis PJ. Naturally occurring anti-angiogenesis agents. In: Mousa SA, Davis PJ, eds. Anti-angiogenesis Strategies in Cancer Therapies. Elsevier, London: Academic Press; 85-97:2016. Mousa SA, *Darwish NHE, Davis PJ. Integrin antagonists and angiogenesis. In: Mousa SA, Davis PJ, eds. Anti-angiogenesis Strategies in Cancer Therapies. Elsevier, London: Academic Press; 99-123:2016. Davis PJ, Mousa SA. Tyrosine kinase inhibitors and angiogenesis. In: Mousa SA, Davis PJ, eds. Anti-angiogenesis Strategies in Cancer Therapies. Elsevier, London: Academic Press; 125-131:2016. Davis PJ, Mousa SA. Tetraiodothyroacetic acid at integrin αvβ3: A model of pharmaceutical anti-angiogenesis. In: Mousa SA, Davis PJ, eds. Anti-angiogenesis Strategies in Cancer Therapies. Elsevier, London: Academic Press; 133-146:2016. Mousa SA, Sudha T, Davis PJ. Anti-angiogenesis therapy and its combination with chemotherapy: Impact on primary tumor and its metastasis. In: Mousa SA, Davis PJ, eds. Anti-angiogenesis Strategies in Cancer Therapies. Elsevier, London: Academic Press; 147-163:2016. Bharali DJ, Rajabi M, Mousa SA. Application of nanotechnology to target tumor angiogenesis in cancer therapeutics. In: Mousa SA, Davis PJ, eds. Anti-angiogenesis Strategies in Cancer Therapies. Elsevier, London: Academic Press; 165-178:2016. Mousa SA, Davis PJ. New directions in anti-angiogenesis research. In: Mousa SA, Davis PJ, eds. Anti-angiogenesis Strategies in Cancer Therapies. Elsevier, London: Academic Press; 179-186:2016. Mousa S. Angiogenesis Modulations in Health and Disease. Edited by Mousa S, Davis PJ, Springer, 2013. Mousa, S. Oxidative Stress and Nanotechnology. Edited by Armstrong D, Bharali D, Humana. Chapter 14-16, 2013. Mousa S: Overview of Current Advances in Antiplatelet, Anticoagulants, and Thrombolytics. Methods In Molecular Medicine Series, The Humana Press Inc., Totowa, NJ, Edited by Mousa S, Humana. 2003

Mousa S: Antiplatelet Therapies from Aspirin to GPIIb/IIIa and beyond. Methods In Molecular Medicine Series, The Humana Press Inc., Totowa, NJ, Edited by Mousa S, Humana. 2003.

Mousa SA: Overview of Current Advances in Antiplatelet, Anticoagulants, and Thrombolytics. Methods In Molecular Medicine Series, The Humana Press Inc., Totowa, NJ, Edited by Mousa S, Humana. 2003.

Shaker A. Mousa, Ph.D. CURRICULUM VITAE Page 58 of 92

Mousa SA: Antiplatelet Therapies from Aspirin to GPIIb/IIIa and beyond. Methods In Molecular Medicine Series, The Humana Press Inc., Totowa, NJ, Edited by Mousa S, Humana. 2003.

Mousa SA: Low Molecular Weight Heparin beyond anticoagulation. Methods In Molecular Medicine Series, The Humana Press Inc., Totowa, NJ, Edited by Mousa S, Humana. 2003.

Mousa SA: Cell Adhesion Molecules in Health & diseases. Methods In Molecular Medicine Series, The Humana Press Inc., Totowa, NJ, Edited by Mousa S, Humana. 2003.

Mousa SA: Tissue Factor / Factor VIIa in Coagulation & beyond. Methods In Molecular Medicine Series, The Humana Press Inc., Totowa, NJ, Edited by Mousa S, Humana. 2003.

Mousa SA, Kaisser B, Iqbal O, Fareed J: Tissue Factor Pathway Inhibitor. Methods In Molecular Medicine Series, The Humana Press Inc., Totowa, NJ, Edited by Mousa S, Humana, 2003.

Iqbal O, Mousa SA: Combination between antiplatelets, anticoagulants, and thrombolytics. Methods In Molecular Medicine Series, The Humana Press Inc., Totowa, NJ, Edited by Mousa S, Humana. 2003.

Mousa S: Low Molecular Weight Heparin beyond anticoagulation. Methods In Molecular Medicine Series, The Humana Press Inc., Totowa, NJ, Edited by Mousa S, Humana. 2003. Mousa S: Cell adhesion Molecules: Potential Therapeutic and Diagnostic Implications. Manual of Clinical Laboratory Immunology, 6/E, Ed. N.R. Rose et al., ASM Press, Washington, DC., Chapter 39, 368-377, 2002.

Mousa S, R. Daly, C. Cannon, R. Giugliano: Oral GPIIb/IIIa antagonists: Second Generation agents. New Therapeutic Agents In Thrombosis and Thrombolysis, Ed. A. Sasahara, J. Loscalzo & Antiplatelet Section Editors: J. Wilerson, R. Giugliano, and Mousa S, Marcel & Deckker, New York, NY, 2002.

Mousa SA: Cell adhesion Molecules: Potential Therapeutic and Diagnostic Implications. Manual of Clinical Laboratory Immunology, 6/E, Ed. N.R. Rose et al., ASM Press, Washington, DC., Chapter 39, 368-377, 2002.

Mousa SA: Cell adhesion Molecules: Potential Therapeutic and Diagnostic Implications. Manual of Clinical Laboratory Immunology, 6/E, Ed. N.R. Rose et al., ASM Press, Washington, DC., Chapter 39, 368-377, 2002.

Mousa SA, Konstantopoulos K, Giugliano R: Oral Antiplatelet Therapies beyond Aspirin and Thienopyridines. In New Therapeutic Agents In Thrombosis and Thrombolysis, Ed. A. Sasahara, J. Loscalzo & Antiplatelet Section Editors: J. Wilerson, R. Giugliano, and Mousa S, Published By Marcel & Deckker, New York, NY, Chapter 28: 451-476, 2002.

Mousa S, R. Giugliano: Other Oral Antiplatelet Agents: Second Generation agents. New Therapeutic Agents In Thrombosis and Thrombolysis, Ed. A. Sasahara, J. Loscalzo & Antiplatelet Section Editors: J. Wilerson, R. Giugliano, and Mousa S, Marcel & Deckker, New York, NY, In Press, 2002.

Shaker A. Mousa, Ph.D. CURRICULUM VITAE Page 59 of 92

J. Willerson, R. Giugliano, Mousa S: Antiplatelet Therapies, Overviews. In New Therapeutic Agents In Thrombosis and Thrombolysis, Ed. A. Sasahara, J. Loscalzo & Antiplatelet Section Editors: J. Wilerson, R. Giugliano, and Mousa S, Marcel & Deckker, New York, NY, In Press, 2002. Mousa S: Cardiovascular, Renal and Metabolic: antithrombotic, hemostasis and hematological diseases. Edited by Mousa S, Current Opin. Invest. Drugs: 2 (8): 2001.

Mousa S: Cardiovascular, Renal and Metabolic: antithrombotic, hemostasis and hematological diseases. Edited by Mousa S, Current Opin. Invest. Drugs: 2 (2): 2001.

Mousa S: Mechanisms of Angiogenesis in Vascular Disorders: Potential therapeutic Targets. In Angiogenesis Inhibitors & Stimulators: Potential Therapeutic Implications. Ed. By Mousa S, R.G. Landes., Georgetown, TX, Chapter 1, 1-12, 2000.

Mousa S, J. Varner, Cheresh D: Integrin v in health & disease- Role of avb3 in metastasis, vascular remodeling and angiogenesis. In Angiogenesis Inhibitors & Stimulators: Potential Therapeutic Implications. Ed. By Mousa S, R.G. Landes., Gorgtown, TX, Chapter 4, 35-42, 2000.

Mousa S: Anti-angiogenesis Strategies: Potential Therapeutic Implications Targets. In Angiogenesis Inhibitors & Stimulators: Potential Therapeutic Implications. Ed. By Mousa S, R.G. Landes., Gorgtown, TX, Chapter 11, 120-123, 2000. Mousa S: Antithrombotic & Hematological Disorders. Current Opinion in Cardiovascular, Pulmonary and Renal Investigational Drugs. Edited by Mousa S, Current Drugs, London, UK Vol 2 (2), 2000.

Mousa S: Antiplatelet Therapies: Platelet GPIIb/IIIa antagonists and beyond. Antithrombotic & Hematological Disorders. Current Opinion in Cardiovascular, Pulmonary and Renal Investigational Drugs. Edited by Mousa S, Current Drugs, London, UK Vol 2 (2) 107-113, 2000.

Mousa S: Antithrombotics: Current Opinion in Cardiovascular, Pulmonary and Renal Investigational Drugs. Edited by Mousa S, Current Drugs, London, UK Vol 1 (1), 1999.

Mousa SA: Antiplatelet Therapies: Recent advances in the development Platelet GPIIb/IIIa Antagonists. Current Interventional cardiology reports, Edited by D. Holmes, 1 (3): 243-252, 1999. Mousa S: Antithrombotic & Hematological Disorders. Editorial overview. Current Opinion in Cardiovascular, Pulmonary and Renal Investigational Drugs. Edited by Mousa S, Current Drugs, London, UK Vol 1 (1)1-2, 1999. Mousa S, Varner J and Cheresh D: Potential Therapeutic Implication of an alpha v/ beta 3 Integrin: In Angiogenesis Book, Ed. Mousa S, Elsevier Science, Amsterdam, Netherland, 1999.

Mousa S: Introduction to Glycoprotein IIb/IIIa & Antiplatelet Agents. IBC-Eight Annual International Symposium on Advances in Anti-Coagulant, Antithrombotic & Thrombolytic Drugs: 1998.

Shaker A. Mousa, Ph.D. CURRICULUM VITAE Page 60 of 92

Mousa S: Antiplatelet / Antithrombotic Profiles of Platelet alpha IIb/ beta 3 receptor antagonists & IBC-Eight Annual International Symposium on Advances in Anti-Coagulant, Antithrombotic & Thrombolytic Drugs: 1998.

Mousa S: Recent advances in Cell Adhesion Molecules and Extracellular Matrix: Potential Clinical Implications. Ed. By Mousa S, Springer-Verlag Berlin Heidelberg New York and R.G. Landes., Gorgtown, TX, Chapter 1, 1-27, 1998.

Mousa S: Antiplatelet Therapies: Platelet an alpha IIb/ beta 3 Antagonists Ed. By Mousa S, Springer-Verlag Berlin Heidelberg New York and R.G. Landes., Gorgtown, TX, Chapter III, 41 - 51,1998.

Reilly T, Mousa S, Racanelli A: New Antiplatelet Drugs. Emerging Drugs: The Prospect for Improved Medicines. Ashly Publications Ltd., Ed. JD Fitzgerald, WC Bowman, JB Taylor, Emerging Drug, 1998.

Mousa S: Soluble Adhesion Molecules as a Potential Diagnostic Marker of Disease States .Ed. By Mousa S, Springer-Verlag Berlin Heidelberg New York and R.G. Landes Company, Georgetown , TX, Chapter XV, 241-248, 1998.

Mousa S: Recent Advances In Adhesion Molecules & Matrix Proteins: Role In Health & Diseases. Expert Opinion on Investigational Drugs. Ashley Publication Ltd, London, UK, 7 (7): 1159-1172, 1998.

Reilly T, Mousa S, Racanelli A: New Antiplatelet Drugs. Emerging Drugs: The Prospect for Improved Medicines. Ashly Publications Ltd., Ed. JD Fitzgerald, WC Bowman, JB Taylor, Emerging Drugs: 2: 73-91, 1997.

Mousa S, Bennett J: Structure and Function of Platelet GPIIb/IIIa Receptors Current Review of Interventional Cardiology, Third Edition. Patrick W. Serruys & David Holmes Ed. Current Medicine, Philadelphia, PA, 14: 1-10, 1997.

Mousa S, E. Topol: Novel Antiplatelet Therapies: Recent Advances In The Development of Platelet GPIIb/IIIa Receptor Antagonists. Current Review of Interventional Cardiology, Third Edition. Patrick W. Serruys & David Holmes Ed. Current Medicine, Philadelphia, PA, 13: 114-129, 1997.

Mousa S: Therapeutic implications & mechanisms of angiogenesis- Inhibitors and stimulators- IBC, Biomedical Lib. Series, Ed. by W. Hori, Introduction, i-xv, 1996.

Mousa S: Antiplatelet/Antithrombotic Effects of Platelet GPIIb/IIIa Receptor Antagonists, Thrombin Inhibitors, And Aspirin: A comparative Analysis. In Advances in Anticoagulants, antithrombotic& thrombolytic therapies. IBC, Biomedical Lib. Series, Ed. by G. Zavoico, C. Sussman, L. Savage, Chapter 3.7, 1996.

Mousa S: Therapeutic Potential of Platelet GPIIb/IIIa Receptor Antagonists as a novel Antiplatelet / Antithrombotic Strategy: Optimization of Thrombolysis. In Advances in Anticoagulants, antithrombotic& thrombolytic therapies. IBC, Biomedical Lib. Series, Ed. by G. Zavoico, C. Sussman, L. Savage, Chapter 6.11, 1996.

Shaker A. Mousa, Ph.D. CURRICULUM VITAE Page 61 of 92

Mousa S. Therapeutic Implications and mechanisms of angiogenesis-Inhibitors & stimulators. IBC's Biomedical Library Series, Boston, MA, Chapter 1, 1996.

Mousa S, K. D. Rainsford, Timmermans P: New therapeutic potential for an established drug: Azapropazone in neutrophil mediated ischemia/reperfusion injury: In Advances in anti-rheumatic therapy. CRC Press, Inc., Chapter 7:129-135, 1995.

Mousa S, T. M.Reilly. Antiplatelet effects of direct thrombin inhibitors versus GPIIb/IIIa receptor antagonists: Comparative analysis. In Cardiovascular Disease: Cellular & Molecular Mechanisms, Prevention, Treatment, Ed. by L.L.Gallo, Plenum Press, New York, 255-267, 1995.

Mousa S et al. AZAPROPAZONE, Azapropazone: 20 years of clinical use. 2nd Edition by K. D. Rainsford, Kluwer Academic Publishers, UK.1991.

Mousa SA, Brown R, W. M. Mackin, Turlapaty P, Smith RD and P. Timmermans. Dual Inhibitory Effects of Azapropazone on Both Neutrophil Migration and Function. Ed. K. D. Rainsford, Kluwer Academic Publishers, Medical Div., UK, Chapter, Azapropazone: 20 Years of Clinical Use, 9,107-122, 1990. R. M. Knabb, M. Thoolen, Mousa SA and P. Timmermans. Reduction of Irreversible Injury in Animal Models of Myocardial Ischemia by Treatment with Azapropazone. Ed. K. D. Rainsford, Kluwer Academic Publishers, Medical Div., UK, Chapter, Azapropazone: 20 Years of Clinical Use, 8, 95-106, 1990. M. Milks, Mousa S and Couri D: Phencyclidines, a Brief Review, "Recent Advances in Clinical Therapeutics II: Psychopharmacology, Neuropharmacology and GI Therapeutics. Ed. J. Yative and J. Bianchine, Grune and Stratton, Inc., Chapter 5, Vol. II, pp. 79-87, 1983. ABSTRACTS CARDIOVASCULAR PHARMACOLOGY / CARDIOLOGY DIAGNOSTICS & THERAPEUTICS:

Published Abstracts from 2002 to present at National and International meetings are not added

Mousa, S: Elevation of plasma von Willebrand factor (vWF) and TNF-alpha in obese subjects and its reduction by the low molecular weight heparin, tinzaparin. Blood, 100 (11), Part I, 1064, 278a, 2002. Mousa, S., Bozarth, J: Inhibitory effect of C-reactive protein on the release of tissue factor pathway inhibitor from human endothelial cells: Reversal by Low Molecular Weight Heparin. Blood, 100 (11), Part I, 1939, 498a, 2002.

Shaker A. Mousa, Ph.D. CURRICULUM VITAE Page 62 of 92

Pixley R.A., Sainz, I.M., Song, J.S., Mohamed, S., Powell J., Mousa, S, Colman R.W: Proangiogenic effect of High Molecular Weight Kininogen (HK) In Vivo: Evidence using a monoclonal antibody and Kininostatin. Blood, 100 (11), Part I, 2684, 681a, 2002. Mousa, S., Mohamed, S: Inhibition of endothelial tube formation and angiogenesis induced by FGF2 or Tissue Factor / VIIa by Low Molecular Weight Heparin or Tissue Factor Pathway Inhibitor (TFPI): Reversal by Anti-TFPI. Blood, 100 (11), 3757, 71b, 2002. Mousa, S., Liu, R: Effect of Low Molecular Weight Heparin and different heparin molecular weight fractions on Aggrecanase activity: Structure-Function Relationship. Blood, 100 (11), 3849, 93b, 2002. Hering, J., Jeske, W., Mousa, S., Fareed, J: Tinzaparin and unfractionated heparin inhibit TRAP-induced activation of platelets in primates after intravenous and subcutaneous administration: Haematological implications. Blood, 100 (11), 4012, 132b, 2002. Mousa, S., Bozarth, J., Johansen, K: Pharmacodynamic effects of subcutaneous administration of the LMWH tinzaparin in Obese and hemodialysis subjects on TFPI and NO. Blood, 100 (11), 3985, 126b, 2002. Mousa, S., Fareed, J: Acute versus chronic effects of LMWH, Tinzaparin on plasma TFPI and NO in DVT and healthy human subjects. Blood, 100 (11), 3987, 126b, 2002.

Fareed, J., Iqbal, O., Schultz, C., Tobu, M., Mousa, S: Optimization of the dosing of Tinzaparin for surgical and Interventional dosing: Correlation of ACT and TEG Results. Blood, 100 (11), 3990, 127b, 2002. Mousa, S., Bozarth, J., Ahmed, S., Hoppensteadt, D., Fareed, J.: Acute versus chronic effects of low molecular weight heparin on plasma nitric oxide in deep vein thrombosis and healthy human subjects. J. Int. Angiology, 2002. Mousa, S., and Bozarth, J.: Elevation of plasma von Willebrand factor (v WF) and TNF-alpha in obese subjects and its reduction by low molecular weight heparin (LMWH), Tinzaparin. J. Int. Angiology, 2002. Mousa, S., Bozarth, J., Hainer, J., Sprogel, P., Johansen, K. and Barrett, J.: Pharmacodynamics of the LMWH Tinzaparin in obese and haemodialysis subjects following subcutaneous administration of 75 IU/kg on plasma tissue factor pathway inhibitor (TFPI) and nitric oxide. J. Int. Angiology, 2002. Mousa, S., Bozarth, J.: Inhibitory effect of C-reactive protein (CRP) on the release of tissue factor pathway inhibitor (TFPI) from human endothelial cells: Reversal by low molecular weight heparin (LMWH). J Am College Cardiology, 2002. Mousa, S., Bozarth, J., Hainer, J. and Fareed, J.: Elevation of plasma von Willebrand factor (v WF) and TNF-alpha in obese subjects and its reduction by low molecular weight heparin. J. Int. Angiology, 2002.

Shaker A. Mousa, Ph.D. CURRICULUM VITAE Page 63 of 92

Mousa S: Anticoagulant in thrombosis & cancer: the missing Link. Thrombosis and Haemostasis Issues in Cancer, 2001. Amirkhosravi, J. Frances, Mousa S: Antimetastatic effect of LMWH tinzaparin and TFPI. Thrombosis and Haemostasis Issues in Cancer, 2001. Marcinkiewicz, Mousa S: Obtustatin, potent inhibitor of alpha 1/ beta 1 integrin, blocks angiogenesis. ISH, 2001. J. Fenton, Mousa S: Statin as cellular antithrombotic and prothrombolytic agents. Acta Haemologica Polonica, 32, Suppl. 1, 60, 2001. Mousa S. Anti-angiogenesis efficacy & mechanism of the LMWH tinzaparin and TFPI: Anti-cancer benefits. Thrombosis and Haemostasis Issues in Cancer, 2001. Ali Amirkhosravi, Shaker A. Mousa, Mildred Amaya, Susan Blaydes, Hina Desai, Todd Meyer and John L. Francis. The Oral GpIIb/IIIa Antagonist (XV454) Inhibits Tumor Cell-Induced Platelet Aggregation in Vivo and Suppresses Experimental Lung Metastasis. Blood, 2001. Mousa, S., Bozarth, J. and Hainer, J.: Pharmacodynamics of low molecular weight heparin (Tinzaparin) in obese, hemodialysis patients following a single subcutaneous administration of 75 IU/kg on plasma tissue factor pathway inhibitor (TFPI). Blood, 2001. Mousa, S., Bozarth, J. and Mohamed, S.: Efficacy of heparin molecular weight fractions and low molecular weight heparins on the release of tissue factor pathway inhibitor from human endothelial cells: Structure function relationship. Blood, 2001. Mousa, S., Bozarth, J., Cohen, M., Wilson, M., Khalil-Ibrahim, M.N.: Plasma levels of inflammatory and soluble adhesion molecule markers pre and post-coronary intervention in acute myocardial infarction. European Congress of Cardiology: P-446, 2001. Mousa S, Mohamed S: Anti-angiogenesis efficacy and anti-tumor effects of Warfarin: Potential mechanisms. FASEB, 15 (4): A118, 149.13, 2001. Mousa S, Bozarth JM, Marc Cohen, Michael F. Wilson, Mofid N. Khalil-Ibrahim: Effects of heparin on plasma tissue factor (TF) and tissue factor pathway inhibitor (TFPI) in patients with acute myocardial infarction (AMI). FASEB, 15 (4): A559, 457.5, 2001. Caron, JF. Theoret, Mousa S, Y. Merhi: Relationship between the antiplatelet effects of GPIIb/IIIa antagonism and platelet activation. FASEB, 15 (4): 2001. Mousa S, Mohamed S: Anti-Angiogenic Efficacy & Mechanism Of The Low Molecular Weight Heparin (LMWH), Tinzaparin And Tissue Factor Pathway Inhibitor (TFPI): Potential Anti-Cancer Benefits. Thrombosis & Hemostasis, P1981, 2001. Mofid N. Khalil-Ibrahim, Bozarth JM, Marc Cohen, Michael F. Wilson, Mousa S. Inflammatory and soluble adhesion molecule markers in acute myocardial infarction patients (AMI) pre- and post-coronary intervention. Thrombosis & Hemostasis, 3517, 2001.

Shaker A. Mousa, Ph.D. CURRICULUM VITAE Page 64 of 92

Mousa S, Forsythe M, Anni Larnkjaer, Kristian Johansen: REVERSAL OF The Anticoagulant Effects Of The Low Molecular Weight Heparin Tinzaparin And Its Molecular Weight Fractions By Protamine Sulfate And Heparinase. Thrombosis & Hemostasis, P2622, 2001. Mousa S, Bozarth J, M. Cohen, Wilson M, M. Khalil-Ibrahim: Effects of heparin on plasma TF and TFPI in patients with acute myocardial infarction (AMI) patients. Int. Congress of the Egyptian Society of Cardiology, 33, 2001. Ali Amirkhosravi, John Francis, Shaker Mousa: Anti-Metastatic Effect of Low Molecular Weight Heparin (LMWH) Tinzaparin and Tissue Factor Pathway Inhibitor (TFPI). Thrombosis & Hemostasis, P1409, 2001. Mousa S, Forsythe M, A. Larnkjaer, K. Johansen: Comparative Efficacy between Different Low Molecular Weight Heparin (LMWH) and Heparin Molecular Weight Fractions In Inhibiting Platelet-Fibrin Clot Formation and Strength under Shear-Mediated by Endotoxin or Tissue Factor (TF) Using Thrombelastography (TEG). Thrombosis & Hemostasis, 3152, 2001. Shaker A. Mousa, Jeffry Bozarth, James W. Hainer, Per Sprogel, Kristen Johansen, Jeffrey S. Barrett: Pharmacodynamic Of Tinzaparin Following 175 IU/Kg Subcutaneous Administration In Healthy Volunteers On Plasma Tissue Factor Pathway Inhibitor (TFPI). Thrombosis & Hemostasis, P2299, 2001. Bozarth J, Anni Larnkjaer, Kristian Johansen, and Shaker Mousa: Plasmatic versus Vascular Effects of Low Molecular Weight Heparin (LMWH) on the Release of Tissue Factor Pathway Inhibitor (TFPI) from Human Endothelial Cells. Thrombosis & Hemostasis, P2056, 2001. Forsythe M, Jawed Fareed, Shaker A. Mousa: Lack Of Platelet Reactivity With Low Molecular Weight Heparin (LMWH) Tinzaparin As Compared To Unfractionated Heparin (UFH) In The Presence Of Plasma From Heparin Induced Thrombocytopenia Subjects. Thrombosis & Hemostasis, P1941, 2001. Mousa S, Forsythe M: Synergistic Interactions between the Low Molecular Weight Heparin (LMWH) Tinzaparin & Different Platelet GPIIb/IIIa Antagonists. Thrombosis & Hemostasis, 3441, 2001. Mousa S, Forsythe M: Anticoagulant efficacy of Low Molecular Weight Heparin (LMWH) In Inhibiting Hypercoagulable State-Induced By Cancer Cells versus Tissue Factor (TF) in Human whole Blood Using Thrombelastography (TEG). Thrombosis & Hemostasis, P1511, 2001. J. Powell, Mousa S: Common Pathways Involved in a chemokine and cytokine mediated angiogenesis. FASEB, 15 (4): A183, 183.3, 2001. Mousa S, Mohamed S: ANTI-ANGIOGENIC AND ANTI-TUMOR EFFICACY OF THE ORAL ANTICOAGULANT WARFARIN: Potential Mechanisms. Thrombosis & Hemostasis, P1510, 2001. Mousa SA, Bozarth JM, Marc Cohen, Michael F. Wilson, Mofid N. Khalil-Ibrahim. Effects of Heparin on Plasma Tissue Factor (TF) and Tissue Factor Pathway Inhibitor (TFPI) in Patients with Acute Myocardial Infarction (AMI) Patients. JACC, 37 (2, Suppl. A): 354A, 1217-83, 2001.

Shaker A. Mousa, Ph.D. CURRICULUM VITAE Page 65 of 92

Mousa S, Richard Liu, Sayed Taheri: Elevation of plasma Tissue Factor along With Differential Elevation of Plasma Matrix Metalloproteinase-2 (MMP-2) in Deep Vein Thrombosis (DVT) & Pulmonary Embolism (PE) Patients. JACC, 37 (2, Suppl. A): 224A, 1025-184, 2001. J. Herring, M. Pulia, W. Jeske, Mousa S, and J. Fareed: Tinzaparin and unfractionated heparin Inhibit TRAP-induced activation of platelets in primates after intravenous and SC administration: Hematological implications. Thrombosis & Hemostasis, P1922, 2001. Hoppensteadt, S. Ahmed, J.M. Walenga, A. Bano, M. Demir, Mousa SA, J. Fareed: Elevated plasma levels of inflammatory markers in heparin-induced thrombocytopenia. Thrombosis & Hemostasis, P2522, 2001. J. Powell, Mousa S: In vitro angiogenic activity of endothelial cells induced by neutrophil. FASEB, 15 (4): A184, 183.10, 2001. Mousa S: Pharmacology of Low Molecular Weight Heparin: Link between thrombosis & cancer. Int. Congress of Egyptian Cardiology, 176, 2001. Mousa S: Platelet GPIIb/IIIa antagonists. Oral versus IV agents. Int. Congress of Egyptian Cardiology, 170, 2001. Mousa S: Surrogate markers in acute myocardial infarction. Int. Congress of Egyptian Cardiology, 2001. Mousa S: Inflammatory and soluble adhesion molecule markers in patients with MI. Int. Congress of Egyptian Cardiology, 34, 2001. Mousa S: Integrin-Mediated synergy in the promotion of human smooth muscle cell migration by PDGF and matrix proteins. . Int. Congress of Egyptian Cardiology, 177, 2001. Mousa S, Mohamed S: Anti-angiogenic efficacy and mechanism of the Low Molecular Weight Heparin (LMWH), Tinzaparin and tissue Factor Pathway Inhibitor. FASEB, 2001. Mousa S, Wilson M, Taheri S: Pro-inflammatory and platelet hyperactivity states in deep vein thrombosis (DVT) & Pulmonary embolism. Blood, 16 (11): 642a, 2760, 2000. Mousa S, Mohamed S: Anti-angiogenic efficacy of the Low Molecular weight Heparin, Tinzaparin and Tissue factor pathway Inhibitor. Blood, 16 (11): 2000. Mohamed S, PK Jadhav, Batt D, Mousa S: SM256, a novel non-peptide potent integrin antagonist for vascular cell integrin avb3 potently inhibit angiogenesis-mediated disorders. Acta Haematologica Vol 103 (S1): 14, 53, 2000. J. Powell, Mousa S: Angiogenic activity of a platelet specific C-X-C chemokine, Neutrophil Activating Protein-2. Acta Haematologica Vol 103 (S1): 23, 90, 2000.

Shaker A. Mousa, Ph.D. CURRICULUM VITAE Page 66 of 92

J. Fareed, S. Ahmed, J. Walenga, D. Hoppensteadt, W. Jeske, M. Demir, Mousa S: Elevated plasma levels of inflammatory markers in heparin-induced thrombocytopenia. Blood, 16 (11): 94, 4088, 2000. Mousa S, Forsythe M, A. Larnkjaer, K. Johanson: Comparative efficacy between different Low Molecular Weight Heparin (LMWH) and various molecular weight fractions in inhibiting platelet/fibrin clot retraction under shear-mediated by tissue factor and endotoxin using thrombelastography (TEG). Blood, 16 (11): 99, 4112, 2000. M. Demir, O. Iqbal, D. Hoppensteadt, Mousa S, Fareed J: Comparative anticoagulant effects of tinzaparin as studied in clot based assays. Turk J Hematol. 17: 3 (Suppl.): 34, 343, 2000. Mousa S, Forsythe M: Synergistic interactions between the Low Molecular Weight Heparin (LMWH) tinzaparin & different platelet GPIIb/IIIa antagonists: Potential implications in thromboembolic disorders. Blood, 16 (11): 99, 4111, 2000. Mousa S, Bozarth J, Forsythe M, T. Hua, R. Daly: Bedside monitoring of antiplatelet efficacy of the GPIIb/IIIa antagonist Roxifiban: correlation with conventional light transmittance aggregometry. Blood, 16 (11): 49, 3880, 2000. M. Pulia, J. Herring, W. Jeske, Mousa S, J. Fareed: Tinzaparin and unfractionated heparin inhibit TRAP-induced activation of platelets in primates after intravenous and subcutaneous administration: Hematological Implications. Blood, 16 (11): 50, 3882, 2000. Mousa S, Bozarth J, A. Larnkjaer, K. Johanson: Vascular effects of heparin molecular weight fractions and LMWH on the release of TFPI from human endothelial cells. Blood, 16 (11): 59, 3928, 2000. Mousa S, Wilson M, Taheri S: Pro-inflammatory and platelet hyperactivity states in deep vein thrombosis (DVT) & Pulmonary embolism. Int. Angiology, 19 (2): 85, p.24, 2000. Mousa S, P. Abulencia, K. Konstantopoulos: Inhibition of human platelet micro-thrombi by the platelet GPIIb/IIIa antagonist, Roxifiban but not Orbofiban in a dynamic flow chamber. Int. Angiology, 19 (2):100, p.27, 2000. Mousa S, Forsythe M, J. Fareed: Comparative efficacy between different Low Molecular Weight Heparin (LMWH) & Interactions with platelet GPIIb/IIIa antagonists: Potential implications in the management of cardiovascular disorders. Int. Angiology, 19 (2): 141, p. 38, 2000. Mousa S, S. Srivatsa: Vascular effects of XT199, v 3 integrin antagonist in acute and delayed vascular occlusion without effect on hemostasis in porcine model of arterial injury. Int. Angiology, 19 (2):54, p.96, 2000. Mousa S, Forsythe M, Bozarth J, Slee, A: Platelet GPIIb/IIIa binding characteristics of small molecule RGD mimetics: Distinct binding profile for Roxifiban. Int. Angiology, 19 (2): 64, p. 98, 2000.

Shaker A. Mousa, Ph.D. CURRICULUM VITAE Page 67 of 92

Mousa S, Forsythe M: Comparative efficacy among different platelet GPIIb/IIIa antagonists in inhibiting platelet-mediated clot retraction in human whole blood induced by Tissue factor (TF) & Endotoxin using Thrombelastography. Int. Angiology, 19 (2):65, p. 99, 2000. Mousa S, Forsythe M: Inhibition of human platelet micro-aggregate formation by GPIIb/IIIa antagonist, Roxifiban but not Orbofiban using Laser scatter aggregometry. Int. Angiology, 19 (2): 66, P. 99, 2000. Mousa S, Forsythe M, Bozarth J, J. Walenga, J. Fareed: Platelet GPIIb/IIIa antagonist, Roxifiban in heparin or Low Molecular Weight Heparin-Induced Thrombocytopenia. Int. Angiology, 19 (2): 104, P. 108, 2000. Mousa S, Mohamed S: Antiangiogenesis efficacy & mechanism of the Low Molecular Weight Heparin (LMWH), tinzaparin and tissue factor pathway inhibitor (TFPI): Potential anticancer link and benefits. Blood, 16 (11): 182, 4502, 2000. Mousa S, Mohamed S: Anti-angiogenesis and anti-tumor efficacy of Warfarin in the chick chorioallantoic membrane (CAM) model. Blood, 16 (11): 182, 4503, 2000. Mousa S, R. Colman: Inhibition of Angiogenesis by peptide derived from kininogen domain 5 & by a monoclonal antibody to Kininogen domain 5. Int Fibrinolysis & Thrombolysis, 2000. Mousa S, Mohamed S, Smallheer J, PK. Jadhav, J. Varner: Anti-angiogenesis efficacy of small molecule 5 1 integrin antagonists, SJ749. Int Fibrinolysis & Thrombolysis, 2000. J. Powell, Mousa S; Angiogenic activity of a platelet specific C-X-C chemokine, Neutrophil Activating Protein-2. Int. Molecular Biol of Hematopoiesis, 2000. Mousa S, Mohamed S: Anti-angiogenic efficacy of the Low Molecular Weight Heparin (LMWH), Tinzaparin and tissue Factor Pathway Inhibitor (TFPI). Int. Molecular Biol of Hematopoiesis, 2000. Mohamed S, PK. Jadhav, Batt D, Mousa S: SM256, a novel non-peptide and potent integrin antagonist for vascular cell integrin avb3 potently inhibit angiogenesis-mediated disorders. Int. Molecular Biol of Hematopoiesis, 2000. Mousa S, B. Sung, P. Somasundram, R. Blum, Wilson M: Is endotoxin a trigger in congestive heart failure (CHF) patients with acute cardiogenic pulmonary edema. J Am College of Cardiology, 35 (2): 1183-150, 224 A, 2000. Mousa S: Interaction between GPIIb/IIIa receptor antagonists and other antithrombotic drugs. In Symposia entitled “New Results with GPIIb/IIIa antagonists. Hemostasis, 110, 2000. Mousa S, Mohamed S, J. Powell, R. W. Colman: Inhibition of angiogenesis by peptides derived from kininogen domain 5 & by a monoclonal antibody to kininogen domain 5. J Am College of Cardiology, 35 (2): 1134-51, 295 A, 2000.

Shaker A. Mousa, Ph.D. CURRICULUM VITAE Page 68 of 92

Mousa S, Mohamed S, P.K. Jadhav, Pitts W: SQ885, a novel non-peptide integrin antagonist for integrins avb3, avb5, and a5b1 potently inhibit angiogenesis-mediated disorders. J Am College of Cardiology, 35 (2): 1157-53, 306 A, 2000. Mousa S, Forsythe M, Bozarth J, J. Walenga, J. Fareed: Platelet GPIIb/IIIa antagonist, Roxifiban in heparin or Low Molecular weight heparin-induced thrombocytopenia. J Am College of Cardiology, 35 (2): 1178-56, 317 A, 2000. Langer, S. Goodman, Reilly T, Mousa S, Racanelli A, C. Connor, W. O’Neill, N. Kleiman, P. Curbel, R. Daly: Second Generation Oral IIb/IIIa blockade: Phase II Experience with Roxifiban. J Am College of Cardiology, 35 (2): 1158-11, 308 A, 2000. G. Bishop, J.A. McPherson, J. sanders, S. Hesselbacher, M.L Feldman, L.W. Gimple, E. Powers, Mousa SA, I.J. Sarembock: Vitronectin (alp v/ beta 3) receptor blockade reduces restenosis and intramural macrophage infiltration associated with a reduction in cellular adhesion molecule expression following balloon angioplasty of the atherosclerotic rabbit femoral artery. J Am College of Cardiology, 35 (2): 1155-115, 71A, 2000. Mousa S: Optimal Profile for oral IIb/IIIa receptor Blockade. Colloquium on GPIIb/IIIa Receptor Blockers. Eur. Soc. Cardiology, 2000. Mousa S: possible reasons for the failure of oral GPIIb/IIIa antagonists. Angiogisches Symposium, 2000. Mousa S: Could stroke be an indication for new GPIIb/IIIa receptor antagonists. Angiogisches Symposium, 2000. Mousa S: Diagnostic use of cell adhesion molecules in vascular diseases. Angiogisches Symposium, 2000. Mousa S: Anti-P Selectin as a novel Approach for Thromboembolic Disorders. Int. Business Comm., 2000. Mousa S: Synergistic Interactions between the Low Molecular weight Heparin (LMWH) Tinzaparin & different Platelet GPIIb/IIIa antagonists. Angiogisches Symposium, 2000. Mousa S: Drug-Drug Interactions. Angiogisches Symposium, 2000. Mousa S, R. Daly: Pharmacology of the second generation GPIIb/IIIa antagonist, Roxifiban & Initial clinical experiences. Angiogisches Symposium, 2000. Mousa S: Failure of the oral delivery of GPIIb/IIIa antagonism: Potential Reasons. Angiogisches Symposium, 2000. Mousa S: Integrin Antagonists: Potential Therapeutic Utility In Angiogenesis-Mediated Disorders. Int. business Comm. Symposia, 6th Annual Conference on Angiogenesis-Novel Therapeutic Development, 2000.

Shaker A. Mousa, Ph.D. CURRICULUM VITAE Page 69 of 92

Mousa S: Low Molecular Weight Heparin: Potential Therapeutic Utility in Angiogenesis-Mediated Disorders. Int. business Comm. Symposia, 6th Annual Conference on Angiogenesis-Novel Therapeutic Development, 2000. Mousa S: Small Molecule Failure of Oral Platelet GPIIb/IIIa antagonists: Possible Reasons. Int. business Comm. Symposia, 11th Annual Conference on AATD, 2000. Mousa S: Combination of antiplatelets, anticoagulants, and thrombolytics in thromboembolic disorders. Int. business Comm. Symposia, 11th Annual Conference on AATD, 2000. Mousa S: Antiplatelets from Aspirin to GPIIb/IIIa antagonists and beyond. Int. Business Comm. Symposia, 6th Annual Conference on AATD, 2000. Mousa S: Low molecular Weight Heparin and Cancer: Potential Mechanisms. Int. Scientific Foundation Meeting on VEGF Modulation in Angiogenesis, 2000. Sung BH, P. Somasundram, Mousa S, Wilson M: Symptomatic improvement of acute cardiogenic pulmonary edema accompanies changes in plasma levels of TNF-a, TNF-a Receptor I, Atrial Natriuretic peptide, and s P-selectin. J. Cardiac Failure 5 (3): Suppl. 1, 067, 20, 1999. Wilson M, Sung BH, P. Somasundram, Mousa S: Elevation of plasma s-VCAM-1, Tissue Factor, s P-selectin, Atrial Natriuretic peptide, TNF-a, TNF-a Receptor I in patients with acute cardiogenic pulmonary edema. J. Cardiac Failure 5 (3): Suppl. 1, 098, 28, 1999. G. Bishop, J.A. McPherson, J. Sanders, S. Hesselbacher, M.L Feldman, L.W. Gimple, E. Powers, Mousa SA, I.J. Sarembock: Vitronectin ( v 3) receptor blockade reduces restenosis and intramural macrophage infiltration associated with a reduction in cellular adhesion molecule expression following balloon angioplasty of the atherosclerotic rabbit femoral artery. Circulation 100 (18) 2368, I-450, 1999. Mousa S, Bozarth J, Forsythe M, Cain G, Slee, A: Platelet GPIIb/IIIa Binding Characteristics of small molecule RGD mimetics: Distinct binding profile for Roxifiban and its implications. Blood 94 (10): Suppl. 1, 222a, 979, 160-II, 1999. Mousa S, Mohamed S: Anti-angiogenesis efficacy of the Low Molecular weight heparin (LMWH), Tinzaparin and Tissue Factor pathway Inhibitor (TFPI). Blood 94 (10): Suppl. 1, 22a, 82-I, 1999. Taheri S, Shenoy S, Mousa S: Urine soluble tumor necrosis factor receptor for diagnosis of pulmonary embolism. European Congress of the Union International of Phlebology, 1999. R. Colman, Mousa SA: Inhibition of tumor angiogenesis by a monoclonal antibody to kininogen domain 5. Blood 94 (10): Suppl. 1, 10a, 29-I, 1999. Mousa S, Mohamed S, Campochiaro P: Key role of alpha v/ beta 3 integrin in hypoxia and cytokine-induced upregulation of vascular endothelial growth factor (VEGF) and other angiogenesis processes: Implications in angiogenesis-mediated disorders. Blood 94 (10): Suppl. 1, 10 a, 28-I, 1999.

Shaker A. Mousa, Ph.D. CURRICULUM VITAE Page 70 of 92

Mousa S, Mohamed S, Smallheer J, PK. Jadhav, J. Varner: Anti-angiogenesis efficacy of small molecule alpha 5 /beta 1 integrin antagonists, SJ749. Blood 94 (10):Suppl. 1, 620a, 2755, 1999. Mousa S, Bozarth J, Forsythe M, P.Gillies: Platelet and vascular-mediated effects of Soy bioactive components. Blood 94 (10): Suppl. 1, 75b, 3492, 1999. Mousa S, Fareed J: Comparative efficacy of different Low Molecular weight heparins (LMWHs) & Interactions with platelet GPIIb/IIIa antagonists: Potential implications in thromboembolic disorders. Blood 94 (10): Suppl. 1, 110b, 3655, 1999. Mousa S, Srivatsa S: Vascular Effects of XT199, an alpha v/ beta 3 integrin antagonist in acute and delayed vascular occlusion without effects on hemostasis in porcine model of arterial injury. Thrombosis Hemostasis. 228, 76, 1999. R.W. Colman, B.A. Jameson, Y. Lin, D. Johnson, Mousa SA: Inhibition of Angiogenesis by peptides derived from Kininogen domain 5. Thrombosis Hemostasis.649, 84, 1999. Mousa S, Bozarth J, M. Cohen: Elevation of circulating smooth muscle cell chemoattractants in patients with coronary artery diseases: Potential role of v 3 integrin. Thrombosis Hemostasis.2557, 809, 1999. Mousa S: Small Molecule Integrin Antagonists: Potential Therapeutic Utility In Angiogenesis-Mediated Disorders. Int. Business Comm. Symposia, 6th Annual Conference on Angiogenesis-Novel Therapeutic Development, 1999. W. Jaske, Mousa S, L. Yang, K. Fu, A. Sheikh, S. Ahmed, J. Walenga, J. Fareed: Short-acting glycoprotein IIb/IIIa inhibitors may be safer for the management of patients with active heparin-induced thrombocytopenic syndrome. Annals of Hematology. 78 (Suppl. 1) A65, 1999. Mousa SA, J. Coleman, R. Hilman, Slee, A, R. Daly: Bedside monitoring test of antiplatelet efficacy for various GPIIb/IIIa antagonists: Validation versus Light Transmittance aggregometry (LTA). Thrombosis Hemostasis. 2379, 753, 1999. Bennett JS, Vilaire G, Helluin O, Mousa SA, DeGrado W: The actin cytoskeleton regulates the avb3-mediated adhesion of platelets to osteopontin and vitronectin. Thrombosis Hemostasis. 729, 232, 1999. Mousa S: Roxifiban. Int. business Comm. Symposia, 10th Annual International Symposia - Advances in Antiplatelet, Anticoagulant, Antithrombotic & Thrombolytic Drugs, 1999. S. A. Taheri, Shenoy S, Mousa SA: Circulating soluble tumor necrosis factor as a marker for diagnosis of pulmonary embolism. Thrombosis Hemostasis. 989,314, 1999. Mousa S: Differential Characteristics among Platelet GPIIb/IIIa Antagonists. Int. business Comm. Symposia, 10th Annual International Symposia - Advances in Antiplatelet, Anticoagulant, Antithrombotic & Thrombolytic Drugs, 1999.

Shaker A. Mousa, Ph.D. CURRICULUM VITAE Page 71 of 92

W. Jeske, J.M. Walenga, S. Ahmed, Mousa SA, D.E. Wallis, B.E. Lewis, M. Bakhos, J. Fareed. Short-acting GPIIb/IIIa inhibitors may be safer for the management of patients with active heparin-induced thrombocytopenic syndrome. Thrombosis Hemostasis.1236, 389, 1999. Mousa SA, J.Bozarth, R. Jordon, J. Fareed. Platelet GPIIb/IIIa binding characteristics of the monoclonal antibody c7E3 versus small molecule RGD mimetics. Thrombosis Hemostasis.2595, 819, 1999. Owen McCarty, Shaker A. Mousa, Konstantinos Konstantopoulos: Molecular Mechanisms of Platelet-Tumor Cell Adhesion under Flow. AICHE, 1999. Mousa SA, Forsythe M. Comparative efficacy of Roxifiban versus other platelet GPIIb/IIIa antagonists on tissue factor-mediated clot strength. Thrombosis Hemostasis.2631, 830, 1999. S. Ali, A. O’Donnell, M. Seyler, Mousa S, Mohamed S, P. Dondona: Estrogen receptor-alpha in the inhibition of cancer angiogenesis. Cancer Research. 40, 455, 1999. Mousa S: Role of Integrin In Health & Diseases: Targeting Integrins for Therapeutics and Diagnostics. Int. business Comm. Symposia, 2nd Annual Conference on Integrins, 1999. J.P. Abulencia, OJT McCarty, Mousa SA, K. Konstantopoulos: Modulation of platelet function by a GPIIb/IIIa antagonist, XV454, in flow models of arterial thrombosis. Thrombosis Hemostasis. 2599, 820, 1999. D.Ho Appensteadt, O.Iqbal, J.M. Walenga, Mousa SA, J. Fareed. Global anticoagulant effect of heparinase depolymerized Low Molecular weight Heparin (Tinzaparin). Thrombosis Hemostasis. 2301, 727, 1999. Mousa S: Small Molecule Integrin Antagonists: Potential Therapeutic Utility In Angiogenesis-Mediated Disorders. Int. business Comm. Symposia, 5th Annual Conference on Angiogenesis-Novel Therapeutic Development, 1999. Mousa SA, Forsythe M. Antiplatelet efficacy for various platelet GPIIb antagonists in citrate versus heparinized whole blood: role of plasma free ionized calcium levels. Thrombosis Hemostasis. 2636, 832, 1999. W.S. Etches, B. Rowe, Mousa SA, L. Larratt, V. Dzavik, R.H. Person, M.W. Stewart. Diversity of response to anti-platelet agents by different patient populations. Thrombosis Hemostasis. 2703, 851, 1999. Mousa SA, Forsythe M, J.M. Walenga, J. Fareed. Platelet GPIIb/IIIa antagonist, Roxifiban in heparin or low molecular weight heparin-induced thrombocytopenia. Thrombosis Hemostasis. , 1999. Mousa SA, Forsythe M, J. M. Walenga, J. Fareed. Comparative efficacy between various Low Molecular Weight Heparin on different mediators-induced clot formation using thrombelastography. Thrombosis Hemostasis. 2724, 857, 1999.

Shaker A. Mousa, Ph.D. CURRICULUM VITAE Page 72 of 92

Mousa SA, Forsythe M, J. Walenga, J. Fareed. Synergy between Low Molecular weight heparin, Tinzaparin and platelet GPIIb/IIIa antagonists, ReoPro and Roxifiban in Improving antiplatelet and anticoagulant efficacy. Thrombosis Hemostasis. 2725, 857, 1999. Mousa S, Forsythe M. Comparative efficacy of different platelet GPIIb/IIIa receptor antagonists on tissue factor (TF)-induced platelet-mediated clot strength using thrombelastography (TEG). The FASEB Journal. 13 (5):A837, 642.4, 1999. Forsythe M, Mousa S. Antiplatelet efficacy for various platelet GPIIb/IIIa antagonists in citrate versus heparinized whole blood: role of free ionized calcium. The FASEB Journal. 13 (5):A837, 642.6, 1999. Jadhav, J. Powell, Mousa S. Anti-angiogenesis efficacy of cyclooxygenase inhibitors. The FASEB Journal. 13 (5):A705, 551.4, 1999. J. Powell, Mohamed S, Kerr J, Mousa S. Anti-angiogenesis efficacy of nitric oxide donor. The FASEB Journal. 13 (5):A705, 551.5, 1999. DeGrado W, J. Powell, Y. Hamouro, D. Suich, Mohamed S, Mousa S. Anti-angiogenesis efficacy of high receptor subtype specific somatostatin analogues. The FASEB Journal. 13 (5):A705, 551.6, 1999. Bozarth J, R. Jordan, Mousa S. Platelet GPIIb/IIIa binding characteristics of c7E3 (ReoPro) versus small molecule RGD mimetics (DMP728 and Roxifiban). The FASEB Journal. 13 (5):A837, 642.5, 1999. Lorelli W, P. Somasundrum, Sung BH, Bozarth J, Wilson M, Mousa S. Elevation of circulating smooth muscle cell chemoattractants & mitogens in congestive heart failure patients: potential role of avb3 integrin. The FASEB Journal. 13 (5):A45, 29.19, 1999. Mohamed S, J. Powell, Mousa S. Antagonist of vascular integrin avb3 and avb5 inhibit angiogenesis. The FASEB Journal. 13 (5):A528, 423.13, 1999. Mousa S, Forsythe M: Comparative efficacy of different platelet GPIIb/IIIa receptor antagonists on tissue factor (TF)-induced platelet–mediated clot strength using thrombelastography. Journal American College of Cardiology, 33(2): 251A, 1102-20, 1999. G. Bishop, J. McPherson, J. Sanders, M. Feldman, L. Gimple, M. Ragosta, E. Powers, S. Mousa, I. Sarembock: v 3 receptor blockade reduces restenosis following balloon angioplasty in atherosclerotic rabbit. Journal American College of Cardiology, 33(2): 31A, 1039-60, 1999. Mousa S, Lorelli W, Bozarth J, Wilson M: Endothelial cell dysfunction and elevation of circulating smooth muscle cell chemoattractants / mitogens in congestive heart failure patients: Potential role of alpha v/ beta 3 integrin. Journal American College of Cardiology, 33 (2), 206A, 856-3, 1999. Mousa S. Discovery of a key role of v 3 integrin in vascular disorders. Thrombosis and Hemostasis J., 1999.

Shaker A. Mousa, Ph.D. CURRICULUM VITAE Page 73 of 92

M. Stewart, W. Etches, L. Larratt, V. Dzavik, Mousa S: Evaluation of anti-IIb/IIIa IC50 in platelet hypo-and hyper-responsive patient populations using a novel platelet function assay. Blood 92 (10) suppl. 1 (part 1), 3297, 74b, 1998. H. Oliver, Chan C, Vilaire G, Mousa S, DeGrado W, Bennett J: The effect of thrombin on platelet adhesion to osteopontin. Blood 92 (10) suppl. 1 (part 1), 2249, 547a, 1998. R.W. Colman, Y. Lin, D. Johnson, and Mousa S: Inhibition of angiogenesis by peptide derived from kininogen. Blood 92 (10) suppl. 1 (part 1), 701, 174a, 1998. Mousa S, Lorelli W, J. Walenga, J. Fareed: Heparin-induced thrombocytopenia syndrome: Platelet activation and degranulation versus platelet membrane shedding. Blood 92 (10) suppl. 1 (part 1), 3357, 78b, 1998. W.P. Jeske, Mousa S, LH.Yang, K.D. Fu, A. Sheikh, S. Ahmed, J. Walenga, J. Fareed: Short-acting glycoprotein IIb/IIIa inhibitors may be safer for the management of patients with active heparin-induced thrombocytopenic syndrome. Blood 92 (10) suppl. 1 (part 1), 730, 181a, 1998. S. Ahmed, Mousa S, J. Walenga, W.P. Jeske, J. Wood, J. Fareed: Differential effects of GPIIb/IIIa –targeting antibodies and short –acting synthetic inhibitors on the serum-mediated C-14 serotonin release: Clinical implications. Blood 92 (10) suppl. 1 (part 1), 732, 181a, 1998. J. Fareed, Mousa S, L.H. Yang, K.D. Fu, D. Hoppenestead, S. Ahmed, H. Messmore. Differential biochemical and pharmacodynamic behavior of two glycoprotein IIb/IIIa-targeting antibodies: Clinical implications. Blood 92 (10) suppl. 1 (part 1I), 3275, 69b, 1998. Mousa S, Lorelli W, Forsythe M, M. Stewart. Adhesion of human platelets to VWF-mediated dense granular secretion is a platelet IIb 3 integrin-dependent process. Blood 92 (10) suppl. 1 (part 1), 3286, 71b, 1998. J. Varner, Mousa S: Antagonists of vascular cell integrin alpha 5 / beta 1 inhibit angiogenesis. Circulation, 98 (17): Suppl. 1, I-795, 4166, 1998. Mousa S, DeGrado W, D. Harrison, Holmes D, S. Srivatsa: Discovery of a key role of alpha v/ beta 3 integrin in acute and delayed vascular occlusion and re-occlusion without effects on hemostasis. Circulation, 98 (17): Suppl. 1, I-525, 2762, 1998. R. Rabbani, H. LeBreton, E. Plow, E. Topol, Mousa S, M. Lincoff: The role of integrin alpha v/ beta 3 and alpha IIb/ beta 3 in an experimental arterial injury model. Circulation, 98 (17): Suppl. 1, I-535, 2813, 1998. Mousa S, Bozarth J, DeGrado W, Bennett J: Activation-dependent v 3 on platelets and lymphocytes binds vitronectin and osteopontin: Potential surrogate for monitoring anti-avb3 integrin efficacy. Circulation, 98 (17): Suppl. 1, I-524, 2753, 1998. Wamholtz, Mousa S, D. Harrison: Vasoactive role of the avb3 integrin in rabbit carotid artery: Endothelium-dependent and independent effects. Circulation, 98 (17): Suppl. 1, I-37, 179, 1998.

Shaker A. Mousa, Ph.D. CURRICULUM VITAE Page 74 of 92

S. A. Taheri, Shenoy S, Mousa S: Circulating soluble tumor necrosis factor as a marker for diagnosis of pulmonary emboli. CHEST, 114 (4 suppl.), 393s, 1998. Mousa SA, Somasundaram P, Sung BH, J.Bozarth, Lorelli W, M. F.Wilson: Elevation of circulating smooth muscle cell chemoattractants / mitogens and endothelial cell dysfunction in congestive heart failure patients: Potential role of alpha v/ ß3 integrin. Naunyn Schmiedeberg’s Archives of Pharmacology, 358 (1): Suppl. 2, P49.19, R477, 1998. Mousa SA, D-X Mu: Antithrombotic Efficacy of Platelet GPIIb/IIIa Receptor Antagonists As Compared To Other Antiplatelet And Anticoagulant Strategies. Naunyn Schmiedeberg’s Archives of Pharmacology, 358 (1): Suppl. 2, P52.17, R512, 1998. Mousa SA, Jeffery M. Bozarth, Joel S. Bennett: Activation-Dependent avb3 on Platelets and Lymphocytes Binds Vitronectin & Osteopontin. Naunyn Schmiedeberg’s Archives of Pharmacology, 358 (1): Suppl.1, P42.16, R286, 1998. Pitts, William J.; Wityak, John; Jetter, James; Harlow, Patricia P.; Corjay, Martha H.; Mousa, Shaker; Wexler, Ruth R.; Jadhav, P. K: Discovery of potent and selective isoxazoline antagonists of the vitronectin receptor. American Chemical Society, 1998. Douglas G. Batt, Gregory C. Houghton, Dilip P. Modi, Joseph J. Petraitis, Patricia Harlow P, Martha H. Corjay, Shaker A. Mousa, Ruth Wexler R. Disubstituted Indazoles as Potent v 3 Integrin Antagonists. Am. Chem. Soc. 1998. Mousa SA, Dun-Xue Mu: Reversal of the Antithrombotic Efficacy of Nitric Oxide (NO) Donor by Epinephrine (Epi) in Arterial Thrombosis Models. Arteriosclerosis Thromb. Vascular Biol., 1998. Mousa SA, V. Kirsten, J.M. Bozarth, M. Cohen: Elevation of circulating smooth muscle cell chemoattractants and mitogens in patients with coronary artery diseases pre- and post- angioplasty / stent: Potential role of alpha v/ß3 integrin. Arteriosclerosis Thromb. Vascular Biol., 1998. Walton H, Mohamed S, Mousa S, L. Santomenna, Reilly T. Hypoxia induces differential expression of the integrin receptor avb3 in cultured human endothelial cells. IOVS, 39 (4): S336, 1998. Wityak J, Pitts W, Tobin E, M. Estrella, Harlow P, Corjay M, Mousa S, Wexler R, P.K. Jadhav: 2- aminoimidazoles as guanidine mimetics in a series of potent and selective alpha-v-beta-3 antagonists. American Chemical Society, 1998. P. K. Jadhav, C. Eyermann, Smallheer J, F. Woerner, W. Baneker, Buynitzky J, Harlow P, Corjay M, Wexler R, Mousa SA: Design and synthesis of spiroisoxazoline based alpha v/ beta 3 antagonists. Int. Medicinal Chemistry Symposia, 1998. Mousa SA, D.X. Mu, Lucchesi B. Restoration of Coronary Flow by Potent Platelet GPIIB/IIIA Antagonist without Exogenous Thrombolytics. FASEB Journal, 12 (5): A718, 4167, 1998. J. M. Bozarth, M. Cohen*, Mousa SA. Role of Avß3 Integrin in Endothelial & Smooth Muscle Cell Migration: Potential Role in Coronary Artery Diseases. FASEB Journal, 12 (4): A402, 2336, 1998.

Shaker A. Mousa, Ph.D. CURRICULUM VITAE Page 75 of 92

Mohamed S, S. Ali. P. Dondona, Mousa S. Role of estrogen receptor on v3 -mediated cell adhesion, migration and secretion of bFGF and VEGF in human endothelial and endometrial epithelial cells. FASEB Journal, 12 (5): A771, 4466, 1998. Forsythe M, Mousa SA*, S. Kurahana. Comparative Efficacy of Different Platelet GpIIb/IIIIa Receptor Antagonists on Platelet-Mediated Clot Strength Using Tissue Factor-Thrombelastography. FASEB Journal, 12 (5): A720, 4177, 1998. Lorelli W, Mousa SA, P. A. Campochiaro.* Integrins In Human Retinal Pigmented Epithelial (Rpe) Cells: Role Of Extracellular Matrix Proteins (Ecms) And Hypoxia On The Secretion Of Growth Factors. FASEB Journal, 12 (5): A770, 4464, 1998. R. Wexler, Robinson C, E. Wexler, P. Cerniak, Slee, A, Mousa S, Mohamed S, Kerr J: Effect of

v3 integrin inhibition on a tumor devoid of this integrin. AACR, 1998. Walton H, Mohamed S, Mousa S, S. Spitz, Reilly T. Hypoxia induces differential expression of the integrin receptor avb3 in cultured human endothelial cells. FASEB Journal, 12 (5): A770, 4465, 1998. R. Hantgan, Mousa S: Inhibition of platelet-mediated clot retraction by integrin antagonists. FASEB Journal, 12 (5): A720, 4176, 1998. Mousa S, Mohamed S, Bozarth J: Role of alpha v beta 3 integrin in endothelial and smooth muscle cell adhesion and migration. FASEB, 1998. S.A. Taheri, L. Lazar, G. Haddad, R. Castaldo, Wilson M, Mousa S: Cardiovascular Surgery, 124: 24.13, 1997. Mousa S, et al: XV454, a novel non-peptide antiplatelet agent with comparable platelet alpha IIb beta 3 binding kinetics to c7E3 and long lasting antiplatelet efficacy after single intravenous or oral administration in non-human primates. Circulation, 96 (8): I-168, 928, 1997. Pedicord DL, Mousa SA, Dicker I: Platelet GPIIb/IIIa antagonists inhibit platelet procoagulant activity. Circulation, 96 (8): I-3, 14, 1997. Mousa SA, Jeffery M. Bozarth, DeGrado W*, Joel S. Bennett*: Activation-Dependent alpha v/ beta 3 on Platelets and Lymphocytes Binds Vitronectin & Osteopontin. Circulation, 96 (8): I-111, 623, 1997. Mousa SA, Dun-X. Mu, Reilly TM, Benedict Lucchesi: Restoration of Coronary Flow by Potent Platelet GPIIb/IIIa Antagonist Without Exogenous Thrombolytics. JACC, 1997. Mousa S, D-X Mu, Reilly T: Intravenous and oral antithrombotic efficacy of a novel non-peptide antiplatelet GPIIb/IIIa antagonist, DMP754 as compared to other antiplatelet & anticoagulant strategies. Thrombosis Hemostasis, Suppl., OC 1600, 392, 1997.

Shaker A. Mousa, Ph.D. CURRICULUM VITAE Page 76 of 92

Srivasata S, Reilly T, Holmes D, Shwartz R, Mousa S: Combined avb3 and platelet IIb/IIIa integrin blockade potently limits neointimal hyperplasia and lumen stenosis in the porcine coronary injury model. JACC 29 (2, Suppl. A), 51 A, 701-4, 1997. Mousa SA, Bozarth J, Forsythe M, Chu-Biao Xue, Wityak J, Olson O, Thoolen M, Reilly T: Discovery of Novel Non-peptide Antiplatelet GPIIb/IIIa Receptor Antagonist, DMP 754: Comparative platelet Binding Affinity profiles with DMP728 and c7E3. Specificity. Thrombosis & Hemostasis, Suppl., 2707, 663,1997. Reilly T, Racanelli A, Olson R, Wityak J, Wexler R, E. Hausner, Thoolen M, Mousa S: Antiplatelet efficacy of orally administered DMP802, a GPIIb/IIIa receptor antagonist, in the conscious dog. JACC, 29 (2, Suppl. A), 67A, 712-2, 1997. Pedicord DL, Mousa SA, Dicker I: Platelet GPIIb/IIIa antagonists inhibit platelet procoagulant activity. Thrombosis & Hemostasis, Suppl., 2693, 660, 1997. Srivasata S, Tsao P, Holmes D, Shwartz R, Mousa S: Temporal and spatial variation in Alpha v Beta 3 integrin expression following deep arterial injury in the porcine coronary restenosis model . JACC 29 (2, Suppl. A), 153 A, 960-110, 1997.

Mousa S: Small Molecule Integrin v3 Antagonists: Potential Therapeutic Utility In Angiogenesis-Mediated Disorders. Int. business Comm. Symposia, Annual Conference on Angiogenesis-Novel Therapeutic Development, 1997. Mousa S, D-X Mu, Hussain M: Intranasal antiplatelet / antithrombotic efficacy of the platelet GPIIb/IIIa antagonist, DMP754. JACC 29 (2, Suppl. A), 154 A, 960-112, 1997. Thomas, J. Bradley, Harlow P, K. Solomon, Dicker I, Mousa S: Soluble vitronectin blocks serum starvation-induced apoptosis in cells overexpressing the alpha-v-beta-3 receptor. FASEB 11(3): A509, 1997. Taheri S, Mousa S: Circulating soluble tumor necrosis factor as a marker for deep vein thrombosis and pulmonary emboli. Int. Society for Cardiovascular Surgery, 1997. Wityak J, Batt D, Tobin E, Mousa S, Racanelli A, L. Hausner, Olson R, Wexler R. GPIIb/IIIa antagonist isoxazolinylacetamides having a modified amide linkage. American Chemical Society, 1997. Wityak J, Tobin E, Mousa S, Racanelli A, L. Hausner, Wexler R, Olson R. GPIIb/IIIa antagonist isoxazolinylacetamides bearing an alpha- phosphoramide moiety. American Chemical Society, 1997. Sielecki T, Liu J, J. Orwat, D. Pinto, Lalka G, Mousa S, Olson R, R. Wexler. Novel non-peptide GPIIb/IIIa receptor antagonists incorporating piperidine and other cyclic structures. American Chemical Society, 1997.

Shaker A. Mousa, Ph.D. CURRICULUM VITAE Page 77 of 92

Sielecki T, Liu J, Mousa S, Racanelli A, L. Hausner, Thoolen M, R. Wexler, Olson R. Synthesis & Pharmacology of novel benzamidine isoxazoline GPIIb/IIIa receptor antagonists. American Chemical Society, 1997. Pinto D, Wityak J, A. Patten, Cain G, Orwat M, Wang S, Bostrom L, S. DiMeo, Thoolen M, Mousa S, Wexler, R. Olson. Synthesis & Pharmacology of novel non-peptide isoxazoline GPIIb/IIIa receptor antagonists with modified basic moieties. American Chemical Society, 1997. Kapil R, T, Emm, Mousa S, Padovani P, C Quon, Lam G: Biological matrix-dependent pharmacokinetic and pharmacodynamic parameters of a novel platelet glycoprotein IIb/IIIa antagonist, XU063, in beagle dogs. Pharm. Res. 14: S-356, 1997. Walton H, Mohamed S, Mousa S, S. Spitz, Reilly T. Hypoxia induces expression of the integrin receptor avb3 in cultured human endothelial cells. FASEB, 11 (3): A117, 1997. Pedicord, Mousa S, Dicker I: Platelet GPIIb/IIIa Receptor Antagonists Inhibit Platelet Procoagulant Activity. FASEB, 1997.

Srivasata S, Shwartz R, Holmes D, Mousa S: Osteopontin and avb3 temporal and spatial distribution in Stent or PTCA coronary artery. J ACC, 29 (2, Suppl. A) 153A, 960-110, 1997. Mousa S, Dun-Xue Mu, Hussain M: Intranasal antiplatelet/antithrombotic efficacy of DMP754. JACC, 29 (2, SUPPL. A) 154A, 960-112, 1997. Mousa S, Bozarth J, Forsythe M, Wityak J, Reilly T, Dun-Xue Mu. Intravenous and oral antiplatelet/antithrombotic efficacy and specificity of XR300, a novel non-peptide GPIIb/IIIa antagonist. Circulation, 94 (8): I-99, 0569, 1996. Mousa SA, D-X. Mu: Antithrombotic efficacy of nitric oxide donor in arterial and venous thrombosis model in pigs. FASEB, 10 (3): A570, 3282, 1996. Mousa S: Recent Advances In Anti-Platelet IIb3 Receptor Antagonists: Potential Therapeutic & Diagnostic Utilities. International Academy of Clinical & Applied Thrombosis/Hemostasis, 1996. Bennett JS, Chan C, Vilaire G, Mousa S, DeGrado W. v3 on activated platelets mediates platelet adhesion to the matrix protein osteopontin. Blood, 88 (10): 112, 31a, 1996. Mousa S: Intravenous and Oral Platelet IIb3 Receptor Antagonists: Potential Therapeutic & Diagnostic Utilities. 7th IBC Int. Symposium: Advances in Anticoagulant, Antithrombotic & Thrombolytic Drugs, 1996. D-X. Mu, Mousa SA: Animal model of arterial and venous thrombosis in dogs: Assessment of the efficacy of various antithrombotic strategies. FASEB, 10 (3): A434, 2506, 1996. Mousa S, D-X. Mu, Reilly T: Antithrombotic Efficacy of Platelet GPIIb/IIIa Antagonist in Arterial Thrombosis / Rethrombosis Models As Compared To Other Antiplatelet Strategies. Fibrinolysis, 10 (Suppl. 3), 72,247, 1996.

Shaker A. Mousa, Ph.D. CURRICULUM VITAE Page 78 of 92

Rackanelli, Kapil R, Mousa S, Reilly T, Thoolen M. Oral antiplatelet effects of DMP754 in dogs and non-human primate. Circulation 94 (8): I-98, 0565, 1996. Mousa S, Tsao P: Dissociation between The Anti-Aggregatory and the Anti-Secretory Effects of Platelet Integrin alpha IIb/b3 (GPIIb/IIIa) Antagonists, c7E3 and DMP728. Fibrinolysis, 10 (Suppl. 3), 123, 423, 1996. Mousa S: Intravenous and Oral Platelet IIb3 Receptor Antagonists: Potential Therapeutic & Diagnostic Utilities. 2nd Int. Academy of Clinical & Applied Thrombosis and Haemostasis, 1996. Pedicord, Mousa S, Dicker I: Platelet GPIIb/IIIa Receptor Antagonists Inhibit Platelet Procoagulant Activity. 7th. IBC Int. Symposium: Advances in Anticoagulant, Antithrombotic & Thrombolytic Drugs, 1996. Mousa SA: Intravenous and oral platelet GPIIb/IIIa receptor antagonists: Potential clinical utility. Cell Adhesion Molecules & Matrix Proteins, IBC 6th Annual Int. Conference, 1996. Mousa SA: Small Molecule Inhibitors of CAMs. CAM Workshop, IBC 1996. LeBreton, R. Rabbani, E. Plow, Mousa S, M. Lincoff, F. Forudi, E. Topol: The role of Integrins Glycoprotein IIb/IIIa & avb3 in a Guinea-Pig Model of Restenosis. Circulation, 94 (8): I-517, 3024, 1996. Mousa SA: Therapeutic Implications & Mechanisms of Angiogenesis: Inhibitors & Stimulators. 2nd Annual International IBC Conference, 1996. Mousa SA, Bozarth J, Forsythe M, Chu-Biao Xue, Wityak J, Rick Olson, Martin Thoolen, Thomas Reilly: Discovery of Novel Non-peptide Antiplatelet GPIIb/IIIa Receptor Antagonist, DMP 754: Receptor Binding Affinity & Specificity Circulation, 94 (8): I-513, 3006 1996. Mousa SA, Dun-Xue Mu: Intravenous and Oral Antithrombotic Efficacy of Novel Non-peptide Antiplatelet GPIIb/IIIa Antagonist, DMP 754, in Different Models of Arterial Thrombosis. ISTH, 1996. Srivasata S, Reilly T, Shwartz R, Holmes D, Mousa S: Selective avb3 integrin blockade limits neointima hyperplasia and lumen stenosis in stented porcine coronary artery injury in Pig. Circulation, 94 (8): I-41, 0231, 1996. Walton H, Corjay M, S. Diamond, M. Kearney, P. Strzemienski, K. Solomon, Mousa SA, Reilly T: Evaluation of monoclonal antibodies against the integrin receptor alpha v beta 3. FASEB, 10 (3): A692, 3998, 1996. C.-B. Xue, Wityak J, Sielecki T, Cain G, Liu J, Bostrom L, Mousa S, et al. Synthesis and pharmacology of orally active, Isoxazoline Glycoprotein IIb/IIIa receptor antagonists. American Chemical Society, 132, 1996. Mousa SA, Dun-Xue Mu: Antithrombotic efficacy of nitric oxide in arterial and venous thrombosis model in pigs. FASEB 10 (3): 3282, A570, 1996.

Shaker A. Mousa, Ph.D. CURRICULUM VITAE Page 79 of 92

Cain G, Bostrom L, S. DiMeo, Mousa S, et al. Novel chalcones as nonpeptide GPIIb/IIIa receptor antagonists. American Chemical Society, 133, 1996. Wityak J, Pinto D, Wang S, Sze J, Mousa S, et al. Design, synthesis and pharmacology of novel isoxazoline glycoprotein IIb/IIIa receptor antagonists. American Chemical Society, 131, 1996. Dun-Xue Mu, Mousa S: Animal model of arterial and venous thrombosis in dogs and pigs: Assessment of the efficacy of various antithrombotic strategies. FASEB, 10 (3): 2506, A434, 1996. Olson R, Wityak J, C.-B. Xue, Sielecki T, Cain G, Mousa S, et al. The discovery of DMP754, an orally active isoxazoline GPIIb/IIIa antagonist. American Chemical Society, 250, 1996. Mousa SA: Antithrombotic Efficacy of different antiplatelet strategies. Advances in Anticoagulant Antithrombotic & Thrombolytic Therapeutics Symposia 1995. Mousa SA: Role of Platelet GPIIb/IIIa in Thrombolysis. Advances in Anticoagulant Antithrombotic & Thrombolytic Therapeutics Symposia 1995. Mousa S: Therapeutic Applications of Anti-angiogenic agents- progress and Issues, Angiogenesis Symposia, 1995. Mousa SA, DeGrado W, Jackson S, Flint S, Forsythe M, Reilly TM: Intravenous and oral antiplatelet/antithrombotic efficacy and specificity of DMP757, a novel platelet GPIIb/IIIa antagonist. Circulation 92 (8): I-488, 2332, 1995. Mousa SA, DeGrado W, Bozarth, Leamy A, Flint S, Lucchesi B, Reilly TM: Oral antiplatelet, antithrombotic efficacy of DMP728, a novel platelet GPIIb/IIIa antagonist in coronary and carotid artery thrombosis model. FASEB Journal, 9 (4): 4852 1995. Lorelli W, Tsao P, Mousa S: Multiple Ligands for Multiple Integrins. Cell Adhesion Molecules Symposia, 1995. Mousa SA, Forsythe M, Lucchesi B, Reilly TM; Thrombolytic and antithrombotic efficacy of the platelet GPIIb/IIIa antagonist DMP728. FASEB Journal, 9 (4): 4853, 1995. Racanelli A, Flint S, Walton H, Mousa SA, Reilly TM: Reversal of GPIIb/IIIa antagonist DMP728-induced bleeding in the dog. Thrombosis & Haemostasis, 73(6), 2092, 1447, 1995. Mousa SA, D-X. Mu, J. Fallon, Reilly TM: Improved and efficient animal model of arterial and venous thrombosis in dogs: Assessment of the efficacy of various antithrombotic strategies. Thrombosis & Haemostasis, 73(6): 1584, 1313, 1995. Mousa SA: Cell adhesion molecules in health and diseases: Potential therapeutic and diagnostic applications. Cell Adhesion Symposia, 1995. Mousa SA, D-X. Mu, Lucchesi B, Reilly TM: Antithrombotic efficacy of DMP728, in coronary and carotid artery thrombosis model. Thrombosis & Haemostasis, 73(6): 1674, 1336, 1995.

Shaker A. Mousa, Ph.D. CURRICULUM VITAE Page 80 of 92

Mousa SA, D-X. Mu, Reilly TM: Antithrombotic efficacy of platelet GPIIb/IIIa antagonist in arterial versus venous thrombosis and re-thrombosis. ISTH, 1995. Mousa SA: Discovery of novel antithrombotic GPIIb/IIIa antagonists. Cell Adhesion Symposia, 1995. B.J. Aungst, Saitoh H, C. Gerard, Mousa SA, D.L. Burchan, S.-M. Huang, M. A. Hussain. Oral absorption enhancement of a cyclic peptide fibrinogen receptor antagonist using sodium caprate. AAPS, 1995. Mousa SA, Pease L, L. Szymanski, P. Wong, Reilly T. Role of platelet angiotensin AII receptors in the modulation of platelet functions. Canadian J. Physiology & Pharmacology, 72, (Suppl. 1), 140, 1994. Tsao P, Jackson S, Bozarth J, Forsythe M, Mousa S. Platelet GPIIb/IIIa receptor occupancy studies using a novel fluoresceinated cyclic RGD peptide. Canadian J. Physiology & Pharmacology, 72, (Suppl. 1), 140, 1994. Mousa SA, Mayo M, J.Bozarth, M. Forsythe, P. Tsao, Reilly TM. Effects of platelet GPIIb/IIIa receptor antagonists on various platelet functions. XIVth Int. Cardiovascular Disease Symposia, 139, 1994. Mousa SA, Bozarth J, Pierce S, M. Forsythe, Reilly TM. Oral antiplatelet, antithrombotic efficacy of DMP728, a novel GPIIb/IIIa receptor antagonist. XIVth Int. Cardiovascular Disease Symposia, 138, 1994. Mousa SA, Mayo M, Bozarth J, Forsythe M, Reilly TM: Antiplatelet effects of thrombin inhibitors versus GPIIb/IIIa receptor antagonists: Comparative analysis. XIVth Int. Cardiovascular Disease Symposia, 44,8, 1994. W.E. Rote, J.H. Davis, Mousa SA, Reilly TM, B. Lucchesi R. Antithrombotic effects of DMP728, a fibrinogen receptor (platelet GPIIb/IIIa) antagonist. The FASEB, 8 (5): 3713, A 640, 1994. Mousa S, De Grado W, Diemer M, Leamy A, Knabb R, Thoolen M, Bozarth J, Rote W, Lucchesi B, Reilly TM. Antithrombotic efficacy of the platelet GPIIb/IIIa antagonist, DMP728, in different models of arterial thrombosis. Atherosclerosis Thrombosis, and Proliferation, 1994. Mousa S, Bozarth J, Pierce S, Forsythe M, Rote W, Lucchesi B, Reilly TM. Oral antiplatelet, antithrombotic efficacy of DMP728, a novel GPIIb/IIIa antagonist. Atherosclerosis, Thrombosis, and Proliferation, 1994. Mousa SA, M. Forsythe, J.Bozarth, Reilly TM: Effect of single oral dose of aspirin on human platelet functions and plasma levels of PAI-1. Thrombosis Hemostasis, 69 (6), 1303,903, 1993. Mousa SA, Mayo M, J.Bozarth, Forsythe M, Reilly TM: Antiplatelet effects of thrombin inhibitors versus GPIIb/IIIa receptor antagonists: Comparative kinetic and mechanistic analysis. Thrombosis Hemostasis, 69 (6), 2792, 1321, 1993.

Shaker A. Mousa, Ph.D. CURRICULUM VITAE Page 81 of 92

Mousa SA, Bozarth J, Mayo M, Forsythe M, Reilly TM: Comparative antiplatelet effects of different thrombin inhibitors: Kinetic analysis. Thrombosis Hemostasis, 69 (6), 1882, 1070, 1993. Mousa SA, De Grado W, Jackson S, Thoolen M, Pierce S, Bozarth J, Hassell S, Reilly TM: Antiplatelet efficacy and safety of the platelet GPIIb/IIIa antagonist, DMP728 in anesthetized dogs. Circulation 88 (4): I-319, 1706, 1993. Rote W, D-X. Mu, Mousa SA, Reilly TM, Lucchesi B: DMP728, a GPIIb/IIIa antagonist, enhances r t-PA - induced coronary thrombolysis and prevents rethrombosis in a chronic canine model. Circulation 88 (4): I-458, 2464, 1993. Mousa SA, Forsythe M, Mayo M, Pease Land T. M.Reilly. Role of platelet GPIIb/IIIa receptors in the modulation of platelet granular secretion. The Pharmacologist, 34(3), 144, 60, 1992. Mousa SA, Forsythe M, Bozarth J, Pease Land Reilly TM. Prolonged effect of a single oral dose of aspirin on human platelet function and plasminogen activator inhibitor type-1 (PAI-1) levels. Keystone Symposia on molecular & cellular biology (Integrins), 1992. Mousa SA, Hassell S, Mayo M, Bozarth J, Forsythe M, T. M.Reilly. Comparative antiplatelet effects of a thrombin inhibitor as compared to a GPIIb/IIIa receptor antagonist. FASEB, 1992. Mousa SA, Bozarth J, Hassell S, Forsythe M and Reilly TM. Abnormal aggregation but normal release of plasminogen activator inhibitor-1 (PAI-1) from Glanzmann's Thrombasthenic (GT) platelets. Fibrinolysis, 6 (Suppl.2), 180,473, 1992. Mousa SA, Forsythe M and Reilly TM. Platelet (P)-Endothelial (EC) interactions in mediating the release of plasminogen activator inhibitor type-1 (PAI-1). Fibrinolysis, 6 (Suppl.2), 169,444, 1992. Mousa S, R. C. Ritger, M. C. Mayo and Diemer M. Efficacy and safety of deferoxamine conjugated to hydroxyethyl starch (HES-DFO). FASEB, 5 (5), 3920, A1045, 1991. Reilly T, Mousa S, Pease L, Bozarth J, Hassell S, Robinson C and Gillies P. Increased platelet GPIIb/IIIa receptor sensitivity in WATANABE(WHHL) as compared to NZW rabbits. FASEB, 5 (4), 3085, A, 1991. Mousa S, Forsythe M, Mayo M and Reilly T. Protective effect of vitronectin on oxidant-induced inactivation of recombinant-plasminogen activator inhibitor type 1. Thrombosis and Haemostasis, 65(6), 1467, 1103, 1991. Mousa S, Pease L, Bozarth J, Mohamed S and Reilly T. Effect of Platelet activation on aggregation and Plasminogen activator inhibitor type 1 (PAI-1) secretion in Glanzmann's thrombasthenic platelets. Thrombosis and Haemostasis, 65(6), 2102, 1276, 1991. S. Grandy, M. Wolka, Mousa S and Turlapaty P. Azapropazone: Pharmacokinetics and effects on neutrophil function. J.Clin.Pharmacol. & Thera. 49 (2), 67, 140, 1991. Kerr J, Mackin W, Turlapaty P and Mousa S. Azapropazone (AZA), a non-steroidal anti-inflammatory drug (NSAID) that blocks PMN functions and protects against pulmonary and

Shaker A. Mousa, Ph.D. CURRICULUM VITAE Page 82 of 92

myocardial ischemia/reperfusion injuries. Symposia on New developments In Free Radical research: Prospects for new drugs, 1991. Mousa S, Ritger R, Turlapaty P and P. Timmermans. Inhibition of oxyradical generating systems by azapropazone: A likely link between its cytoprotective efficacy in myocardial ischemia/reperfusion injury & inflammation. XIIth European Congress of Rheumatology, Budapest, 1991. Reilly TM, S. M. Spitz, A. L. Racanelli, Forsythe M and Mousa S. Recombinant plasminogen activator inhibitor-1 protects platelets against the proteolytic effects of plasmin. Circulation, 84(4), 309, II-78, 1991. Mousa SA, Forsythe M, Mayo M, Dwivedi A and Reilly TM. Vitronectin's protective effect on recombinant plasminogen activator inhibitor-1: Structural and Functional analysis. Circulation, 84(4), 310, II-78, 1991. S. Grandy, Mousa S and Turlapaty P. Methodology to evaluate neutrophil migration and function in man-effect of IV Azapropazone. XIIth European Congress of Rheumatology, Budapest, 1991. Knabb R, Thoolen M, Mousa S and P. Timmermans. Protection against irreversible injury in animal models of myocardial infarction by treatment with the non-steroidal anti-inflammatory drug zapropazone. XIIth European Congress of Rheumatology, 1991. S. A.Mousa, T. M.Reilly, Pease L, Bozarth J, A. Chiu, H. L. Walton, Mohamed S, R.Knabb, A.Racanelli. Inhibition of human Platelet Plasminogen activator inhibitor-1 release by GPIIb/IIIa receptor antagonists. Int. Congress Fibrinolysis, 4(suppl.3), 43, 1990. T. M.Reilly, R.Seetharam, J. L.Duke, G. L.Davis, D. Kingsley, R. M.Knabb, H. L.Walton and S. A.Mousa. Purification and characterization of a biologically active recombinant Plasminogen activator inhibitor-1 from E. Coli. Int. Congress Fibrinolysis, 4 (suppl.3), 45, 1990. Racanelli A, Diemer M, J. Dubin, Knabb R, Mousa SA and Reilly T. Antagonism of tissue Plasminogen activator induced blood loss by recombinant PAI-1 and Epsilon aminocaproic acid. Int. Congress Fibrinolysis, 4 (suppl.3), 1990. Mousa SA, Brown R, J. Hsieh and Smith RD. Effects of Azapropazone on Neutrophil Migration in a Rabbit Model of Regional Myocardial Ischemia/Reperfusion Injury. J. Mol. Cell. Cardiol. 21 (Suppl. II), S149, 1989. Mousa SA, Brown R, J. Hsieh and Smith RD. Effects of Azapropazone on Neutrophil Migration in Anesthetized Swine Using a Multiblister Suction Technique. J. Mol. Cell. Cardiol. 21 (Suppl. II), S173, 1989. Mousa SA, M. Maina and Williams SJ. Myocardial Uptake and Retention of Tc-99m-RP30: Evidence for Specificity. Circulation, 74(4), 2047, II 513, 1988. Mousa SA, Cooney JM, B. A. Khaw, Williams SJ and Haber E. Assessment of myocardial infarction with Tc99m Hexamibi as compared to 111In-antimoyosin and TL201 in Rabbit J. Mol. Cell. Cardiol.

Shaker A. Mousa, Ph.D. CURRICULUM VITAE Page 83 of 92

1988. Mousa SA, Cooney JM, M. J. Thoolen and P. Timmermans. Antiischemic Efficacy of Azapropazone in canine heart model. J. Mol. Cell. Cardiol. 1988. Patil G, L. Mateir, R. Sato, J. Schaffer and Mousa SA. Structure Activity Relationship of Novel B-Adrenoceptor Blockers as an Anti-glaucoma Agent. Am. Chem. Soc., 1988. Mousa SA, Cooney JM, M. J. Thoolen and P.Timmermans. Myocardial cytoprotective efficacy of azapropazone in reperfused-infarcted/ischemic canine heart model. Fed. Proc., 72, 3632, 1988. Williams SJ, Mousa SA, T. R. Carroll, L. J. Maheu and R. A. Morgan. Characterization of Tc-99m-Hexakis-Ether Isonitriles for Myocardial Perfusion Imaging. Japanese Nuclear Medicine Society, 1987. Mousa SA, Cooney JM and Williams SJ. Assessment of Different Degrees of Coronary Artery Stenosis in Canine Models using RP30. Eur. Nuclear Medicine Congress, Nucl. Medicine, 5, 56, 1987. Williams SJ, Mousa SA, T. R. Carroll and L. J. Maheu. Tc-99m- Hexakis-Ether Isonitriles: Agents for Tc-99m Myocardial Perfusion Scintigraphy. X Int. World Congress of Cardiology, 999, 133, 1987. Mousa SA, Cooney JM and Williams SJ. Flow Distribution Characteristics of Tc-99m-Hexakis-2-Methoxy, 2 Methylpropyl Isonitrile in Animal Models of Myocardial Ischemia and reperfusion. J. Am. Coll. Cardiol., 9(2), 137A, 1987. Mousa SA, M. Maina, B. A. Brown and Williams SJ. Retention of Rp-30 in the Heart May be Due to Binding to a Cytosolic Protein. J. Nucl. Medicine, 28(4), 619, 1987. Mousa SA, Cooney JM and Williams SJ. Regional Myocardial Distribution of Rp-30 in Animal Models of Myocardial Ischemia and Reperfusion. J. Nucl. Medicine, 28(4), 620, 1987. Mousa SA, Cooney JM and Williams SJ. Kinetics of the New Myocardial Perfusion Imaging Agent, Tc-99m-Hexakis-2-Methoxy-2-Methylopropyl Isonitrile (Cardiolite) in Reperfused-Infarct Canine Heart Models. J. Mol. Cell Cardiol. 19 (Suppl. IV), S.75, 1987 Mousa SA, M. Maina, B. A. Brown and Williams SJ. Studies on the Mechanisms of Retention of Rp30 in the Heart. Eur. Nuclear Medicine Congress. Nucl. Med. 4, 55, 1987. Williams SJ, Mousa SA, T. R. Carroll, L. J. Maheu and R. A. Morgan. Characterization of Tc-99m-Hexakis-Ether Isonitriles for Myocardial Perfusion Imaging. Japanese Nuclear Medicine Society, 1987. Mousa SA, Cooney JM and Williams SJ. Assessment of Different Degrees of Coronary Artery Stenosis in Canine Models using Rp30. Eur. Nuclear Medicine Congress, Nucl. Medicine, 5, 56, 1987.

Shaker A. Mousa, Ph.D. CURRICULUM VITAE Page 84 of 92

Williams SJ, Mousa SA, T. R. Carroll and L. J. Maheu. Tc-99m-Hexakis-Ether Isonitriles: Agents For Tc-99m Myocardial Perfusion Scintigraphy. X Int. World Congress of Cardiology, 999, 133, 1987. Mousa SA, Cooney JM and Williams SJ. Flow Distribution Characteristics of Tc-99m-Hexakis-2-Methoxy, 2 Methylpropyl Isonitrile in Animal Models of Myocardial Ischemia and reperfusion. J. Am. Coll. Cardiol., 9(2), 137A, 1987. Mousa SA, M. Maina, B. A. Brown and Williams SJ. Retention of Rp-30 in the Heart May be Due to Binding to a Cytosolic Protein. J. Nucl. Medicine, 28(4), 619, 1987. Mousa SA, Cooney JM and Williams SJ. Regional Myocardial Distribution of Rp-30 in Animal Models of Myocardial Ischemia and Reperfusion. J. Nucl. Medicine, 28(4), 620, 1987. Mousa SA, Cooney JM and Williams SJ. Kinetics of the New Myocardial Perfusion Imaging Agent, Tc-99m-Hexakis-2-Methoxy-2-Methylopropyl Isonitrile (RP30, Cardiolite) in Reperfused-Infarct Canine Heart Models. J. Mol. Cell Cardiol. 19 (Suppl. IV), S.75, 1987. Mousa SA, M. Maina, B. A. Brown and Williams SJ. Studies on the Mechanisms of Retention of Rp30 in the Heart. Eur. Nuclear Medicine Congress, Nucl. Med. 4, 55, 1987. Williams SJ, D. B. Pendleton, B. A. Burgess and Mousa S. Structure-localization Relationships of Tc-99m (Isonitrile)+ Analogs as Potential Myocardial Perfusion Imaging Agents. Fourth International Symposium on Radiopharmacology, 9, 1985.

CNS PHARMACOLOGY Van Loon GR, Mousa SA and R. Kvetnansky. Adaption of the Sympathoadrenal Met- Enkephalin and Catecholamine Responses to Repeated Stress. Endocrine Soc. Ann. Meeting, 1985. T. W. Sherraden, Mousa SA, F. Bobbitt, W. Robinson and Van Loon GR. Differential Plasma Net-enkephalin and Catecholamine Responses to Repeated Insulin - induced Hypoglycemia in Dogs. Endocrine Soc. Ann. Meeting, 1985. Van Loon GR, Mousa SA, J. A. Kiritsy-Roy and R. Kvetnansky. Adaption of the Sympathoadrenal Met-Enkephalin Responses to Repeated Stimuli. Int. Narcotic Res. Conf., 1985. Mousa SA and Van Loon GR. Acid-lyophilizable Met-enkephalin in Plasma: An Index of Total Plasma Met-enkephalin. Int. Narcotic Res. Conf., 1985. Aloyo VJ, Mousa SA and Van Loon GR. Stabilization of Met-enkephalin in Human and Rat Blood. Int. Narcotic Res. Conf., 1985. J. Friedman, J. P. Friedman, B. Beihn and Mousa SA. The Effect of Dynorphin on Thallium Uptake in Cultured Myocardial Cells. Am. Heart Assoc., 1985.

Shaker A. Mousa, Ph.D. CURRICULUM VITAE Page 85 of 92

Van Loon GR, Mousa SA and R. Kvetnansky. Adaptive Mechanisms in the Met-enkephalin and Catecholamine Responses to Repeated Stress. Clin. Res. 33: 537A, 1985. Van Loon GR, J. A. Kiritsy-Roy and Mousa SA. Differential Sympathoadrenal Catecholamine Responses to Central and Peripheral Nicotine. Soc. Neurosci., 1985. Van Loon GR, Mousa SA, P. Zeman and R. Kvetnansky. Adaption of the Sympathoadrenal Met-enkephalin to Stress. Winter Conf. Brain Res., 1985. T. W. Sherraden, Mousa SA, F. Bobbit, W. Robinson, L. Brown and Van Loon GR. Prior Hypoglycemia Potentiates the Adrenomedullary Response to Insulin-induced hypoglycemia. Clin. Res. 33: 876A, 1985. Mousa SA and Van Loon GR. Measurement of Proenkephalin A-derived Peptides in Tissues by HPLC Coupled with Amperometric Electrochemical Detection (A-ECD). The Pharmacologist, 27(3), 376, 1985. Van Loon GR and Mousa S. "Nicotinic Regulation of the Secretion of Immunoreactive Met-enkephalin". Neuroscience, 10(2), 324.1, 1107, 1984. Mousa SA and Van Loon GR. Enkephalin - Containing peptides of pheochromocytoma. Clin. Res. 32: 270A, 1984. Mousa SA, Aloyo VJ and Van Loon GR. Effect "Tobacco Smoke and Nicotine on Pain Sensitivity in Rats. Neuroscience, 10(1), 32.5, 104, 1984. R. Van Loon and Mousa SA. "Enkephalin-Containing Peptides of Pheochromocytoma". IUPHAR 9th International Congress of Pharmacology, London, England, 325, 1984. Mousa SA, Aloyo VJ and Van Loon GR. "Central and Peripheral Methionine-Enkephalin Responses to Chronic Nicotine". IUPHAR 9th International Congress of Pharmacology, London, England, 331, 1984. Mousa SA and Van Loon GR. "Nicotinic Regulation of Met-Enkephalin Secretion", International Narcotic Research Conference, Cambridge, England, pp. 54, 1984. Van Loon GR and Mousa SA. Enkephalin-Containing Peptides of Pheochromocytoma. Prog. 7th Int. Congr. Endocrinology, Quebec, 1984. Van Loon GR and Mousa SA, C. Malchoff and R. Cavey. Enkephalin Related Peptides of Pheochromocytoma. Clin. Res. 32: 786A, 1984. Mousa SA, Couri D, and C. H. Miller, Jr. "Enkephalin Release and Metabolism: Effect of Stress and Corticosteroid Modulation". Endocrinology, 1983. Couri D, Mousa S, and C. H. Miller, Jr. "Role of B-endorphin in Stress-Induced Analgesia and Eating: Modulation by Corticosteroid". Fed. Proc., 2793, 769, 1983.

Shaker A. Mousa, Ph.D. CURRICULUM VITAE Page 86 of 92

P. Fardal, Mousa S, Couri D, L. Tate and W. Adrion. "Endorphins and Enkephalins in Sudden Infant Death Syndrome". American Academy of Forensic Sci., G36, 23, 1983. Mousa SA, Miller CH and Couri D. "Analysis of Enkephalin, B-endorphins Analogs by HPLC-EC". Fed. Proc., 42(3), 2120, 654, 1983. H. Miller, Mousa S and Couri D. "Catecholaminergic and Serotonergic Systems and Stress Induced Analgesia". Fed. Proc., 42(4), 2794, 769, 1983. Mousa SA, S. Tjioe and Couri D. "Effect of Postnatal Phenobarbiturate Treatment on Enkephalin Metabolism by Rat Brain Amino and Endopeptidases". Neuroscience, 9(2): 233, 16, 1983. Mousa SA and Couri D. "Corticosteroid and Food Intake in Stressed and Unstressed Rats". Fed. Proc., 5539, 1219, 1982. H. Miller, Jr., Mousa S and Couri D. "Comparison of Methods Used to Evaluate Rat Tail Flick Latency Measurements with Antagonism or Potentiation of Analgesia". Fed. Proc., 6027, 1302, 1982. Mousa SA, Couri D, G. Bronn, H. Abou-Issa and L. C. Carey. "Role of B-endorphin in Food Intake and Obesity and its Modulation by Corticosteroid". Endocrinology, 1220, 384, 1982. H. Miller, Jr., Mousa S and Couri D. "Analysis of Factors Affecting the Hot Plate (HP) and Tail Flick (TF) Methods". The Pharmacologist, 24(3), 727, 230, 1982. Mousa SA, Miller CH and Couri D. "Dexamethasone and Stress-Induced Analgesia". 12th Ann. Meeting for the American Society for Neurochem. 30, 89, 1981. H. Abou-Issa, D. Bronn, Mousa S, Couri D and J. P. Minton. "In Vitro and In Vivo Effects of Caffeine on Cyclic Nucleotides Metabolism in Mammary Tissue. Fed. Proc., 2491, 65, 1981. Mousa SA, Miller CH and C. Couri. "Steroid Modulation and Stress-Induced Analgesia in Rats", Brain-Gut Axis: The New Frontier Symposia, Florence, Italy, 136, (Ed. N. Basso) June 1981. Mousa SA and Couri D. "Sensitive and Specific High Performance Liquid Chromatographic Method for Enkephalins". Fed. Proc., 410, 305, 1981. Mousa SA and Couri D. "Separation of Enkephalin and Endorphin Analogs by a Reverse Phase High Performance Liquid Chromatographic Method". Int. Symposium on HPLC of Proteins and Peptides, 176, 509, 1981. Mousa SA, C. H. Miller, Jr. and Couri D. "Metyrapone and Stress-Induced Analgesia (SIA) in Rats". Midwestern Pharmacol. Soc., 9, 5, 1981. Tejwani GA and Mousa S. "The Purification and the Properties of the Rat Lung Phosphofructokinase". Fed. Proc., 39, 2267, 1980.

Shaker A. Mousa, Ph.D. CURRICULUM VITAE Page 87 of 92

Dr. Mousa’s Keynote lectures & participation at international conferences (Example 2016-2017), same apply to evey year for over the past 30 years February 11-13, 2016 Penary lecture and Award of Excellence for Dr. Mousa at 5th Pan Arab

Hematology Association Conference, Cairo, Egypt April 4-8, 2016 Keynote Speaker, Alternative and Complementary Medicines, King Abdulaziz University, Jeddah, Saudi Arabia April 21-23, 2016 Keynote Speaker, 6th Global Experts Meeting & Expo on Nanomaterials

and Nanotechnology Congress and Expo, Dubai, United Arab Emirates April 21-23, 2016 Keynote Speaker, World Congress & Expo on Pharmaceutics & Drug

Delivery Systems, Dubai, UAE May 4-7, 2016 Chair, session on VTE in Cancer/Surgery, 24th International Congress on

Thrombosis, Istanbul, Turkey June 9-11, 2016 Keynote speaker, 8th World Medical Nanotechnology Congress,

Dallas, Texas October 13-15, 2016 Keynote Speaker, 4th International Drug Design Congress, Istanbul, Turkey October 28, 2016 Keynote Speaker, Special Session on Heparin Diversifications, Loyola University, Chicago, Illinois December 14-16, 2016 Keynote Speaker, Immigrant Egyptian Oncology Forum, Luxor, Egypt Feb 27-28. 2017 Keynote Speaker, Pediatric Oncology Congress, Jeddah, Saudi Arabia April 3-5, 2017 International Conference on Pharmacy and Drug Delivery, Dubai, UAE April 3-5, 2017 Keynote Speaker, Global Nanotech 2017, Dubai, UAE

Dr. Mousa is a member on the panel of the study sections listed below for the past several Years:

Center for Scientific Review Special Emphasis Panel Center for Scientific Review ZRG1 CVRS-H (11) ZRG1 CVRS-H (11 II)

Respiratory Sciences Small Business - NIH SBIR/STTR

Center for Scientific Review Special Emphasis Panel (Physiology and Pathology of Cardiovascular and Respiratory Systems)

Center for Scientific Review F30, F31, F32, and F33 International Exchange Program (Non-Degree). To promote global research partnerships between ACPHS, under the guidance of PRI, and other academic institutes worldwide.

o Melis Coskun, Ph.D. student, Uludag University, Turkey, was at PRI for 1.5 years of cancer research training (Improve Efficacy and Safety of Chemotherapy), returned to Turkey in October.

o Dr. Shimaa Motawei, M.D., Ph.D., Forensic Medicine & Clinical Toxicology, Mansoura University, Egypt has a 1 year Fulbright Scholarship at PRI to research the effect of lead and preeclampsia on angiogenesis in an animal model.

Shaker A. Mousa, Ph.D. CURRICULUM VITAE Page 88 of 92

o Dr. Murat Yalcin, D.V.M., Ph.D., Professor, Uludag University, Turkey is visiting PRI for 6 months beginning Jan. 2017 to participate in animal research studies.

o PRI partners and collaborates with Wadsworth in joint research projects toward NIH R01, R21 and DOD submissions. There are 2 R01s and 2 R21s submitted and pending NIH review.

o PRI partners and collaborates with the Albany Medical Center New York Hematology Oncology in a joint research project on the molecular mechanisms involved in Sickle Cell Disease.

o PRI partners and collaborates with UNYTE network (University of Rochester, University of Syracuse, and Cornell) in joint research projects toward joint NIH submission.

LECTURES / SYMPOSIA / WORKSHOPS Keynote speaker at national and international conferences from 2013-present are not added. American Heart Association Annual Meeting, Dallas, TX, “Bioequivalence of Chemoenzymatically Synthesized Bioengineered Heparin versus Porcine USP Heparins, November 17-20, 2013. Invited Lecturer at Louisiana State University Health Sciences Center, Stanley S. Scott Cancer Center, New Orleans, "The Future of Nanotechnology and biotechnology in various disorders, with special emphasis on cancer", September 18-19, 2013. Invited Lecturer at Bioconnex’s Capital Region Commercialization of Life Sciences Innovation Day. Commercializable Biotechnology in Upstate NY (East). Albany Molecular Research Inc., Albany, New York. July 7, 2013. Third Annual ACPHS Research Forum. Albany College of Pharmacy and Health Sciences, Albany, New York. Saturday, January 19, 2013. Continuing Medical Education (CME credited) Worldwide Lecture series, 1998-Present. Extracellular Matrix Proteins Graduate course, University of Delaware, DE, 2001. Antithrombotic therapies: The Johns Hopkins University, Baltimore MD, 2001. Heparin in Thrombosis & cancer: The missing Link. University of Vanderbilt, TN; Loyola University, IL; Temple Univ., PA; University of Illinois, IL; Univ of Wisconsin, WI. Angiogenesis in Health & Diseases, the Johns Hopkins University, Baltimore MD, 2000. Cell adhesion Molecules & Matrix Proteins in Health & Diseases, University of Delaware, DE 2000. Role of Heparin in Thrombosis & cancer: The Missing Link. Temple University, PA 2000. Anti-angiogenesis & anti-tumor effects of Low Molecular Weight Heparin, Jefferson Univ., PA 2000. Integrins in Angiogenesis, the Johns Hopkins University, Baltimore MD, 1999.

Shaker A. Mousa, Ph.D. CURRICULUM VITAE Page 89 of 92

Therapeutic Implications of Integrin Blockade, Thomas Jefferson University, Dept. Physiology, 1999. Integrins: Potential Therapeutic & Diagnostic Implications, Temple University, 1999. Integrin in Angiogenesis, Thomas Jefferson University, Medical school, 1999. Organizer and chairman of the Annual Symposia, Antiplatelet, Anticoagulants & Thrombolytics Symposia. Boston, MA, October 1999. Organizer and chairman of the Annual Symposia, Angiogenesis, October 1999. Cell Adhesion Molecules in Health & Diseases, University of Minnesota, 1998. Organizer and chairman of the Annual Symposia, Antiplatelet, Anticoagulants & Thrombolytics Symposia. Boston, MA, September 1998. Role of beta 3 Integrins in vascular biology & thromboembolic disorders: Therapeutic & diagnostic implications. Seminar at the DuPont Merck Pharmaceutical Co., 1998. Role of beta 3 Integrins in vascular biology & thromboembolic disorders: Therapeutic & diagnostic implications. The Scripps Res. Institute, San Diego, CA. 1997. Cell Adhesion Molecules in Vascular Disorders. State University of New York at Buffalo, Dept. of Medicine, Buffalo, NY. 1997. Role of alibi/b3 Integrins in thromboembolic disorders: Therapeutic & diagnostic implications. Merck Pharmaceutical Co., 1997. Organizer and chairman of the 3rd Annual Symposia "Therapeutic Implications & Mechanisms of ANGIOGENESIS. Boston, MA 1997. Organizer and chairman of the 7th Annual Symposia, Cell Adhesion Molecules & Matrix Proteins. San Francisco, May 1997. Organizer and chairman of workshop on Small Molecule Inhibitors of CAM. San Francisco, May 1997 Organizer and chairman of the 1st Annual Symposia Matrix Metalloproteins in Tissue remodeling. San Francisco, May 1997. Organizer and chairman of the 1st Annual workshop Novel Therapeutic Developments in remodeling mediated disorders. San Francisco, May 1997. Organizer and chairman of the Annual Symposia, Anticoagulants, Antithrombotics & Thrombolytics Symposia. Boston, MA, October 1996. Organizer and chairman of the Annual Symposia, Therapeutic Implications of ANGIOGENESIS Inhibitors & Stimulators Symposia. San Francisco, CA, May 1996.

Shaker A. Mousa, Ph.D. CURRICULUM VITAE Page 90 of 92

Organizer and chairman of the Annual Symposia, Adhesion Molecules & Matrix Proteins: Targeting CAMs for Therapeutic & Diagnostics. San Francisco, May 1996. Organizer and chairman of the Annual Symposia, Therapeutic Implications of ANGIOGENESIS Inhibitors & Stimulators Symposia. Philadelphia, PA, 1995. Potential Clinical Utilities of Anti- 3 integrins. Seminar at the John Hopkins Univ., 1995. Organizer and chairman of the Annual Symposia, Adhesion Molecules in Health & Diseases: Potential Therapeutic & Diagnostic Implications. Cell Adhesion Symposia, San Francisco, 1995. Cyclic RGD peptides. Satellite FASEB Symposia, Atlanta, GA, 1995. Discovery of novel platelet GPIIb/IIIa Antagonists. Cell Adhesion Symposia, San Francisco, CA, 1995. ASPET symposia on "Antithrombotics and thrombolytics"- Invited speaker, Ann Arbor MI, 1995. Platelet GPIIb/IIIa antagonists: Cyclic peptides. ASPET, Ann Arbor, MI, 1995. Potential clinical utility of Platelet GPIIb/IIIa antagonists. Vascular biology and remodeling in: Atherosclerosis Thrombosis & Restenosis, NJ, 1995. Discovery of novel Cyclic RGD Compounds: Potential Clinical Utilities. Seminar Series at Univ. of Illinois, Chicago, IL 1994. Platelets In Health & Diseases: The Discovery of novel platelet GPIIb/IIIa antagonists. The 3rd Annual ADHESION MOLECULES SYMPOSIA. San Francisco, CA 1994. Platelets In Health & Diseases: The Discovery of novel platelet GPIIb/IIIa antagonists. Seminar series at Univ. of Buffalo, NY 1994. Platelets in Health & Diseases: The Discovery of novel platelet GPIIb/IIIa antagonists (DMP728). Seminar series at Johns Hopkins, MD 1994. Platelets in Health & Diseases. Session Chairman & Speaker at the SCC, Univ. of Delaware, DE 1993. Anti-integrins as Potential Therapeutics. Seminar Series, Exp. Station, Wilmington, DE 1993. Adhesion Molecules in Health & Diseases. Session Chairman & Speaker at the SCC, Baltimore, MD 1992. Leukocyte functions in health & diseases. McMaster UNIVERSITY, Dept. Of Pharmacol. & Rheumatic Diseases, Hamilton, Ontario, CANADA, 1992. Recent advances in the diagnosis of ischemic heart diseases. Ohio State University, Medical School, Columbus, OH, 1989.

Shaker A. Mousa, Ph.D. CURRICULUM VITAE Page 91 of 92

Non-invasive diagnosis of coronary artery diseases, at Illinois Institute of Technology, Chicago, IL, 1988. Basic and clinical research that led to the emergence of Cardiolite*. Univ. of Wisconsin Medical Center, Madison, WI, 1988. Diagnosis of ischemic heart diseases and future therapeutic modalities at Dept. Pharmacol., Medical College of Wisconsin, WI, 1988. Latest development in the non-invasive diagnosis of coronary artery diseases: Cardiolite, Du Pont Critical Care, Waukegan, IL, 1987 and 1988. Overview about the pharmacology of Azapropazone in relation to myocardial ischemia/reperfusion injury. Du Pont Critical Care, Waukegan, IL, 1988. Overview about "preclinical data on Cardiolite" to Cardiologist, Nuclear Medicine and Radiologist at American Heart Meeting, Anaheim, CA, 1987. Glucocorticoid Modulation of Stress-Induced Analgesia, Seminar at Research Triangle Park, North Carolina, 1983. Adrenal-Pituitary Axis and Stress-Induced Analgesia, Seminar to Department of Medicine, University of Kentucky, Lexington, Kentucky, 1983. Enkephalins, endorphins and the Autonomic Nervous System, Pharmacology & Surgery Departments, Medical School, Ohio State, 1982. PREVIOUS RESEARCH EXPERIENCES: Screening, Qualitative and Quantitative Structure Activity Relationships (SAR) Cyclic Nucleotides, Calcium and Mechanical Changes in Smooth Muscles in Tissue Culture Neuroblastoma Cells in Tissue Culture as a Model to Study Receptors Pharmacokinetic and Drug Metabolism of Anti-Cancer Drugs Axonal Transport Mechanisms Establishment of a New Technique for Studying the Release of Acetylcholinesterases (AchE) and its Regulations Hormonal Regulations of Catecholamines Synthesizing and Degrading Enzymes with Respect to the Sub-Cellular Mechanisms Glycolytic Enzymes (rate limiting step enzyme) Phosphofructokinase (PFK)

Shaker A. Mousa, Ph.D. CURRICULUM VITAE Page 92 of 92

Chronic Stress and Enkephalins in Brain and Adrenal Medulla Dimethylsulfoxide (DMSO) effects on different Pain pathways. Corticosteroid Modulation and Stress Induced Analgesia Corticosteroid Modulation and Food/Alcohol Consumption (Possible Role for Endorphins) Corticosteroid Modulation on Enkephalins and Endorphins in Brain, Adrenal Medulla, and Plasma The Correlation between Caffeine and Breast Cystic Fibrosis (Experimental Animals and Humans) The Role of Endorphins in Obesity (Experimental Animals and Humans) Mechanism of Tolerance to Nicotine (Biochemical Mediations via the Catecholaminergic and Enkephalinergic Systems) Developed various in vivo and in vitro animal models of myocardial ischemia/reperfusion Identification of a Myocardial Perfusion Agent for Diagnosis of Myocardial Ischemia and Infarction (Define an optimal agent/QSAR, pharmacodynamics, pharmacokinetics and mechanisms) Identification of a diagnostic myocardial metabolic indicator (differentiate between "Stunned", Irreversibly Damaged and Normal Myocardium) Provide and prepare preclinical for IND and NDA submission to the FDA on the non-invasive diagnostic imaging agent, Cardiolite* CURRENT RESEARCH INTERESTS: Biotechnology/ Nanotechnology and Stem cell in drug discovery and drug development Adhesion Molecules and Angiogenesis in Heath and Diseases Search for novel Therapeutic and Diagnostic Targets in vascular disorders Treatment and Prevention of ischemic and Coronary Artery Diseases: a) Identification of Novel Antithrombotic, Anti-restenosis Therapies. b) Identification and development of an anti-ischemic therapeutic modalities Angiogenesis-mediated disorders (Cancer, Diabetic retinopathy, Macular degeneration, inflammatory diseases). Site directed delivery of chemotherapeutics into tumor using novel Nanotechnology based strategies. Novel mechanism for optimal inhibition of tumor invasion and metastasis.